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ABSTRACT
FACULTY OF MEDICINE, HEALTH AND LIFE SCIENCES
SCHOOL OF MEDICINE
Doctor of Philosophy
THE ROLE OF NERVE GROWTH FACTOR AND P75 NEUROTROPHIN
RECEPTOR IN RECOVERY FROM LIVER FIBROSIS
by Timothy James Kendall
Rodent hepatic myoﬁbroblasts are susceptible to nerve growth factor-mediated apop-
tosis through p75 neurotrophin receptor ligation. Hepatic myoﬁbroblast apoptosis is
critical to resolution of liver ﬁbrosis. I show that human hepatic myoﬁbroblasts ex-
hibit differential responses to mature and pro-nerve growth factor/p75 neurotrophin
receptor-mediated signals. Whilst mature nerve growth factor is proapoptotic, pro-
nerve growth factor protects human hepatic myoﬁbroblasts from serum-deprivation and
cycloheximide-induced apoptosis. To deﬁne the dominant effect of p75 neurotrophin
receptor-mediated events in experimental liver ﬁbrosis I have used a mouse lacking the
p75 neurotrophin receptor ligand-binding domain but expressing the intracellular do-
main. I show that absence of p75 neurotrophin receptor ligand-mediated signals leads
to signiﬁcantly retarded architectural resolution and reduced hepatic myoﬁbroblast loss
by apoptosis. Lack of the ligand-competent p75 neurotrophin receptor limits hepatocyte
proliferative capacity in vivo without preventing hepatic stellate cell transdifferentiation.
Moreover, in recovery from experimental liver ﬁbrosis the fall in pro-nerve growth factor
mirrors loss of hepatic myoﬁbroblasts by apoptosis. Thus, nerve growth factor species
have a differential effect on hepatic myoﬁbroblast survival, and p75 neurotrophin recep-
tor ligand-mediated events facilitate reduction of liver ﬁbrosis via regulation of hepatic
myoﬁbroblast proliferation and apoptosis, and hepatocyte proliferation.“Convictions are more dangerous enemies of truth than lies.”
Friedreich Nietzsche; Human, All-Too-Human
“First you guess. Don’t laugh, this is the most important step. Then you compute
the consequences. Compare the consequences to experience. If it disagrees with
experience, the guess is wrong. In that simple statement is the key to science. It
doesn’t matter how beautiful your guess is or how smart you are or what your name is.
If it disagrees with experience, it’s wrong. That’s all there is to it."
Richard FeynmanContents
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Introduction
Hepatic ﬁbrosis is the generic wound healing response of the liver which
occurs as a consequence of a variety of injurious stimuli. Iterative or chronic
injury mediated by viruses, autoimmune diseases and toxins such as alcohol
all lead to a common histopathological outcome.
In ﬁbrosis the normal liver architecture becomes increasingly effaced. With
continued damage the gross architectural distortion that characterises
cirrhosis develops. Fibrosis is characterised by qualitative and quantitative
abnormalities of extracellular matrix. Increased amounts of ﬁbrillar matrix,
usually found only in the liver capsule and around large portal tracts, are
present throughout the entire liver parenchyma, although the distribution
may differ depending on the exact nature of the injury. Cirrhosis can be
considered the extreme end of the ﬁbrotic spectrum, being characterised
by the complete loss of normal liver architecture with nodules of
regenerating hepatocytes surrounded by thick ﬁbrous bands.
The key effector cell co-coordinating the development of liver ﬁbrosis is the
hepatic stellate cell (HSC), [1, 2] previously known as the Ito cell or lipocyte.
As a consequence of liver injury, the HSC undergoes a phenotypic change
called activation . [3] The HSC is normally present as a quiescent cell with
cellular processes that may encircle the sinusoid but after activation
becomes a hepatic myoﬁbroblast (hMFB). [4] The hMFB expresses a different
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range of genes that have a net proﬁbrotic effect and produces the
characteristic ﬁbrotic extracellular matrix.
Whilst contributing greatly to the change in the extracellular environment in
ﬁbrotic liver, hMFBs are themselves inﬂuenced by the signals provided by this
specialised environment . [5, 6] Extracellular matrix functions as a
mechanical framework anchoring cells, and also enables migration. [7] The
underlying extracellular matrix of any given cell greatly inﬂuences the
phenotype and range of genes expressed by interaction between
extracellular matrix components and cell surface receptors, such as
integrins. [8] Signals provided by extracellular matrix components can
inﬂuence cell survival by promoting or preventing apoptosis, and modifying
proliferative potential, in addition to inﬂuencing differentiation. [9–11]
Additionally, extracellular matrix acts to sequester and present or prevent
exposure of soluble factors to cells, also inﬂuencing cell behaviour and
survival. [12, 13]
Liver ﬁbrosis is not an immutable entity that steadfastly replaces the normal
architecture. Rather, it is a bi-directional process with a large capacity for
signiﬁcant architectural recovery from severe injury and ﬁbrosis, and on the
basis of current evidence, limited recovery from cirrhosis, once the
proﬁbrotic injury has ceased or been removed . [14–17] There are two major
features evident during the recovery process; a reduction in hMFB numbers
and a remodelling of ﬁbrotic extracellular matrix with restoration of the
original architecture. The interactions between hMFBs and the extracellular
matrix are critical to this process.
1.1 The micro-architecture of the hepatic sinusoid
The liver is arranged microscopically into a sinusoidal pattern (Figure 1.1).
Plates of hepatocytes, the epithelium, are separated from the endothelial
cells lining the sinusoid by the space of Disse. Branches of the hepatic
artery, hepatic portal vein and a bile duct form the portal tracts at one end
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Figure 1.1. Schematic representation of the sinusoidal structure of the liver.
Plates of hepatocytes are supplied with blood by branches of the hepatic
artery and hepatic portal vein, and are drained by a branch of the hepatic
vein. A bile ductule is also present within the portal tract. Figure taken from
Cunningham et al. [18]
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of the sinusoids, and a tributary of the hepatic vein is at the other. The
endothelial cells form a sheet with numerous fenestrations. The fenestrations
are of two types, small (0.1m diameter) and large (up to 1m diameter).
The small fenestrations are intracellular and the larger ones are thought to
be intercellular. The fenestrations may be capable of changing in size in
response to factors such as alcohol. [19] Experimental evidence suggests
that the composition of the extracellular matrix within the space of Disse is
necessary for maintaining this fenestrated phenotype. Culture of sinusoidal
endothelial cells in the absence of this complex cell-matrix contact, for
example on type I collagen, results in loss of the fenestrations, whereas
culture on the basement membrane side of human amnion allows the
fenestrations to persist. [20]
There is a free connection between the environment of the space of Disse
and the sinusoidal lumen since there is no membrane over the fenestrations,
nor is there a classical basement membrane (in humans), although a loose
matrix of basement membrane components can be demonstrated. This
allows the fenestrations to ﬁlter the sinusoidal blood so that solutes including
large proteins within the blood can easily diffuse into contact with the plates
of hepatocytes but larger particles are unable to do so.
The space of Disse separates the sinusoidal endothelial cells from the plates
of hepatocytes. The sinusoidal surface of hepatocytes is covered by
numerous microvilli, facilitating exchange of substances between the
hepatocytes and the extravascular ﬁltrate.
The extracellular matrix present within the space of Disse does not act as a
diffusion barrier. It is a low density matrix with both an interstitial and a
basement membrane-like component. There is a small amount of ﬁbrillar
collagens I, III and V, and microﬁbrillar collagen VI in addition to basement
membrane-like collagens IV and XVIII, and non-collagenous components
such as decorin, ﬁbronectin, tenascin, laminin, heparan sulfate
proteoglycans and others. [21] The proteoglycan components function to
regulate matrix assembly and the architectural construction. Some
proteoglycans molecules have glycosaminoglycans side-chains, allowing
them to interact with collagens and glycoproteins.
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There are differences in the extracellular matrix components in the space of
Disse according to the distance from the portal tracts. [22] In the periportal
areas laminin, heparan sulfate and collagen IV predominate but in the
perivenular regions there is more collagen III and dermatan sulfate.
Interstitial-type extracellular matrix, composed of ﬁbrillar collagens and less
basement membrane type components, is found under physiological
circumstances around portal tracts, central veins and the liver capsule. The
true basement membrane of the endothelium of bile ducts and blood
vessels in these areas is an exception to this.
The specialised environment of the space of Disse contains quiescent HSCs.
These are responsible for producing the majority of extracellular
components present in the space of Disse, [21] and the specialised matrix is
responsible for maintaining the quiescent non-proliferative phenotype. The
matrix also has a role in maintaining the normal physiological function of the
other cell types it has contact with, namely Kupffer cells, sinusoidal
endothelial cells and hepatocytes. [23] Hepatocytes have receptors on
their cell surfaces to recognize matrix components such as ﬁbronectin,
laminin and collagen type IV. [24, 25]
1.2 The ﬁbrotic sinusoid
In liver ﬁbrosis there is a quantitative and qualitative change in the
extracellular matrix. There is increased deposition of all matrix components,
however ﬁbrillar collagens are increased disproportionately. This leads to
phenotypic changes in all cells exposed to this neo-matrix. Hepatocytes
lose their villi, endothelial cells lose their fenestrations and hMFBs are
maintained in the activated state (Figure 1.2).
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Figure 1.2. The normal sinusoid maintains fenestrated endothelial cells and
hepatocytes with villi. The space of Disse contains basement
membrane-type extracellular matrix maintaining HSCs in their quiescent
phenotype. As a consequence of liver injury stellate cell activation leads to
the deposition of scar matrix within the space of Disse causing phenotypic
changes in hepatocytes and endothelial cells. Figure taken from Friedman
et al. [26]
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1.3 Hepatic stellate cell activation and the
activated phenotype
Hepatic stellate cell activation represents a key step in the ﬁnal common
pathway that results from acute and chronic liver injury. [3] Phenotypically,
HSCs undergo a range of fundamental changes (Figure 1.3). They adopt a
myoﬁbroblast-like phenotype and shed stored retinoids (Figure 1.3). In
addition, a number of contractile proteins are expressed, characteristically
including -smooth muscle actin (-sma). [4]
The hepatic myoﬁbroblast expresses a range of different receptors on its cell
surface, allowing it to respond in differing ways from the quiescent hepatic
stellate cell, and reﬂecting its role as a wound healing myoﬁbroblast. For
example, hMFBs express PDGF receptors, facilitating a proliferative response
on exposure to PDGF. [27] IL-10 expression has been demonstrated in hMFBs
in vitro and in vivo, and IL-10 receptor mRNA expression was induced by
injury in vivo and culture activated hMFBs. [28] Hepatic MFBs also express
TGF- receptors. [29]
The process of activation follows a predictable course both at the
molecular and cellular level. The nuclear events underlying this change are
complex but increasingly understood. [30]
The activation of HSCs is accompanied by proliferation, accounting for the
greatly increased numbers of hMFBs observed in ﬁbrotic livers when
compared with the numbers of quiescent HSCs seen in normal livers.
1.4 The production of ﬁbrotic matrix
Hepatic MFBs secrete excess amounts of ﬁbrillar collagens I and III that
predominate in the matrix of ﬁbrotic liver, in addition to a range of other
matrix components. As discussed previously, there is an increase in all matrix
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Figure 1.3. The hMFB is a proliferative cell that expresses contractile proteins,
ﬁbrillar collagens and other matrix components, and promotes degradation
of normal matrix. Retinoids are lost during activation. Figure taken from
Friedman et al. [26]
components and collagen types in ﬁbrotic liver but with the production of
the ﬁbrillar collagens being increased disproportionately and deposited in
unfamiliar sites.
The major cellular source of this is the hMFB. [1, 2] Using the model of HSC
activation in vitro by culture on tissue culture plastic, increased levels of
mRNAs coding for pro-collagens I, III and IV have been identiﬁed in hMFBs.
[31] Transcripts and protein of non-collagenous matrix components such as
laminin, ﬁbronectin, elastin, and tenascin have also been identiﬁed.
[21, 32–35] Dystroglycan, a membrane component of the
dystrophin-glycoprotein transmembrane complex needed for the spatial
organization of laminin is up regulated in hMFBs compared with their
quiescent counterparts. [36]
1.5 Extracellular matrix degradation by MMPs
The accumulation of matrix in liver ﬁbrosis is a result of a reduction in the
normal matrix degradation pathways as well as increased production,
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resulting in a net increase.
Matrix metalloproteinases (MMPs) are a group of enzymes with a
physiological role in normal matrix homeostasis, and a pathological role in
the development of liver ﬁbrosis. [37, 38] There are a wide range of
substrates susceptible to the action of these enzymes, including both
collagenous and non-collagenous matrix components.
The activity of the MMPs is not purely regulated by the rate of their
transcription and translation but also heavily dependent on
post-translational processing. MMPs are transcribed and translated initially
as pro-enzymes, requiring the cleavage of a prodomain that functions to
inhibit the catalytic domain. This is achieved in vivo in a number of different
ways, depending in part on the speciﬁc MMP concerned.
The MMPs can be broadly grouped together based on their substrate
speciﬁcity although there is a degree of overlap using this system. Those
MMPs that are able to degrade mature interstitial collagen (Types I, II, III,
and X) by cleaving  chains of a speciﬁc Gly-Ile/Leu site are said to have
interstitial collagenase activity. MMP-1 (Interstitial collagenase), -8
(Neutrophil collagenase), -13 (Collagenase- 3) and -14 (MT1-MMP) [39] have
this ability, although their individual afﬁnities for the various substrates vary.
The gelatinases, gelatinase-A (MMP-2) and gelatinase-B (MMP-9), are
enzymes that degrade denatured interstitial collagen (i.e. gelatin) in
addition to other non-collagenous matrix components. MMP-2 may also
have interstitial collagenase activity. [40]
The membrane-type MMP (MT-MMPs) are a subgroup that have a
transmembrane domain or anchor to glycosyl phosphatidyl inositol (GPI),
thus rendering them membrane bound. They have a broad substrate range,
some with interstitial collagenase activity, as well as being able to act upon
a variety of non-collagenous and gelatin substrates. Importantly, certain
MT-MMPs have a role in the activation of pro-MMPs.
Activation of pro-MMPs is achieved in vivo in a number of different ways
(Figure 1.4) . MMP-3 (stromelysin) activates a number of other pro-MMPs.
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Figure 1.4. All MMPs are released as inactive precursor forms (proMMPs)
and require activation in the extracellular space by limited proteolysis
(proteolytic activation) or chemical modiﬁcation of the cysteine residue in
the conserved PRCGVPD motif of the autoinhibitory domain (chemical
activation). MMPs thus activated not only degrade extracellular matrix
(ECM) macromolecules, but also contribute to the extracellular release of
cell-surface molecules, or inactivate soluble bioactive proteins, which
promote tissue injury and inﬂammatory response. Figure taken from
Okamoto et al. [41]
MMP-3 can be activated by plasmin and a number of enzymes related to
inﬂammation such as tryptase from mast cells [42] and neutrophil elastase.
[43] This means that inﬂammation can produce widespread MMP activation
and matrix destruction. The stromelysins and MMP-1 and -8 are activated by
plasmin, which is itself produced from plasminogen by the action of the
plasminogen activators uPA or tPA, a step that is inhibited by plasminogen
activator inhibitor-1 (PAI-1). [44] The full activation of MMP- 1 requires the
action of MMP-3 in addition to plasmin. [45] Gelatinase A is activated by
MT1-MMP at the cell surface, [46] a process which requires TIMP-2 to form
the activating complex. [47]
1.6 Inhibition of MMPs - TIMPs
Natural inhibitors of MMP activity are present within the liver under normal
conditions and their expression changes during the development of liver
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ﬁbrosis with the net outcome facilitating excess matrix deposition. [48]
2-macroglobulin is a large serum proteinase inhibitor that inhibits all MMPs
in a general manner. [49] Within the liver 2-macroglobulin is produced by
hepatocytes and HSCs [50]. However in vivo probably the most
quantitatively signiﬁcant inhibitors of MMPs are the Tissue Inhibitors of
Metalloproteinase (or TIMPs). [48]
There are four TIMPs described (TIMPs 1-4) and all are able to inhibit all
MMPs, but with differing afﬁnities. [51] The only exception to this is that
TIMP-1 is unable to inhibit MT1-MMP , MT2-MMP , and MT5-MMP . [52] They bind
non-covalently and reversibly to the active site of the MMPs. The TIMPs are
often produced by the same cell types that produce the MMPs themselves.
Both TIMP and MMP expression can be inﬂuenced by soluble factors in a
complex manner, increasing or decreasing expression of either type of
molecule. For example, TGF-ß1 induces TIMP-1 and inhibits TIMP-2 expression
[53] but also inhibits MMP-3 and -1. TIMPs also appear to function as survival
factors, preventing certain cells from undergoing apoptosis. [54, 55]
1.7 TIMP and MMP expression by hMFBs in ﬁbrotic
liver
In vivo and in vitro experimentation has helped to delineate the role of
hMFB expression of MMPs and TIMPs in the development of liver ﬁbrosis.
Much work has utilised a tissue culture model of activation of HSCs by
culture on tissue culture plastic in serum containing medium. This produces
a fully activated phenotype; the retinoids are shed early in this process, and
there is expression of -smooth muscle actin and pro-collagen 1 after 14
days of primary culture, and this phenotype persists with subsequent
passaged cultures.
The study of cultured rat HSCs has demonstrated that hMFBs express MMPs
and TIMPs in a sequence during the course of activation. During the ﬁrst
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Figure 1.5. Expression of MMPs and TIMP during activation of HSCs. There is
expression of collagenolytic components during the initial stages of
activation in contrast to the persistent expression of ﬁbrillar collagens and
TIMPs to promote ﬁbrogenesis once activation is achieved.
three days of primary culture, HSCs have a predominantly matrix-degrading
pattern of gene expression, expressing MMP-3, [56] MMP-13 [57] (in rats) but
not TIMP-1 or -2. It has been suggested that this is an acute phase response
that could contribute to tissue damage seen with an acute liver injury.
HSCs in early primary culture also express elements of the plasminogen
activating system that are necessary for MMP-1 activation. [58] Similar
results were obtained with cultured human HSCs except that the main
interstitial collagenase expressed is MMP-1. [59] After the initial stages of
activation, MMP- 1 or -13 expression is markedly reduced, and TIMP-1 and -2
expression increases [57, 59, 60] (Figure 1.5) . This pattern of expression
favours the accumulation of ﬁbrillar collagen-rich matrix. There is also
increased expression of MMP-2 [61] and MT1-MMP .
Plasma-membrane enriched fractions from hepatocytes and conditioned
medium from pure cultures together promote activation of MMP-2. [62] The
combination of MMP-2, MT1-MMP and TIMP-2 allows the activation of
MMP-2. This means that hMFBs have the capacity to degrade matrix rich in
collagen IV that is found in normal liver within the space of Disse.
In culture, the activation of MMP-2 was enhanced in the presence of
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collagen I, but not laminin. [63] This effect was blocked by antibodies
against 21 integrins [64] and demonstrates that hMFBs are responsive to
the extracellular matrix in which they reside. MMP-2 was shown to be
expressed at maximal levels corresponding to the peak time of hMFB
proliferation, and antisense oligonucleotides to pro-MMP-2 or experimental
MMP inhibitors reduced the proliferation of cultured hMFBs by >50%. [61]
However, although there is still potential gelatinase activity allowing the
degradation of such substrates as collagen IV, the overall amount of all
matrix components including collagen IV is increased in ﬁbrotic liver. It may
be that the gelatinase activity is restricted to the sinusoidal areas where
ﬁbrillar matrix is deposited, and other regions see increased deposition.
Indeed, in tissue culture experiments where the inhibitory effect of TIMP is
removed by chromatography, the activity of hMFB derived MMP-2 increases
20 fold, indicating that hMFBs mediate a profound inhibition of matrix
degradation. The inhibition of hMFB TIMP-1 expression by antisense TIMP-1
recombinant plasmids increases collagenase activity in the media of
cultured hMFBs and inhibits accumulation of type I and III ﬁbrillar collagens
in vitro. This illustrates the complex nature of the interactions between
matrix, TIMPs, and MMPs in relation to HSCs and hMFBs. [65]
Much of this work has been supported by in vivo studies, both in animal
models and studying diseased human liver. Increased TIMP-1 and -2 mRNA
and protein expression has been described in the ﬁbrotic livers of patients
with primary sclerosing cholangitis, primary biliary cirrhosis, biliary atresia
and autoimmune chronic active hepatitis. [60]
During the development and progression of chronic liver ﬁbrosis in animal
models, the levels of MMP-13 or -1 expression do not change [66] but there
is a marked increase in the expression of TIMPs -1 and -2. [57, 67] In situ
hybridization studies have localized the expression of these mainly to hMFBs.
This increased expression of TIMP-1 has been shown to occur prior to the
increase in pro-collagen I expression and collagen I deposition, [57]
implying that ﬁbrotic matrix is deposited in a microenvironment where the
degradative capacity has already been reduced. The production of active
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MMP-2 and MT1-MMP demonstrated in vitro has also been borne out by in
vivo studies. [66, 68, 69] In chronic liver ﬁbrosis, there is a prolonged increase
in pro-MMP-2 expression, and increased active MMP-2. [70, 71] The
production of pro-MMP-2 and MT1-MMP has been localised in sections of
diseased liver to hMFBs. [69]
The importance of TIMP-1 in the development of liver ﬁbrosis has been
further highlighted by studies using mice overexpressing human TIMP-1.
Overexpression of TIMP-1 in the absence of liver injury did not produce any
liver ﬁbrosis, as adjudged by hepatic collagen accumulation. [72] There was
also no difference between -smooth muscle actin mRNA expression in
wild-type and TIMP-1 overexpressers, implying that TIMP-1 by itself did not
produce any HSC activation. However after experimental liver injury with
carbon tetrachloride the over-expressing group had a seven fold increase in
liver ﬁbrosis measured by densitometric analysis and hydroxyproline content.
Collagen I and IV accumulation was also markedly increased.
TIMPs are also able to inﬂuence other cellular behaviour. They have been
shown to affect apoptosis and proliferation in various cell types. For
example, TIMP-1 protects human breast epithelial cells against apoptosis,
[54, 55] an effect independent of the MMP inhibiting property of the
molecule. However, in human T lymphocytes, TIMP-2 is pro-apoptotic, [73]
and acts as a growth factor for mesenchymal cells in rat kidney. [74]
TIMP-1 mediates the development and persistence of liver ﬁbrosis not merely
by inhibiting MMP activity but also by enhancing hMFB survival, acting as an
autocrine and paracrine survival factor. TIMP-1 protein was shown to inhibit
apoptosis induced by cycloheximide, serum deprivation or nerve growth
factor in cultured hMFBs, and in human hMFBs by cycloheximide and serum
deprivation. [75] The autocrine and paracrine role of TIMP-1 in hMFB cultures
was established by the demonstration that the addition of a TIMP-1
neutralizing antibody to hMFB cultures in normal growth media increased
the rate of apoptosis. In hMFBs, this anti-apoptotic effect of TIMP-1 was
dependent on the MMP-inhibiting capacity since a mutated form of TIMP-1,
whose MMP inhibiting domain was defective but was otherwise normal, did
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not produce the same anti-apoptotic results. Moreover, a synthetic
MMP-inhibitor was shown to protect hMFBs from apoptosis. [75] As a
consequence of both inhibition of matrix remodelling and prevention of
hMFB apoptosis there was reduced spontaneous resolution of liver ﬁbrosis in
mice that overexpressed TIMP-1 in the liver, under the control of the albumin
promoter. [76]
1.8 Evidence for reversibility
The concept of reversibility of liver ﬁbrosis and cirrhosis is not a radical one.
Connective tissue stains have allowed identiﬁcation of the presence of, and
subsequent remodelling of, both immature and mature ﬁbrotic matrix. The
reticulin stain identiﬁes gross bundles of collagen ﬁbres but this appearance
can also be seen with extensive hepatocyte necrosis and subsequent
sinusoidal collapse. An orcein stain in parallel identiﬁes orcein positive
ﬁbrotic matrix that is present only around portal tracts in the normal liver,
differentiating ﬁbrotic matrix from collapse. In addition, both Masson’s
trichrome and Verhoeff’s elastic stains are able to indicate the maturity of
ﬁbrotic matrix; thick, mature collagen bundles are stained darker with both
tinctorial stains. [77]
Reversal of cirrhosis was reported over 30 years ago in patients with
haemochromatosis after long-term intensive venesection. [78] Regression of
scarring has also been reported in patients with autoimmune chronic active
hepatitis, [16, 79] illustrated in Figure 1.6, and primary biliary cirrhosis [80]
after successful immunosuppressive therapy. Further support has also been
accrued from lamivudine treatment in chronic hepatitis B patients [81] and
following treatment of chronic delta hepatitis with long-term interferon-.
[82] In addition, a recent study demonstrated regression of liver ﬁbrosis after
surgical biliary decompression in patients with chronic pancreatitis and
stenosis of the common bile duct. [83]
A justiﬁed criticism of many of the earlier reports of reversibility of ﬁbrosis and
cirrhosis was the relatively small numbers of patients analyzed. However, the
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results from large-scale clinical trials in the treatment of chronic hepatitis C
have more recently provided compelling and robust data. Poynard et al
[84] analysed the results of 4 previous major clinical trials involving 3010
patients with chronic hepatitis C randomised to various treatment regimens
with either interferon or pegylated interferon, with or without the addition of
ribavirin. Major beneﬁcial effects of antiviral therapy on liver ﬁbrosis were
observed, particularly with combination therapy. The diverse aetiologies in
which these observations of reversibility have been made suggest the livers
capacity to remodel scar tissue is a generic phenomenon [85] which, if
harnessed and manipulated, may offer innovative therapeutic approaches.
1.9 Hepatic MFB apoptosis and recovery from
ﬁbrosis
The mechanisms underpinning the principle that liver ﬁbrosis is not
irreversible have been delineated using animal models. These have
conﬁrmed a great capacity for resolution and remodelling of ﬁbrotic matrix
if the pro-ﬁbrotic injury is withdrawn. [14]
In both bile duct ligation and carbon tetrachloride (CCl4) induced rat liver
ﬁbrosis [14, 76] there is spontaneous recovery of the normal liver architecture
after reanastomosis of the bile duct [86, 87] or cessation of CCl4
administration, [14, 69] respectively. During this recovery period the liver
architecture is remodelled, with resorption of ﬁbrotic matrix and
reconstitution of the normal architecture. The number of hMFBs is reduced
dramatically during this period. A signiﬁcant part of this loss of hMFBs results
from apoptosis.
Apoptosis is a mechanism of cell death that utilises the biochemical
machinery of the dying cell in a tightly controlled manner. It was ﬁrst
described as a mode of cell death distinct from that caused by trauma in
rat liver based on electron microscopic appearances, when it was
described as programmed cell death. [88] It was ﬁrst termed apoptosis,
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Figure 1.6. Photomicrograph of 2 liver biopsies from a patient with acute
onset autoimmune chronic active hepatitis at the time of presentation prior
to treatment with corticosteroids (A) and 18 months later (B), demonstrating
almost complete resolution of extensive ﬁbrosis. Reticulin stain, scale bar
100m.
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from the Greek meaning “dropping off”, in 1972, reﬂecting the
characteristic blebbing of the cytoplasm to form apoptotic bodies. [89]
1.9.1 Physiological and pathological apoptosis
Apoptosis can occur in physiological or pathological situations. The carefully
regulated death of an apoptotic cell does not lead to inﬂammation, and
thus bystander tissue damage. It is therefore ideal as a means of deleting
unwanted individual cells or populations, for example during
embryogenesis. [90] It is also a signiﬁcant mechanism in the immune system,
deleting both lymphocytes recognising self antigens during maturation and
removing inﬂammatory cells after an appropriate immune response. [91]
Loss of cells by apoptosis also occurs in pathological situations. The intimate
link between the cell cycle and apoptosis allows cells whose DNA is too
badly damaged to be repaired by native cell processes to be deleted. [92]
In this context apoptosis represents a signiﬁcant host oncosupressor
mechanism. In some viral infections, for example hepatitis C virus infection,
cell loss is mediated by apoptosis. [93]
1.9.2 Morphology of apoptosis
An apoptotic cell undergoes a number of characteristic morphological
changes (Figure 1.7). [94, 95] The cell shrinks and the chromatin condenses,
accounting for the intense bright staining pattern visible with acridine
orange. The nucleus fragments, and nuclear material and cytoplasmic
components form blebs, ultimately becoming apoptotic bodies. These are
removed by phagocytes.
A group of cysteine proteases called caspases broadly account for these
morphological changes. [97] These are present as inactive procaspases,
and a protein activation cascade follows initiation of the process,
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Figure 1.7. Morphological changes during apoptosis. During apoptosis there
is shrinkage and blebbing of the cytoplasm, ultimately leading to
fragmentation into apoptotic bodies. In contrast there is loss of membrane
integrity and leakage of cell contents in necrosis. Figure taken from Robbins
and Cotran Pathologic Basis of Disease. [96]
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Figure 1.8. Initiation of apoptosis. Apoptosis can be triggered by a
pro-apoptotic stimulus or by the withdrawal of survival factors. Figure taken
from Robbins and Cotran Pathologic Basis of Disease. [96]
producing active effector caspases. Active effector caspases have
endonuclease activity, cleaving chromatin between histones thus creating
fragments that are multiples of 200bp. When fragments of this nature are
separated on an agarose gel they produce a characteristic “DNA ladder”.
In contrast the haphazard degradation that occurs in a necrotic cell
produces a smear when separated.
1.9.3 Mechanisms of apoptosis
Apoptosis can be triggered by 2 broad means, the extrinsic and intrisnsic
pathways. (Figure 1.8) . Although the triggering event differs, and the
molecules that take part in the proximal pathways are different, both
mechanisms lead to a ﬁnal common executioner pathway.
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1.9.3.1 Extrinsic pathway
Apoptosis can be triggered by an extracellular ligand providing a
pro-apoptotic signal via a “death receptor” - death by design. Many
receptors can provide a pro-apoptotic signal, and many of these are
members of the tumour necrosis factor receptor superfamily (TNFRSF) that
possess an intracellular death domain (DD). The DD mediates
protein-protein interactions after ligation. Some members of the TNFRSF do
not have a formal DD but are still able to provide a pro-apoptotic signal (for
example p75NTR, TNFRSF 16). The most well known example of this type is the
receptor Fas. Hepatocytes express Fas and upon ligation a massive amount
of hepatocyte death occurs. [98–101] Protein-protein interactions lead to
the formation of a death inducing signalling complex (DISC) and conversion
of procaspase-8 to active caspase-8. [102] That, in turn, leads to activation
of the ﬁnal common executioner caspase pathway involving caspase-3.
1.9.3.2 Intrinsic pathway
A diverse range of non-receptor mediated stimuli act to initiate the intrinsic
pathway. They all act through mitochondrial events. Withdrawal of
extracellular stimuli that usually provide a cell with growth promoting or tonic
survival signals can can trigger these events - death by neglect. A range of
positive stimuli such as toxins, radiation and free radicles also initiate this
pathway. All of these stimuli lead to loss of the mitochondrial membrane
integrity allowing leakage of pro-apoptotic proteins into the cytosol. [103]
One group of proteins that enters the cytosol includes cytochrome c, which
activates APAF-1 and procaspase-9 to form an apoptosome, [104] leading
to caspase-9 activation.
The control of these mitochondrial mediated events occurs through the
bcl-2 family of proteins. [105] Bcl-2 family members share a number of BH
homology domains and are either anti-apoptotic or pro-apoptotic. Bcl-2 is
the archetypal anti-apoptotic family member, ﬁrst described and named
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after identiﬁcation in B cell lymphoma. Bcl-2 and other anti-apoptotic
proteins are present within the mitochondrial membrane. If levels of the
anti-apoptotic proteins fall relative to the pro-apoptotic bcl-2 family
members, pro-apoptotic proteins replace the anti-apoptotic proteins in the
mitochondrial membrane. This increases the permeability of the
mitochondrial membrane and allows the pro-apoptotic mitochondrial
components to leak out.
Despite their description as 2 separate pathways there is more recent
evidence that there is cross-talk between components classically thought of
as part of the extrinsic pathway and the intrinsic pathway.
1.9.3.3 Common execution pathway
The extrinsic and intrinsic pathways both lead to the initiation of the
execution pathway, characterised by caspase activation, leading to
endonuclease and protease activity. Caspase-3, -6 and -7 are effector
caspases of this nature, with a diverse range of substrates. [106, 107] It is the
activity of these caspases that leads to the characteristic morphological
disintegration of apoptotic cells. Caspase-3 has been identiﬁed as the most
potent effector caspase, and is activated by a number of different initiator
caspases. It is for this reason that measurement of caspase-3 activity or
identiﬁcation of cleaved caspase-3 in tissue is a recognised means of
quantifying apoptosis.
The ﬁnal part of apoptosis is phagocytosis of apoptotic bodies and debris.
Changes is membrane lipid distribution and the externalisation of
phosphatidylserine (PS) are observed, events that also may be caspase
mediated. [108] The appearance of PS on the external surface of apoptotic
cells and bodies aids their phagocytosis. [109] This allows the entire process
of apoptosis and removal of debris to occur without inﬂammation and, thus,
bystander tissue damage.
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Figure 1.9. Mammalian neurotrophin isoforms. Each of the 4 neurotrophins is
translated as a precursor that is cleaved to release the mature protein.
BDNF has 2 cleavage sites. Figure taken from Roux et al. [111]
1.9.4 Factors inﬂuencing hMFB apoptosis
A number of factors have been shown to inﬂuence hMFB apoptosis. Some
soluble factors, such as insulin-like growth factor I (IGF-1), prevent hMFBs from
undergoing apoptosis triggered by the removal of growth factor-containing
serum. [87] Other soluble factors, such as nerve growth factor (NGF) are
proapoptotic. [110] Hepatic MFB survival is also inﬂuenced by cell-matrix
interactions [5] and appears to be promoted by contact with collagen I.
1.10 Neurotrophins
The neurotrophins comprise nerve growth factor (NGF), the archetypal
family member and ﬁrst growth factor described, brain-derived neurotrophic
factor (BDNF), neurotrophin 3 (NT-3), and neurotrophin 4/5 (NT-4/5) [111]
(Figure 1.9). This family of growth factors is best described in the neurological
system and neuronal cell types. The cellular effects of the neurotrophins
depend on the combination of receptors present on the cell surface. In
many neuronal cells neurotrophins promote survival and differentiation
although depending on the speciﬁc context they can also cause apoptosis.
The neurotrophins are highly conserved across vertebrates. [112] All 4
neurotrophin genes transcribe 30-33 kDa precursor proteins, the
pro-neurotrophins. These glycosylated proteins, classically, require the
cleavage of a prodomain to release the active mature neurotrophin. This
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cleavage event occurs intracellularly, and is achieved by the action of
members of the mammalian subtilisin/kexin-like family of serine proteases
called prohormone convertases, speciﬁcally furin and convertases 1 and 2
(proprotein convertase subtilisin/kexin type 1 and 2). [113–118] All
neurotrophins exist in their mature form as non-covalently linked
homodimers.
ProNGF is a 32kDa glycosylated precursor that is processed to mature NGF,
a 13.2 kDa protein. NGF is released by sensory target organs to direct the
growth of neurons towards the target, and some neurotrophins are secreted
by neurons themselves. Disordered neurotrophin production can be
associated with disease, [119] and neurotrophins can be released as a
consequence of cellular injury, for example ischaemia. [120–122]
Neurotrophins can also be synthesized by non-neuronal cells, for example
pancreatic adenocarcinoma cells [123] and activated mast cells. [124, 125]
Expression in non-neuronal cells can be either constitutive or inducible by a
variety of stimuli.
1.11 Neurotrophin receptors
The diverse functions of neurotrophins are mediated by 2 classes of cell
membrane receptor - the tyrosine kinase receptors (Trk) and p75
neurotrophin receptor (p75NTR). These 2 classes, when present on the same
cell, interact to produce effects that can vary signiﬁcantly from those
produced by a single receptor alone.
1.11.1 Trk receptors
The tropomyosin-related kinase (Trk) tyrosine kinase receptors are a closely
related family of proteins sharing signiﬁcant homology. [126] TrkA was ﬁrst
identiﬁed as a trk proto-oncogene product as a cell membrane receptor
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Figure 1.10. Mammalian Trk tyrosine kinase isoforms. The 3 genes encode a
full-length receptor and alternatively spliced isoforms. TrkA and TrkB
receptor isoforms lacking a short sequence in the extracellular domain, TrkB
and TrkC receptors lacking the intracellular kinase domain, and a TrkC
receptor with an insert in the kinase domain are produced by alternative
splicing. Figure taken from Roux et al. [111]
whose tyrosine kinase activity was triggered by ligation with NGF, [127, 128]
and which mediated the mitogenic effects of NGF and NT-3 in NIH 3T3 cells.
[129]
The 3 Trk receptors (TrkA, TrkB and TrkC) are type I transmembrane proteins.
The extracellular domain of the receptor contains 2 IgG-like domains
immediately adjacent to the membrane (domains 4 and 5). The N-terminal
part of the protein consists of 2 cysteine cluster regions, domains 1 and 3,
ﬂanking a leucine rich repeat domain (Figure 1.10). Ligand interaction is
with the Ig-like domains with some interaction with the leucine rich repeats
of domain 2. [130, 131]
Interaction of neurotrophins with their appropriate Trk receptor produces
receptor dimerisation and autophosphorylation [132, 133] of 7 intracellular
tyrosine residues. [134] The phosphorylated tyrosine residues allow
interaction with cytoplasmic signalling molecules that signal cell growth and
differentiation through a variety of pathways.
These pathways are reasonably well described and include Ras, through
MAPK/ERK pathways, [135–137] phosphatidylinositol 3’-kinase via Ras
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independent and dependent mechanisms, [138–140] and phospholipase
C- pathways. [141–143]
In contrast with p75NTR, the 3 Trk receptors vary in their afﬁnity for the different
neurotrophins when they are partnered with p75NTR. [144, 145] In the
absence of p75NTR each Trk receptor has the same afﬁnity for all of the
neurotrophins. In the presence of p75NTR the afﬁnity and speciﬁcity of TrkA for
NGF is increased signiﬁcantly, [146] the afﬁnity and speciﬁcity of TrkB for
BDNF is increased signiﬁcantly, [147–149] NT-4/5 binds preferentially to TrkB
[150] and TrkC interacts with NT-3. [151]
1.11.2 The low afﬁnity nerve growth factor receptor p75NTR
p75NTR is a member of the TNF receptor superfamily (TNFRSF16), the ﬁrst
receptor described for NGF. [152] In the absence of any Trk receptors p75NTR
binds all neurotrophins with equal afﬁnity, orders of magnitude lower than
the interaction between Trk receptors and their ligands in the presence of
p75NTR - for this reason p75NTR is also known as the low-afﬁnity nerve growth
factor receptor (LANGFR). [144]
As a member of the TNF receptor superfamily that includes Fas and CD40,
p75NTR shares cysteine rich regions in the extracellular domain (Figure 1.11).
p75NTR is well preserved in vertebrate species, and in humans the gene is
present on 17q12-17q22. [152–154]
p75NTR is a type I 399 amino acid transmembrane protein, and is initially
translated with an additional 28 amino acid signal peptide. In the
extracellular domain there is a single N-linked glycosylation at position 33,
and there are a number of O-linked glycosylations in the juxtamembrane
region. The extracellular domain contains the characteristic TNFR
superfamily structure of 4 cysteine rich domains, each containing 6 cysteine
residues. Each cysteine rich domains contains 3 disulphide bridges. Highest
afﬁnity binding of a ligand with p75NTR requires all 4 cysteine-rich domains
[155, 156] although the most critical may be the second repeat. [157]
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Figure 1.11. Schematic representation of p75NTR. p75NTR is type I membrane
protein with an extracellular domain containing 4 cysteine-rich domains
and multiple glycosylation sites. The intracellular domain contains a type II
death domain, 2 TRAF binding sites, a palmitoylation site, a potential G
protein activation domain and a PDZ binding motif. Figure taken from Roux
et al. [111]
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The intracellular domain contains a juxtamembrane palmitoylation [158]
site, and is phosphorylated on serine and threonine residues. [159] The TNFR
superfamily members do not possess intrinsic enzyme activity but signal via
interaction between domains in the intracellular region and cytoplasmic
signalling proteins. Various TNFR-associated factors (TRAFs) have been
shown to interact with p75NTR and signal via different pathways. [160, 161]
TRAFs are able to interact with a number of different intracellular pathways
in order to mediate neurotrophin-p75NTR axis signalling, for example Src,
NF-B [162] and JNK. [162–164]
The p75NTR intracellular domain also includes an approximately 80 amino
acid death domain (DD). This was originally identiﬁed and named for its
ability to interact with adaptor proteins that lead to caspase activation and
apoptosis. However, death domains do not always function in this way, [165]
and the p75NTR DD is structurally grouped with non TNFR proteins (such as
ankyrin) rather than receptors like Fas. [111] The cytoplasmic proteins that
interact with the DD in Fas are not able to interact with that of p75NTR, [166]
so the role of the DD in p75NTR is uncertain and, despite the nomenclature,
may not be responsible for the proapoptotic effects of p75NTR signalling.
1.11.2.1 Receptor variants
A splice-variant isoform, called s-p75NTR, results from the removal of exon III
producing a protein lacking the ligand binding domain. [167] This short
isoform is expressed in a variety of tissues but the functional consequence of
this receptor is unclear. The s-p75NTR variant is still expressed in
p75NTR/exonIII-/- mice, which are therefore hypomorphs rather than full
knockouts.
Homologues of p75NTR have been identiﬁed (Neurotrophin receptor
homologs, NRH); [168] called NRH1 in ﬁsh, birds and amphibians, and NRH2
(PLAIDD [169] or NRADD [170]) in mammals. NRH2 does not have the
cysteine rich ligand binding domains but does have the cytoplasmic death
domain. It is expressed in vivo in a number of cell types. It is not capable of
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binding NGF but does interact with TrkA receptors to produce high afﬁnity
neurotrophin binding. [171] Expression of this protein alone produced
apoptosis in a number of cell types. [170]
1.11.2.2 p75NTR functions
In the absence of Trk, p75NTR is a proapoptotic receptor, although this is still
dependent on the cellular context. For example, cultured cortical neurons
that express p75NTR in the absence of TrkA are protected from glutamate
induced cell death by NGF. [172, 173] In addition to survival, there is
evidence that p75NTR can promote other cellular functions such as
migration. [174]
The most well-described effect of p75NTR signalling in the absence of Trk
receptors is apoptosis. The crystal structure of NGF complexed with p75NTR
has shown that NGF homodimers bind asymmetrically to a single p75NTR
molecule. By binding with the homodimeric interface this interaction
produces a conformational change that disables the second p75NTR
binding site on the dimer [175] (Figure 1.12) .
Most evidence supports JNK activation as the pathway that mediates
apoptosis, in a mechanism distinct from the death-domain mediated cell
death produced by other TNFR family members. Brieﬂy, JNK activation leads
to c-jun phosphorylation that in turn leads to the activation of BH-3 only
pro-apoptotic bcl-2 family members Bad and Bim. [177, 178] Interaction of
these molecules leads to mitochondrial translocation of Bax with the
consequent release of cytochrome c and caspase activation. [178]
1.11.2.3 p75NTR receptor processing
In common with many transmembrane or membrane anchored receptors,
p75NTR is subject to proteolytic processing and receptor-intramembrane
proteolysis. [179] -secretase [180] and TNF convertases (TACE-dependent)
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Figure 1.12. Structure of NGF complexed with p75NTR. (A) p75NTR binds along
one side of the NGF homodimer. Backbone representation of NGF
monomer A is coloured green; monomer B, blue; and p75NTR, purple.
Disulﬁde bonds are shown as green sticks. Other ﬁgures have the same
colouring scheme. (B) p75NTR binds across the NGF dimerisation interface.
Front view, with a horizontal rotation of 90° from the orientation of the
complex seen in (A) with NGF depicted as surface and p75NTR as tube. (C)
p75NTR uses the opposite side as TNFR-SF members for ligand binding, but
both bind within their ligands’ oligomer interfaces. One copy of TNF-R1 from
the TNF--TNF-R1 complex [176] is superimposed with p75NTR from the
NGF-p75NTR complex. The two receptors used in superimposition are
depicted in main-chain traces, and the other molecules in space-ﬁlling
format. Figure taken from He et al. [175]
November 12, 2008 30Chapter 1. Introduction
[181] shedding of the majority of the extracellular domain of p75NTR means
that ligand-dependent signalling of the receptor is abolished but the
remaining membrane anchored intracellular domain may still be able to
function to generate the high-afﬁnity interactions of Trk receptors with their
favoured neurotrophin. The release of ligand-binding domains into the
extracellular milieu may serve to create decoy receptors and thus reduce
ligand-dependent cellular effects. Furthermore, -secretase cleavage and
release of the extracellular domain can be followed by -secretase
cleavage within the intracellular domain. [179, 182]
Although nuclear translocation of the liberated product has been shown,
this product is not, in itself, a transcription factor. Interaction of this
intracellular product with factors that are known transcriptional regulators
suggests that some signalling effect may be achieved. [183] However,
binding of NGF to p75NTR does not lead to -secretase cleavage of the
receptor and so the importance of this potential signalling mechanism is
unclear. [182] Metalloproteinases within the extracellular environment may
also be able to release the extracellular domain, the signiﬁcance of which is
also unclear. [181]
1.12 The role of proNGF
Pro-neurotrophins were readily dismissed as mere precursors of their mature,
active counterparts. They were thought to be simply involved in assisting the
folding and secretion of the protein. [184, 185] However, the last 10 years
has provided a resurgence in the importance of the proneurotrophin,
particularly proNGF.
1.12.1 ProNGF as an extracellular molecule
The highly conserved nature of the prodomain regions across species [186]
lead to speculation that they may serve additional functions. [187]
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In order to obtain sufﬁcient proNGF in an uncleaved form Lee et al [187]
generated a proNGF molecule that had a point mutation at the site of furin
cleavage, and was thus secreted into the media of transfected cells in
larger amounts. Binding studies showed that this furin-resistant proNGF did
not bind to TrkA but bound to p75NTR with 5 times greater afﬁnity than
mature NGF. The activity of furin-resistant proNGF was consistent with these
ﬁndings since it did not produce TrkA autophosphorylation even at high
concentration but it was 10 times more potent than mature NGF at
producing apoptosis in an NGF-sensitive vascular smooth muscle cell line.
The activity of proNGF was conﬁrmed by Fahnestock et al [188] who
produced a cleavage-resistant proNGF molecule of their own in baculovirus
transfected insect cells, using different modiﬁcation from that of Lee et al.
[187] This form of proNGF produced the same results as mature NGF in a cell
survival assay using an NGF dependent cell type (postnatal day 1 SCG
neurons). Using neurite outgrowth of SCG neurons and PC12 cells as an
alternative bioassay, the Fahnestock cleavage-resistant proNGF exhibited
approximately 20% the activity of mature NGF. In contrast, data from TrkA
cross-linking experiments and determination of the degree of TrkA
phosphorylation showed that the Fahnestock proNGF bound and activated
TrkA in the absence of p75NTR, albeit at 8 fold less efﬁciency than mature
NGF. The difference in the activity and binding properties of these 2 modiﬁed
proNGF molecules may be due to the differences in their generation,
although they have not be compared directly using the same assays.
Conditioned media from activated microglial cells (MGCM) has been
shown to induce apoptosis in a photoreceptor cell line (661w). [189] In light
of the demonstration of proNGF activity it was shown that proNGF was a
constituent of MGCM that accounted for much of this proapoptotic activity,
and this activity was p75NTR dependent [190] but did not involve TrkA.
In Alzheimer’s disease proNGF is the dominant form of NGF in the brain, and
is increased in the brains of patients with AD compared with controls. [191]
This has been implicated in causing the increased neuronal apoptosis
observed in this disease. To demonstrate that the proNGF observed was
November 12, 2008 32Chapter 1. Introduction
biologically active it was isolated and puriﬁed by chromatography from the
brains of patients with AD. The puriﬁed proNGF induced apoptosis in a
p75NTR dependent manner in sympathetic cells and a p75NTR stably
transfected cell line. [192]
ProNGF forms were identiﬁed in the supernatants of cultured cells,
demonstrating that unprocessed forms could be released in both artiﬁcially
transfected and constitutively expressing cells. [187, 193] Furthermore, the
expression of proneurotrophins has been demonstrated in a number of
tissues in vivo, and in the context of disease. [191, 194, 195] In a number of
reports the proneurotrophins are signiﬁcantly more abundant than their
cleaved counterparts. [194, 196, 197]
Whilst the release of proneurotrophins in culture or after transfection is
interesting it does not necessarily follow that proneurotrophins are released
in vivo since the presence of precursors in tissue homogenates would be
expected irrespective of the maturity of the released product. Using a rat
model of brain injury using internal capsule axotomy, proNGF species were
identiﬁed in cerebrospinal ﬂuid by western blotting, demonstrating that
proNGF is released extracellularly in vivo. When CSF from injured animals
was added to oligodendrocyte cultures an increase in apoptosis was
observed, demonstrating that the secreted ligand was active. [198]
ProBDNF is also secreted unprocessed. [117, 187] This extracellular
proneurotrophin is active, shown by its ability to bind to TrkB and induce
autophosphorylation. [117] To exclude the possibility that this effect was due
to cleavage of proBDNF generating active mature BDNF, a furin-cleavage
resistant proBDNF was generated in a manner similar to cleavage resistant
proNGF. This had the same receptor interaction proﬁle as mature BDNF,
binding p75NTR and TrkB but not TrkA or TrkC, and induced TrkB
phosphorylation when added to cells expressing TrkB. [199]
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Figure 1.13. The mammalian Vps10p family. Domain structures of each
receptor are represented. The Vps10p domains extend into the Golgi
network lumen or are extracellular. PKD domains deﬁne an Ig-like region,
and LDL-A/LDL-B and FN-III repeats are motifs originally identiﬁed in the
low-density lipoprotein receptor and ﬁbronectin, respectively. Figure taken
from Barker et al. [201]
1.12.2 Sortilin - a putative proNGF receptor?
Although proNGF is agreed by all researchers to be secreted extracellularly,
and active, it is not clear if its activity is more or less pronounced than
mature NGF. The means by which cleavage-resistant proNGF has been
generated may account for some of this confusion. However, those who
propose proNGF is much more efﬁcacious at producing the effects
observed with mature NGF alone have identiﬁed an authentic high-afﬁnity
receptor for proNGF to account for this apparent difference - sortilin [200]
(Figure 1.13) .
Sortilin is a member of the Vps10p-domain receptors. There are 5 vertebrate
family members, based on a shared N-terminal domain that is very similar to
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the yeast sorting protein Vps10p. [202] Sortilin is ~95kDa type 1
transmembrane protein, and 90-95% of cellular sortilin is located
intracellularly, spanning Golgi membranes. [203] However a small proportion
is present on the cell membrane, leading to sortilin’s description as a non
G-protein coupled neurotensin receptor (NTR3). [204]
The circumstantial relationship between the expression of sortilin and the
timing of apparently proNGF mediated neuronal apoptosis lead to
speculation that sortilin may be an additional receptor mediating this
action. It was demonstrated by Nykjaer and co-workers that whilst mature
NGF bound to sortilin with a lower afﬁnity than its interaction with p75NTR and
TrkA, proNGF bound to sortilin with a much higher afﬁnity that its interaction
with p75NTR and TrkA. [200] ProNGF formed a high-afﬁnity association with
p75NTR and sortilin, and the prodomain speciﬁcally interacted with sortilin.
Using bioassays in which cleavage-resistant proNGF was a much more
potent apoptogen, blockade of sortilin using an excess of neurotensin
reduced the amount of apoptosis by 90%. Schwann cells expressing p75NTR
but not sortilin were resistant to proNGF induced killing but after transfection
with sortilin they became sensitive. Superior cervical ganglion (SCG)
neurons, expressing both p75NTR and sortilin were subject to proNGF induced
apoptosis but this effect was not observed in SCG neurons from p75NTR
deﬁcient mice.
Sortilin may function as a neurotrophin prodomain receptor rather than
being restricted to proNGF. Using a similar approach with cleavage-resistant
proBDNF and a cell line that was susceptible to proBDNF induced apoptosis
it has been demonstrated that both sortilin and p75NTR mediate the effect.
[205] Of note is the apparent inability of this cleavage-resistant proBDNF to
activate TrkB, in contrast to that generated by Fayard et al. [199]
1.13 p75NTR and NGF in liver disease
Expression of neurotrophins and their receptors has been examined in both
normal and diseased livers. In normal human and normal rat livers
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perisinusoidal stellate-shaped cells stained positively for NGF, BDNF, NT-3,
NT-4/5, p75NTR, TrkB and TrkC. [206] There was also NGF positivity in portal
vessel endothelial cells. In the background liver from resections for
hepatocellular carcinoma ﬁbroblast-like cells and hMFBs were
immunopositive for p75NTR; about 60% of -smooth muscle actin positive cells
were p75NTR positive. [207] In this study of HCCs, hMFBs also expressed NGF,
and hepatocyte expression of NGF was not observed in normal livers but
was seen weakly in patients with background cirrhosis or chronic hepatitis.
TrkA expression could not be demonstrated in hepatocytes or sinusoids.
A series of 22 cirrhotic human liver specimens taken from explant livers, a
mixture of post-HCV, post-alcoholic, PBC and PSC, showed a varying
proportion of hMFBs expressing p75NTR and NGF, although no comment
about expression in hepatocytes was made. [208] In biopsies taken from
patients with ﬂorid steatohepatitis and extensive ﬁbrosis or cirrhosis there was
marked expression of NGF within hepatocytes, [209] and marked NGF
expression was observed in the cytoplasm of HCC cells in 61% of cases
examined. [207]
Rodent models of liver ﬁbrosis have also shown modulation of neurotrophin
expression. After a single dose of CCl4 in cohorts of mice, hepatic levels of
Ngfb mRNA determined by real-time PCR were induced after 24 hours,
peaking at 48 hours but returning to normal by 96 hours. [209] This expression
was localised by in situ hybridisation to hepatocytes within acinar zones 2
and 3. A different mechanism of injury, a single intraperitoneal injection of
Gal that induced acute hepatitis, also demonstrated a signiﬁcant increase
in the number of cells reactive for NT-3, NGF, p75NTR and TrkC 36 hours after
the event. [206]
In both CCl4-induced ﬁbrotic and bile duct ligation rat livers there was NGF,
BDNF, NT-3, NT-4/5, TrkB, TrkC and p75NTR immunopositivity in the hMFB
population. [110, 208] Additionally, normal rat cholangiocytes express both
TrkA and NGF and this expression is upregulated in proliferating bile ductules
following 1-week bile-duct ligation (BDL). [210] In a cohort also treated with
anti-NGF neutralising antibody the bile duct mass was reduced with an
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associated decrease in ductular proliferation and an increase in epithelial
cell apoptosis.
Isolation and culture of rat hepatic stellate cells has shown that hMFBs, and
activated pancreatic stellate cells, express p75NTR in vitro. [110] The addition
of recombinant mature NGF in the presence of serum increased the
amount of apoptosis observed on morphological grounds, [110] increased
the number of TUNEL positive cells and increased caspase-3 activity. [209]
NGF also increased hMFB apoptosis in the absence of serum, an effect
inhibited by TIMP-1. [211]
Recent work has examined the role of p75NTR in murine hepatic stellate cell
activation. [212] HSCs isolated from p75NTR deﬁcient mice failed to activate
in the manner observed in wild-type (WT) cells. There was a failure to
achieve a stellate morphology, no identiﬁable -sma and collagen-1
protein, and a reduction in Col1a1 and Tgfb1 gene expression. Adenoviral
delivery of either full-length or intracellular domain p75NTR restored the
wild-type activation phenotype. Lentiviral short hairpin RNA–mediated
knockdown of p75NTR in WT HSCs decreased transdifferentiation into hMFBs
compared with controls. These data suggest a critical role for the
intracellular domain of p75NTR in facilitating HSC transdifferentiation, in a
ligand-independent manner.
1.14 Hypothesis
I examined the hypothesis that nerve growth factor inﬂuences the
development and resolution of liver ﬁbrosis, by inducing hMFB apoptosis via
p75/sortilin stimulation. I undertook the following series of experiments to
achieve the objectives described below:
• To deﬁne the potential paracrine loop involving NGF in established
animal models of reversible liver ﬁbrosis and established ﬁbrosis that
undergoes only partial resolution.
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• To determine the pattern of NGF expression in injured and cirrhotic
human liver.
• To characterise the liver ﬁbrosis phenotype in p75NTR/exonIII-/-
gene-deleted (ligand-incompetent) mice.
• To characterise the mechanisms by which NGF/p75NTR/sortilin inﬂuence
hepatic stellate cell phenotype and behaviour.
• To determine any differential effect of proNGF versus mature NGF on
hMFBs, and the possible mechanisms underlying this difference.
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2.1 Experimental model of progressive ﬁbrosis and
ﬁbrosis recovery
2.1.1 Carbon tetrachloride injury
Carbon tetrachloride (CCl4) is metabolised in the liver by cytochrome P450
to the highly reactive trichloromethyl radical (CCl3). Free radical damage
leads initially to fatty metamorphosis and centrilobular necrosis, followed
longer term by ﬁbrosis and cirrhosis. [213, 214] This type of liver injury, which
shows some features of human steatohepatitis in its pattern of pathologic
evolution, is characterised by early neutrophil inﬁltration with later
macrophage invasion.
2.1.2 Rat CCl4 model
This model had been completed previously in the laboratory. Archived tissue
was available for the work undertaken in this thesis. Liver injury was induced
as described previously. [14] Brieﬂy, cohorts of 12 Sprague Dawley rats were
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injected intra-peritoneally with 0.2ml/100g sterile CCl4 dissolved in a 1:1 ratio
with olive oil twice weekly for 4, 6 and 8 weeks to generate an early
reversible ﬁbrosis and early and established cirrhosis respectively. In addition
a cohort was treated for 12 weeks to establish advanced micronodular
cirrhosis which undergoes only partial resolution over 1 year of follow-up.
For each model, animals were sacriﬁced by schedule one procedure and
livers harvested at peak ﬁbrosis (immediately after the ﬁnal injection of CCl4)
and at 14, 28, 84, 168 and 366 days of spontaneous recovery (n=4 at each
time point in each model). Three normal, untreated rat livers were also
harvested for use as controls in individual experiments.
Harvested livers were split and ﬁxed for subsequent immunohistochemical
analysis or snap frozen in liquid nitrogen for biochemical and molecular
analysis.
2.1.3 p75NTR/exonIII-/- knockout mouse model of hepatic
ﬁbrosis and spontaneous resolution
Breeding pairs of p75NTR/exonIII−/− mice were purchased from Jackson
Laboratories (Bar Harbor, ME). The genotype of the founding pairs of mice
was veriﬁed by PCR following the genotyping protocol and using the primer
sequences provided (using sequences and conditions published by Yeo et
al). [215]
Liver ﬁbrosis was induced in cohorts of age-matched male p75NTR/exonIII−/−
and wild-type (WT) C57BL/6 mice by treatment with 1µl [CCl4:olive oil
(1:3)v/v]/g body weight by intraperitoneal injection twice weekly for 11
weeks. At days 1, 3, 7 and 10 after the last injection animals were killed by
cervical dislocation and livers harvested, n=4-6 at each time point. 6
p75NTR/exonIII−/− and 5 WT mice received olive oil only and served as
vehicle controls.
Harvested livers were split and ﬁxed in formalin for subsequent
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immunohistochemical studies or snap frozen into liquid nitrogen for
biochemical and molecular analysis.
2.1.4 Morphological analysis of rodent livers
Harvested livers from different time points of CCl4 injury and recovery were
ﬁxed in paraformaldehyde, and subsequently processed, embedded in
parafﬁn wax and sectioned by the University of Southampton Medical
School Histochemistry Department. A section from each liver was also
stained with haematoxylin and eosin (H+E) and, for the historical rat model
only, picrosirius red by that department. Immunohistochemical staining of all
rodent models and tinctorial staining of the murine p75NTR/exonIII−/− model
was undertaken personally on unstained sections cut by the department.
Staining with picrosirius red was undertaken to allow morphological
examination (Details in Appendix B).
2.1.4.1 Manual scoring of the degree of ﬁbrosis
Each section was viewed in a blinded fashion and assigned a score based
on an ordinal score of severity of ﬁbrosis. Scoring systems are used in liver
pathology in an attempt to allocate treatment and monitor
histopathological outcome in a standardised manner. This is mainly in the
case of hepatitis C virus infection where a number of scoring systems have
been devised and validated. A modiﬁed version of one of these scoring
systems has been applied to CCl4 induced liver injury in rodents (Table 2.1).
[216]
This scoring system is based upon the presence and distribution of large
ﬁbrotic bands. To assess ﬁne perivenular pericellular sinusoidal ﬁbrosis that
has a “chicken-wire” appearance and is characteristic of steatohepatitis a
second scoring system was employed, modiﬁed from one used previously
(Figure 2.2). [217]
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Score Morphological feature
0 No abnormal ﬁbrosis
1 Focal ﬁbrosis - perivenular and pericellular in zone
3
2 Fibrous tissue linkage of adjacent terminal
hepatic venules but intact architecture
3 Fibrous tissue linkage of adjacent terminal
hepatic venules plus disturbed architecture but
not cirrhotic
4 Early or established cirrhosis
Table 2.1. Gross ﬁbrosis scoring system based on the distribution of ﬁbrotic
bands and gross architectural distortion. [216]
Score Morphological features
0 No sinusoidal ﬁbrosis
1 Occasional sinusoidal ﬁbrosis affecting <25% of
central veins
2 Sinusoidal ﬁbrosis affecting 25-75% of central veins
3 Extensive sinusoidal ﬁbrosis affecting >75% of
central veins
Table 2.2. Scoring system identifying sinusoidal ﬁbrosis. Adapted from Issa et
al 2003. [217]
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To assess the reproducibility of the scoring system for gross architectural
ﬁbrosis the sections of liver from the p75NTR/exonIII-/- murine model were
scored a second time whilst blinded to both the genotype and recovery
time, and the prior assigned score. Unweighted and weighted kappa
statistics were then calculated using the Vassar University online tool. [218]
2.1.4.2 Quantitative image analysis to determine extent of ﬁbrosis
For morphometric analysis of picrosirius red-stained collagen, 10 images
from n=5 or 6 control (olive oil) and n=4-6 CCl4-treated p75NTR/exonIII−/−
and WT mice were acquired digitally whilst blinded to the genotype and
recovery time-point at x400 magniﬁcation. The percentage collagen of
each image was measured using ImageJ [219] running a k-means clustering
algorithm to mask picrosirius red positive areas from the counterstain. [220]
2.2 Tissue culture methods
2.2.1 Isolation of rat HSCs
Appropriate home ofﬁce licences were obtained before any animal work
was undertaken.
Rat HSCs were extracted from normal rat liver by pronase and collagenase
digestion and puriﬁed by centrifugal elutriation as described. [221] Brieﬂy,
after the rat was anaesthetised with an intraperitoneal injection of Sagatal
(12mg/100g body weight), the portal vein was cannulated and secured
with a suture. The liver was perfused with approximately 200ml of HBSS
without Ca2+ at a rate of 15ml/minute and then the liver was removed from
the carcass. Enzymatic digestion of the liver was undertaken ﬁrst with 100ml
of pronase solution (100mg/100ml HBSS with Ca2+, Roche Diagnostics). This
was followed by perfusion with a collagenase solution for approximately 20
minutes (20mg/200ml HBSS with Ca2+, Roche Diagnostics).
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Next the liver was transferred to the tissue culture hood, the capsule of the
liver cut open, and the liver digest ﬁltered through a Nybolt membrane ﬁlter.
HSCs were separated from other cells on the basis of their lower density due
to high vitamin A content. The crude extract was then washed twice in HBSS
with Ca2+ and DNase solution (Roche Diagnostics) and then the cell
suspension was made up to 44.4ml and are separated by adding to a
density gradient made from 15.6ml HBSS with Ca2+ and 14ml of Optiprep -
Density 1.320 g/l (Axis-Shield, Oslo, Norway). This mixture was divided
between two sterile 50ml conical tubes and carefully balanced, and spun in
a centrifuge at 1400g for 17 minutes with the brake off. Once the spin has
stopped the HSCs appear as a cloud visible immediately beneath the
cushion of HBSS with Ca2+ at the top of the two conical tubes. This layer was
carefully removed and washed again in HBSS with Ca2+ and DNase solution.
Typical rat preparation from one liver would yields 100 million HSCs.
2.2.2 Isolation of mouse HSCs
HSCs were isolated from normal livers of p75NTR/exonIII−/− and WT male
mice. Livers were washed in HBSS without Ca2+ and then cut into small
pieces and digested with collagenase and pronase. Enzymatic digestion
was followed by discontinuous density centrifugation in 11.5% Optiprep (Life
Technologies, UK). HSCs were cultured on plastic in Dulbecco’s modiﬁed
Eagle’s medium supplemented with penicillin, streptomycin, gentamicin
and 16% fetal calf serum and maintained at 37C at an atmosphere of 5%
CO2. All experiments using HSC-derived myoﬁbroblasts were performed on
cells passaged between one and three times.
2.2.3 Isolation of human HSCs
Human HSC were extracted from the normal margins of human liver
resected for colonic metastatic disease as previously described. [57]
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Local ethics committee approval was obtained and prior consent was
taken from the patient the day before surgery (Local Research Ethics
Committee no. 215/99). A letter was also sent to the patients General
Practitioner. Brieﬂy, the liver specimen was collected from the operating
theatres and taken to a histopathologist who cut a piece of normal liver
from the liver resection specimen.
The normal liver specimen was taken to the tissue culture hood and cut into
ﬁne pieces with scissors and decanted into a sterile glass bottle. A mixture of
collagenase (20mg/20ml HBSS with Ca2+), pronase (100mg/20ml HBSS with
Ca2+) and 5ml of DNase solution (10mg/20ml HBSS with Ca2+) were added
to the liver. This was then incubated at 37C with shaking. After 1 hour the
liver digest was ﬁltered through a Nybolt membrane ﬁlter. This crude extract
is processed in the same manner as the rat stellate cell preparation
described above. Typically, there would not be sufﬁcient cells to use the
elutriator to further purify the cells. Usually a small liver slice would yield 20
million human stellate cells. Potential contaminating cells include
hepatocytes, Kupffer cells and sinusoidal endothelial cells.
2.2.4 Culture of hepatic stellate cells
Extracted HSCs from rodent or human liver were tested for viability by trypan
blue exclusion. Typically greater than 95% of the cells were viable.
Quiescent HSCs were identiﬁed by their characteristic autoﬂuoresence
because of the presence of vitamin A droplets within cells, and cell
preparations are typically 90-95% pure. Extracted HSCs were cultured on
plastic until they were activated to hepatic myoﬁbroblasts after 7-10 days.
Human and rat HSC were used for experiments after activation in primary
culture or after passage (<3). Cells were cultured in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) (Bio Whittaker, UK) in the presence of 16% fetal calf
serum and antibiotics penicillin, streptomycin and gentamicin (Gibco, UK).
Cells were passaged by ﬁrst washing three times in HBSS without Ca2+, then
exposing the cells to trypsin in HBSS for 3-5 minutes at 37C. The cell
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suspension was collected, centrifuged gently at 1800rpm for 7 minutes,
resuspended in 1ml of fresh medium, and the cells split into new plastic
ware.
2.2.5 Stimulation and quantiﬁcation of apoptosis
2.2.5.1 Overview of quantiﬁcation of apoptosis
There are numerous methods that measure apoptosis, [222] all with
drawbacks. The process of apoptosis can be deﬁned by a series of
morphological changes. [89] The characteristic features are best observed
by electron microscopy but can be observed at the light microscope using
nucleic acid binding dyes, such as haematoxylin, acridine orange, or
propidium iodide. [223, 224] There is an increasing volume of work in the
ﬁeld of apoptosis which has led to a proliferation in the number of available
methods of quantiﬁcation. The biochemistry of apoptosis is now known in
some detail but can vary depending on the apoptogen studied. Many
methods use one speciﬁc part of the apoptotic pathway as a surrogate
marker of apoptosis. Annexin V expression on the cell surface is thought to
be an early event in apoptotic cells. Caspase-3 activation is considered an
intermediate step in apoptosis. DNA fragmentation is thought to be a late
manifestation of apoptosis. A generic problem with apoptosis measurement
is that for a given population of cultured cells exposed to an apoptotic
stimulus at the same time, the lead in or lag time before morphologic
features of apoptosis occur is variable. Once apoptosis has started, it
occurs in an efﬁcient manner and some reports claim that in as little as 1-2
hours a cell can undergo apoptosis and the apoptotic cell debris be
removed by neighbouring cell by phagocytosis. [223] To attempt to
measure apoptosis by a single method is therefore subject to caveats.
Measurement of apoptosis usually involves static measurement and so it is
incorrect to discuss “apoptotic rates”. For this reason, morphological
techniques e.g. acridine orange staining are normally expressed as an
apoptotic index or percentage.
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2.2.5.2 Examination of nuclear morphology after acridine orange staining
Apoptosis of hMFBs was induced by absolute serum deprivation +/-
cycloheximide treatment, [87] as previously described. [110, 225] hMFBs
were cultured in 24-well tissue culture plates and exposed to pro-apoptotic
stimuli with and without neurotrophins and other manipulations as detailed
below. Following 24 hours incubation at 37C, nuclear morphology was
assessed by adding 1l of 1mg/ml acridine orange (Sigma, UK) to each well
(ﬁnal concentration 1g/ml) and observing the cells under blue
ﬂuorescence with an inverted ﬂuorescence microscope. The total number
of apoptotic bodies were counted and any apoptotic bodies ﬂoating in the
supernatant included by racking up the objective lens. The total number of
cells per ﬁeld was counted and an apoptotic index calculated. Each
condition was performed in duplicate and ﬁve high power ﬁelds were
counted for each well.
2.2.6 Quantiﬁcation of cellular proliferation
The effect of neurotrophins on proliferation of activated human or murine
hMFBs was measured using [3H]-thymidine incorporation. Experiments were
conducted in duplicate wells for each condition in 24-well plates.
Activated hMFBs, between passage 1 and 3, were trypsinised and plated
into 24-well plates at a density of 20000 cell/well and grown in media
containing 16% FCS for 24 hours followed by complete serum deprivation for
24 hours. Cells were then cultured for an additional 16 hours in serum-free
media in the presence of neurotrophins, or 10ng/ml recombinant human
PDGF-BB (Calbiochem) prior to the addition of 1Ci of [methyl-3H]-thymidine
(Amersham Biosciences). Cells were incubated for a further 24 hours before
washing with HBSS, and ﬁxing in ice-cold methanol. The ﬁxed cells were
solubilised in 0.25M sodium hydroxide/0.2% (w/v) SDS (Sigma) and
neutralised with 5M hydrochloric acid. The lysates were added to OptiPhase
HiSafe 3 scintillation ﬂuid (Wallac, Turku, Finland), and scintillation was
counted using a MicroBeta 1450 Scintillation Counter (Elkay).
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2.2.7 Determination of total cell number
After treatment of cell cultures with different conditions the total cell
number at the end of the treatment time will be a product of both the
proliferation and cell loss occurring during this period. Therefore it is
important not to measure proliferation or apoptosis in isolation, and also to
measure ﬁnal cell number.
2.2.7.1 Cell number determination by MTS assay
The Promega CellTiter 96 AQueous One Solution Cell Proliferation Assay was
used to determine total cell number after treatment. This assay is a
colourimetric method to determine the number of viable cells present that
uses the bioreduction of the MTS tetrazolium compound by cells into a
coloured formazan product. This is achieved by NADPH or NADH produced
by dehydrogenase enzymes in metabolically active cells. The soluble
coloured product formed is measured by recording absorbance at 490nm
with a 96-well plate reader, and this reading is taken to be proportional to
cell number.
In order to conﬁrm that the assay gave an accurate assessment of the
number of human hMFBs, and to determine how many cells/well to seed for
subsequent experiments, human hMFBs were trypsinised and seeded at
densities from 0 to 80000 cells/well in a total volume of 100l per well. After
24 hours 20l of the MTS reagent was added and then incubated for 1-4
hours at 37C, 5% CO2. Absorbance was then read at 490nm.
Cells were prepared and treated in the same manner as those used to
determine apart from using 2000 cells/well of a 96-well plate in a total
volume of 100l per well. After 24 hours of culture cells were serum-deprived
for 24 hours and then triplicate wells were treated for 24 hours. At this time
20l of the MTS reagent was added and then incubated for 1-4 hours at
37C, 5% CO2. Absorbance was then read at 490nm.
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2.3 Protein methods
2.3.1 Protein extraction (whole liver)
An appropriate volume of 1x RIPA buffer (Cell Signaling) was prepared.
400l of buffer was aliquotted into sterile microfuge tubes and chilled on ice.
1-2l of protease inhibitor cocktail (Sigma) were added to each 400l of 1x
RIPA. This mixture was vortexed thoroughly. 0.5 cm3 pieces of frozen liver
tissue were cut and transferred to each microfuge tube. A 2ml syringe plus
19 gauge needle were used to break up the tissue thoroughly. Samples
were kept on ice.
Homogenates were transferred to a Qiashredder column (Qiagen) and
centrifuged at room temperature at 13000 rpm for 2 minutes. The
supernatants were decanted into fresh sterile microfuge tubes and placed
on ice. The Qiashredder columns were discarded. Samples were then
assayed to establish protein concentration and aliquotted for storage at
-20C to keep freeze-thawing to a minimum.
2.3.2 Measurement of protein concentration in whole liver or
cell extracts
The protein concentration of whole liver or cell extracts was performed using
a protein dye binding kit (Dc Protein assay kit, BioRad, USA).
Brieﬂy, 2l of protein extract was added to 18l of deionised water and
vortexed. 100l of reagent A was added and vortexed. Next, 800l of
reagent B was added and vortexed. Samples were incubated for 20
minutes at room temperature. Parallel standards were made using BSA
(0-20mg/ml). Absorbance was measured at 750nm using a
spectrophotometer (Ultrospec 2100 pro UV/Visible spectrophotometer). A
standard curve was plotted and the protein concentrations calculated
from the standard curve equation, which was formed by linear regression.
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2.3.3 Concentration of cell conditioned media
To increase the protein concentration of cell conditioned media a
precipitation with trichloroacetic acid (TCA)/sodium deoxycholic acid
(DOC) was performed. This gives quantitative recovery and desalts the
sample.
To each sample 0.25 volume of TCA-DOC (0.1% (w/v) sodium deoxycholic
acid, 100% trichloroacetic acid (w/v) in ddH20) was added. This is mixed by
inversion and incubated on ice for 30 minutes. After incubation samples
were centrifuged in a bench-top microfuge at full speed for 15 minutes at
4C. The supernatant was carefully removed and 0.5ml of -20C acetone
was added before centrifugation at full speed for 10 minutes at 4C. The
acetone was then removed and the pellet was allowed to air dry at room
temperature before it was resuspended in one tenth the starting volume in
SDS-PAGE sample buffer.
2.3.4 Western blot analysis
2.3.4.1 Gel Electrophoresis
Bis-tris (Novex Nupage, Invitrogen) 4-12% pre-cast gels were utilised and run
with pre-prepared 1X MES/SDS running buffer (+ anti-oxidant for reduced
samples). The Invitrogen XCell SureLock Mini-Cell system was used. All
reagents were provided by Invitrogen. Samples were prepared slightly
differently (See table 2.3)
Samples were heated at 70C for 10 minutes, then brieﬂy centrifuged at
13,000 rpm and loaded into the gel wells. In addition, 5l of MultiMark
(Invitrogen) and/or 2.5l of MagicMarker XP Western protein standard
(Invitrogen) plus 7.5l of the 2x loading buffer were loaded in separate wells
of the gel. Electrophoresis was performed at 200V constant for 35 minutes.
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Reduced(l) Unreduced(l)
Sample x x
Reducing agent 1 0
LDS sample buffer 2.5 2.5
Ultrapure water up to 6.5 up to 7.5
Table 2.3. Preparation of reduced and unreduced samples for Western
blotting.
2.3.4.2 Western Transfer
Samples were transferred onto PVDF using the Xcell II Blot Module. 1x
transfer buffer plus methanol was prepared as detailed in the
manufacturer’s instructions and anti-oxidant added for reduced samples. 2
pieces of high-grade ﬁlter paper and 4 cassette sponges (Invitrogen) and
were soaked in 1x transfer buffer. An appropriately sized piece of PVDF
membrane (Hybond) was soaked brieﬂy in methanol. Next, a “sandwich”
was assembled: 1 pre-soaked ﬁlter paper was placed on top of 2 sponges,
followed by the PVDF membrane, then by the gel and lastly 1 more
pre-soaked ﬁlter paper and 2 further sponges.
The transfer for 1 gel was undertaken at 30V constant for 1 hour and for 2
gels at 30V for 2 hours. Then, the equipment was disassembled and the
PVDF membrane removed. Successful transfer was indicated by
visualisation of the rainbow marker on the membrane.
2.3.4.3 Western Blotting
After successful transfer, the membrane was placed in plastic box with the
protein facing inwards and 10ml of 10%(w/v) dried skimmed milk (made with
1xTBS/0.3% Tween 20) added. The tube was placed on a shaker for 1 hour at
room temperature or at 4C overnight. The milk solution was decanted.
10ml of primary antibody (appropriately diluted with 5%(w/v) dried skimmed
milk made with 1xTBS/0.05% Tween 20) was added and the tube placed
onto a shaker and incubated for 1 hour at room temperature or at 4C
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overnight. Primary antibodies used were: NGF, rabbit polyclonal Ab (Santa
Cruz sc-548), 1:1000; pro-NGF, rabbit polyclonal Ab (Chemicon AB5583),
1:666; p75NTR, rabbit polyclonal Ab (Promega G323A), 1:1000; sortilin, mouse
monoclonal Ab (BD Biosciences 612100, clone 48), 1:250; -actin, mouse
monoclonal (Sigma A-5441), 1:500); -smooth muscle actin, mouse
monoclonal (Sigma A-2547), 1:1000.
The solution was again decanted. The membrane was washed quickly with
wash buffer (1x TBS/0.05% Tween 20) before 20ml of wash buffer was added
to the membrane and placed on the shaker at room temperature for 20
minutes. This process was repeated twice more.
The secondary HRP-linked antibody (goat anti-mouse secondary, Sigma,
1:5000; goat anti-rabbit secondary, Sigma, 1:7500 dilution) was diluted
appropriately with 5%(w/v) dried skimmed milk made with 1xTBS/0.05%
Tween 20 and incubated with the PVDF membrane for 1 hour at room
temperature on a shaker. This solution was discarded and an identical series
of washes was performed to that after the primary antibody step.
The advanced ECL detection kit (Amersham) was removed from the fridge
and allowed to equilibrate to room temperature before opening. In the
dark room, an acetate sheet was ﬁxed with tape inside the hypercassette.
The membrane was placed onto the acetate sheet with the protein side
facing upward. 1.5ml of detection solution (Solution A with Solution B in 1:1
ratio, volume required = 0.1ml/cm2) was pipetted to cover the PVDF
membrane and incubated at room temperature for 5 minutes (protected
from the light). Another acetate sheet was positioned on top of the
membrane and taped down, ensuring no air bubbles were present.
A sheet of hyperﬁlm ECL (Amersham) was placed on top of the membrane
and exposed for 1-2 minutes. Subsequent exposures required
longer/shorter periods of time depending on how the ﬁrst ﬁlm appeared.
The ﬁlm was processed in the developer. Alternatively, the membrane was
imaging using a Versadoc imager (BioRad).
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2.3.5 Immunohistochemical techniques
Formalin-ﬁxed parafﬁn-embedded tissue sections from normal and injured
liver were stained immunohistochemically for a variety of different antigens.
Antibodies (and appropriate controls) were applied at various
concentrations after appropriate antigen unmasking (See Table 2.4).
2.3.5.1 Antigen Retrieval
Parafﬁn-embedded tissue sections were dewaxed twice through xylene for 5
minutes each time, then rehydrated through graded alcohols (Industrial
Methylated Spirit (IMS) 100%, IMS 70%) and ﬁnally in tap water.
Antigen retrieval was performed using a commercial citrate-based low pH
solution (Vector antigen unmasking solution) or a pH 8 EDTA solution. A
solution of 1mM EDTA, 0.05% Tween 20 and ultra-pure water was adjusted to
pH 8 and added to a microwavable container. The slides were then placed
into the container and microwaved until the solution boiled on full power
(850W) for 5 minutes, at which point the solution was topped up. This was
repeated twice. The container was removed from the microwave and run
gently with cold water for 10 minutes.
2.3.5.2 General immunohistochemistry protocol
The following immunohistochemical technique was carried out at room
temperature, apart from the heat-induced antigen retrieval step. A polymer
based signal ampliﬁcation system was used (Impress, Vector) following the
manufacturer’s instructions. Details of additional protocols including
preparation of slides and tissue section cutting are included in Appendix B.
Antigen retrieval was performed at this stage if necessary followed by 3 x 5
minute washing steps in phosphate-buffered saline (PBS). Endogenous
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peroxidase was blocked with H2O2/methanol (0.2ml/11.8ml) for 30 minutes.
Sections were then washed 3 x 5 minutes in PBS.
Sections were blocked with 2.5% normal horse blocking serum, as supplied,
for 20 minutes. Without washing, the primary antibody was added at the
appropriate concentration and incubated overnight at 4C. Non-speciﬁc
staining was controlled for by incubation with rabbit immunoglobulin (or
other non-immune serum) instead of the speciﬁc primary antibody.
After incubation, sections were washed in PBS 3 x 5 minutes and incubated
for 30 minutes after addition of the polymer Impress reagent. Sections were
again washed in PBS 3 x 5 minutes.
DAB chromagen substrate was incubated for 5-10 minutes until a colour
change was observed. Stained slides were rinsed in tap water. A brief
counterstain was performed using Meyers Haematoxylin (Gurr). Slides were
again rinsed in tap water. Sections were dehydrated through graded IMS
and xylene for 5 minutes each time then mounted in DPX and coverslipped.
2.3.6 Immunoﬂuorescence
2.3.6.1 Immunoﬂuorescence on cultured cells
Isolated murine hMFBs were grown on sterile glass cover slips in 6-well plates.
After washing brieﬂy with PBS cells were ﬁxed for 10 minutes at -20C in
methanol:ethanol 1:1(v/v). Cover slips were air dried for 10 minutes and
rehydrated in PBS before non-speciﬁc binding was blocked with 5% normal
goat serum. Cells were incubated with a mouse monoclonal antibody
raised against -smooth muscle actin (A2547, 1:1000, Sigma), a rabbit
polyclonal antibody raised against p75NTR (ab8874, 1:500, Abcam) or a
rabbit polyclonal antibody raised against sortilin (ab16640, 1:500, Abcam)
diluted in PBS at 4C overnight. After washing, cells were incubated with a
FITC-conjugated horse anti-mouse antibody (1:200, Vector Laboratories) for
30 minutes in the dark, and viewed by ﬂuorescence microscopy with the
appropriate ﬁlters.
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2.3.6.2 Immunoﬂuorescence in tissue sections
To demonstrate that the majority of apoptotic cleaved caspase-3 positive
cells in recovery from liver ﬁbrosis are -sma positive hMFBs, dual staining for
cleaved capase-3 and -sma was performed.
Parafﬁn-embedded tissue sections were dewaxed twice through xylene for 5
minutes each time, then rehydrated through graded alcohols (Industrial
Methylated Spirit (IMS) 100%, IMS 70%) and ﬁnally in tap water. Antigen
retrieval was performed in the same manner as that performed for single
staining for cleaved caspase-3 with Vector Antigen Unmasking solution.
Sections were allowed to cool for 20 minutes before non-speciﬁc binding
was blocked by incubation for 30 minutes with Vector Impress normal horse
serum block (2.5%).
For dual staining a combined primary antibody solution containing 1:500
anti--sma (Sigma A2547) and 1:200 anti-cleaved caspase-3 (Promega
G7481) in 1XTBS was incubated with sections at 4C overnight. After washing
in 1XPBS buffer, 3x5min, sections were incubated for 1 hour at room
temperature in a combined secondary antibody solution in the dark.
Secondary antibody solution contained 1:500 dilutions of Alexa Fluor 546
conjugated F(ab’)2 fragment of goat anti-mouse IgG (H+L) (to detect
mouse monoclonal clone 1E4 anti--sma) and Alexa Fluor 488 conjugated
goat anti—rabbit IgG (to detect rabbit polyclonal anti-cleaved caspase-3).
All subsequent steps were performed in the dark.
To quench autoﬂuorescence present as a consequence of lipofuscin in
sections of liver a 0.1% (w/v) solution of Sudan Black B in 70% ethanol was
prepared. The solution was heated to boiling , cooled and then ﬁltered.
After incubation with secondary antibody solution sections were washed in
1XTBS 3x5 minutes prior to incubation with the Sudan Black B solution for 10
minutes at room temperature. After brief washing with 1XTBS sections were
incubated at room temperature for 10 minutes in Hoechst 33258 to give a
nuclear counterstain. Sections were mounted with Vector Vectashield
mounting medium and viewed using appropriate ﬁlters sets with ﬂuorescent
light.
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2.4 RNA methods
2.4.1 General methods
2.4.1.1 Prevention of Contamination
All equipment, consumables and glassware used were DNase/RNase-free.
All buffer solutions were made using DEPC water (Appendix B) and were
either autoclaved for 20 minutes at 121C and/or ﬁltered through a 0.2m
ﬁlter (other DNase/RNase-free materials and chemicals used were
purchased). DNase/RNase-free ﬁlter tips (Greiner) were used for all
procedures.
2.4.1.2 RNA extraction with RNeasy Mini Kit (Qiagen)
First, 10l of -mercaptoethanol (-ME) was added per 1ml of buffer RLT.
Next, 4 volumes of 96-100% ethanol were added to buffer RPE for a working
solution.
Approximately 30mg pieces of liver (previously frozen at -80C) were cut
with a sterile scalpel. 10mg of liver yielded approximately 40g total RNA.
350l of buffer RLT (+-ME) was added. Homogenisation was performed with
a 19G needle and syringe, followed by the addition of the homogenate to
a Qiashredder column (Qiagen) and centrifugation at room temperature at
13000 rpm for 2 minutes.
Tissue lysates were centrifuged for 3 min at 13000 rpm. Supernatants were
transferred to new microcentrifuge tubes by pipette. 350l of 70% ethanol
(v/v) was added to the cleared lysates and mixed immediately by pipetting.
Up to 700l of sample, including any precipitate formed, was transferred to
an RNeasy mini column placed in a 2ml collection tube. Samples were
centrifuged for 15 seconds at 10000 rpm. The follow-through was discarded
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and collection tubes reused. If the volume exceeded 700l the excess was
reloaded into the mini column and spun again as above.
700l of buffer RW1 was added to each RNeasy column. Samples were
centrifuged for 15 seconds at 10000 rpm. Follow-through and collection
tube were discarded. RNeasy columns were transferred into a new 2ml
collection tube. 500l buffer RPE (containing ethanol) was pipetted into
each RNeasy column. Samples were centrifuged for 15 seconds at 10000
rpm to wash the columns. Follow-through was discarded and the collection
tubes reused.
Another 500l of buffer RPE was added to each RNeasy column. Samples
were centrifuged for 2 minutes at 10000 rpm to dry the RNeasy silica-gel
membranes of ethanol.
RNeasy columns were transferred to new 1.5ml collection tubes. 30-50l of
RNase free water was pipetted directly onto silica membranes. Samples
were ﬁnally centrifuged for 1 minute at 10,000 rpm to elute RNA. A second
elution using the ﬁrst eluate was performed to give a higher concentration
of RNA.
Absorbance at 260nm was measured. In addition, the ratio at 260/280nm
gave an estimate of RNA purity.
2.4.1.3 Preparation of cDNA from total RNA - Reverse Transcription
Total RNA from liver homogenates or cultured cells was extracted as
described. First strand cDNA synthesis was undertaken brieﬂy as follows
(Promega, all reagents)
Template RNA was thawed on ice, along with other reagents, then brieﬂy
vortexed and centrifuged. 1g RNA from each sample in a total volume of
8l was DNAse treated by the addition of 1l DNase/1l DNase buffer and
incubation at 37C for 30 minutes. The reaction was stopped by adding 1l
DNase stop solution and incubating for 10 minutes at 65C. 0.5l random
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Volume/reaction(l) Final concentration
5x MMLV buffer 4 1x
dNTPs 1 0.5mM each
RNasin (20-40u/l) 0.5 10-20u/20l
MMLV reverse transcriptase 1 200u/20l
RNase-free water 2
Table 2.5. Constituents of reverse transcription reaction master mix.
hexamers was added and incubated at 70C for 5 minutes, immediately
followed by incubation on ice for 5 minutes. A master mix was prepared, see
table 2.5.
8.5l master mix was added to each reaction and gently mixed. Samples
were incubated at 42C for 60 minutes. cDNA was stored at -20C or used
for PCR.
2.4.1.4 Basic RT-PCR protocol
DNA ampliﬁcation was performed using Taq DNA polymerase for
semi-quantitative PCR comparing the levels of particular gene mRNA in
different samples. Primer sequences see Appendix A. Brieﬂy, the PCR
reactions were set up in the following manner.
2.5l of both sense and antisense primers (at 2.5M/l) were added to 1l of
cDNA template with 12.5l of complete 2X Master Mix (Promega) and 6.5l
of nuclease-free water in a total volume of 25l. This mixture was then pulse
spun and 30l of mineral oil carefully pipetted on top to prevent
evaporation. The cDNA was then cycled as follows: 5 minutes at 94C to
denature; 25-40 cycles of 45 seconds at 94C, a 1 minute annealing step at
the appropriate temperature for each primer pair and a 1 minute extension
step at 72C; ﬁnal elongation reaction of 10 minutes at 72C to ensure the
formation of full-length transcripts.
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2.4.1.5 Agarose gel electrophoresis
All PCR reactions were loaded onto a 1 or 2% agarose gel containing
ethidium bromide and separated for 45-60 minutes by electrophoresis at
80V, along with a 100 base pair ladder (Promega) to allow estimation of the
fragment size. DNA was visualised under UV light and a photographic
record taken.
2.4.2 Determination of messenger RNA using quantitative
real-time quantitative PCR
2.4.2.1 General principles of quantitative real time PCR
The quantitative real-time PCR technique uses primers and probes that are
designed to detect a speciﬁc target region in the cDNA of interest. The
probe is labelled with a quenching molecule and a ﬂuorescent molecule.
Cleavage of the annealed probe by taq polymerase results in a loss of
quenching, and an increase in ﬂuorescence signal. Normal PCR products
are formed leading to an accumulation of cleaved probe during each
cycle (See ﬁgure 2.1). After each thermocycle the ﬂuorescence signal
increases log linearly and reaches a threshold (Rn) that is set to be the
same for the gene of interest and the reference gene. The threshold cycle
(CT) is the number of PCR cycles after which there is a detectable
ﬂuorescent signal from the reaction tube and this is directly related to the
starting quantity of cDNA. Figures taken from School of Medicine, University
of South Carolina website. [226]
To quantitate the amount of cDNA in a sample from data generated by
real-time PCR a number of methods are available. However in many cases
the key information is the change in gene expression, hence cDNA copy
number, in cells or tissue after an experimental manipulation. In this situation
expression of a target gene after an experimental treatment is compared
with expression of the same gene under control conditions. In order to
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Figure 2.1. The principles of quantitative real-time PCR. The probe is labelled
with a quenching molecule and a ﬂuorescent molecule. Cleavage of the
annealed probe by taq polymerase results in a loss of quenching, and an
increase in ﬂuorescence signal. Normal PCR products are formed leading to
an accumulation of cleaved probe during each cycle.
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Figure 2.2. Illustrative example of quantiﬁcation of gene expression using
Ct method. RPLP0 is the control gene and IL-1 is the target gene,
before and after treatment with vitreous humour.
control for cell number the expression of a reference gene is also examined.
An ideal reference gene should be expressed at the same level in all cells
and its expression should not be inﬂuenced by the experimental
manipulation being examined.
To illustrate the principles of the comparative CT method (CT) for relative
quantitation of gene expression illustrative data from
http://pathmicro.med.sc.edu/pcr/realtime-home.htm has been used
(Figure 2.2) . In this example cells derived from the eye have been treated
with vitreous humour (vit) or control (con). The target gene is IL1- and the
control gene is RPLPO.
It is expected that there is greater expression of the reference gene than
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the target gene, hence a lower Ct value. The ﬁrst calculation is the
difference in Ct values between target and reference gene in both control
and experimental treatments (Ct):
Ct = Ct(target) - Ct(reference)
The next step is to calculate the difference in Ct between control
conditions and each experimental group (Ct); assuming that expression
of the target gene is lowest in control conditions these Ct are expected
to be negative:
Ct = Ct(control) - Ct(experiment)
The ﬁnal step is to transform these values into comparative change in
expression of the target gene under experimental condition:
Comparative change in expression = 2Ct
In the case of the example above, comparative change in expression of
IL1- after treatment with vitreous:
Fold change = 211.4= 2702.35
This method was used to determine Ngfb expression in the rat model of liver
ﬁbrosis.
2.4.2.2 Determination of house-keeping genes
To enable accurate quantiﬁcation of gene expression by real-time PCR the
amount of starting template in the PCR reaction must be normalised. A
common strategy is to normalise to the total mass of RNA. However the
majority of total RNA is ribosomal RNA, and there is often poor correlation
with the mRNA fraction. Also, the relative abundance of 18S and 28S rRNA is
many fold greater than most mRNA species, making the use of the former to
assess the latter problematic. Internal control genes (house-keeping genes)
are often used instead. An ideal house-keeping gene should be expressed
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at about the same level in the tissue examined as the target genes, and its
own expression should not change in the different conditions examined.
However the expression of many of the commonly used house-keeping
genes is known to vary under different treatment or disease conditions
[227–229], and this is often not formally assessed when data is analysed.
In order to address this problem a strategy has been developed to assess a
panel of candidate house-keeping gene on the cell or animal model in
question, using equal numbers of treated and non-treated samples. The
data derived from real-time PCR for these genes is then analysed by
geNorm, a freely available software tool. This determines the relative
stability of each gene, and also allows estimation of the number of genes to
ultimately choose. The geometric mean of these chosen house-keeping
genes is then used for normalisation in the experimental analysis [230].
To determine the appropriate house-keeping genes for normalisation in the
analysis of gene expression in the p75NTR/exonIII-/- mouse model the 12
gene geNorm kit (PrimerDesign, UK) was used, following manufacturers
protocols. I determined the relative stability of the 12 possible
house-keeping genes (Actb, Eif4a2, Sdha, Canx, Rpl13a, B2m, Ymhaz, 18s,
Cyc1, Ubc, Atp5b, Gapdh) using cDNA derived from the livers of 10
wild-type mice, 5 treated with 11 weeks CCl4 and 5 treated with olive oil.
2.4.2.3 Primer sequences
For determination of the expression of Ngfb in rat samples, primers and
probe for the reference gene 18s were purchased from Applied Biosystems,
with a FAM labelled probe. Sequences for the detection of rat Ngfb were
identical to those previously used [209] (See Appendix A ).
For studies of gene expression in the p75NTR/exonIII-/- mouse model of
reversible liver ﬁbrosis, a combination of 4 house-keeping genes was chosen:
B2m (-2 microglobulin), Ywhaz (tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein, zeta polypeptide), Rpl13a (ribosomal
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protein L13a), and Sdha (succinate dehydrogenase complex, subunit A,
ﬂavoprotein). PerfectProbe primer/probe combinations for the 4 genes
were purchased from PrimerDesign, and used following the manufacturers
instructions. PerfectProbe primer/probe combinations for Acta2 (a-smooth
muscle actin), Col1a1 (procollagen-I) and Timp-1 were designed and
manufactured by PrimerDesign, based on accession numbers from public
databases (See Appendix A).
2.4.2.4 Quantitative real-time PCR protocol
All plasticware was purchased from Applied Biosystems. TaqMan 2X
Universal PCR master mix (Applied Biosystems) or Precision 2X Mastermix
(PrimerDesign) was used. Standard precautions for PCR were employed. In
addition, pipettes, gloves and ﬁlter tips were irradiated under UV light prior
to use.
For determination of Ngfb expression in rat samples, 10-30 ng of ﬁrst strand
cDNA was used per reaction. A reaction mixture consisting of 12.5l TaqMan
2X Universal PCR master mix, 0.3M of primers, 0.3M of probe and cDNA
plus nuclease-free water made up to a ﬁnal volume of 25l. Samples were
added to 96 well optical reaction plates. A protective adhesive strip was
applied to the reaction plate after sample addition and the plate brieﬂy
centrifuged. The conditions of the reaction were as follows:
• Initial steps: 50C for 2 min and 95C for 10 min
• Denaturing step: 15 sec at 95C
• Annealing/extension step: 60C for 1 min
For analysis of the p75NTR/exonIII-/- mouse model 20 ng ﬁrst strand cDNA (5 l
of 4 ng/l cDNA stock solution) was used per reaction. A reaction mixture
consisting of 1 l reconstituted primer reaction mix (producing 300nM
working primer concentration in the 20 / reaction volume) and 10 l
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PrimerDesign 2X Precision mastermix, 4 l PCR-grade water was added to
the cDNA template, producing a total reaction volume of 20 l. Samples
were added to 96 well optical reaction plates. For each gene target
reactions in which the cDNA template was replaced by PCR grade water or
no-RT control were also included. Each reaction was performed in triplicate.
A protective adhesive strip was applied to the reaction plate after sample
addition and the plate brieﬂy centrifuged. The conditions of the reaction
were as follows:
• Enzyme activation: 95C for 10 min
• Denaturation: 95C for 15 sec
• Data collection: 50C for 30 sec
• Extension: 72C for 15 sec
2.4.3 In situ hybridisation
In situ hybridisation (ISH) was used to localise gene expression (mRNA) within
injured and recovering liver tissue in a quantitative and region-speciﬁc
manner.
Probes were purchased from Genedetect (Appendix A)
2.4.3.1 Tissue preparation
All solutions were made up fresh and used only once, at room temperature
unless indicated otherwise. Sections were dewaxed by 2 x 10 mins washes in
xylene, then rehydrated as follows:
• 100% IMS 1 x 5 mins wash
• 95% IMS 1 x 5 mins
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• 70% IMS 1 x 5 mins
• 2 quick washes in DEPC-treated dH20
• 2 x 5 mins DEPC-PBS
• 1 x 15 mins DEPC-PBS/0.3% Triton-X
• 2 x 5 mins DEPC-PBS
2.4.3.2 Permeabilisation
Sections were permeabilised for 5 minutes at room temperature with
RNase-free Proteinase K (Dako). This was followed by washing for 30-60
seconds in DEPC-PBS + 2mg/ml glycine to stop proteolysis. Slides were then
washed 2 x 5 minutes in DEPC-PBS.
2.4.3.3 Post-ﬁxation and peroxidase block
Sections were post-ﬁxed in 4% paraformaldehyde in PBS for 5 minutes,
followed by 2 further washes, each of 5 minutes, in DEPC-PBS. Endogenous
peroxidase activity was blocked by incubation in 1% H202 in methanol for 20
minutes. Sections were washed twice for 5 minutes each in DEPC-PBS prior
to pre-hybridisation.
2.4.3.4 Prehybridisation
Excess buffer was carefully blotted from around tissue sections using a cloth.
Each section was carefully overlaid with prehybridisation buffer warmed to
37C (Dako), then covered with a piece of Paraﬁlm. Slides were incubated
in a sealed humid chamber for 2 hours at 37C. While the sections were
incubating, the Genedetect probes were added at 100-200ng/ml to
prehybridisation buffer (brought to 37C) to make hybridisation buffer. The
solution was mixed well by vortexing brieﬂy.
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2.4.3.5 Hybridisation with probe
At the end of 2 hours, the Paraﬁlm was removed from the tissue sections
using forceps, before tipping off the prehybridisation buffer and putting the
slides into 2X SSC for 5 minutes. Excess buffer was wiped from around the
tissue sections. Each section was then overlaid with hybridisation buffer and
covered with Paraﬁlm. Slides were incubated in a humid chamber overnight
(18 hours approximately) at 37C.
2.4.3.6 Post-hybridisation washes
At the end of overnight hybridisation the Paraﬁlm was removed,
hybridisation buffer tipped off and slides put into wash solution. Using an
incubator with shaking platform, at 55C, slides were given the following
washes:
• 2 x 15 mins 2X SSC
• 2 x 15 mins 1 X SSC
• 2 x 15 mins 0.25X SSC
• 1 x 10 mins Buffer A (100mM TrisHCl, 150mM NaCl ph7.5)
2.4.3.7 Detection steps
Sections were washed in DEPC-PBS for 5 minutes followed by incubation in
blocking solution (DMEM, 20% fetal calf serum, 0.5% bovine serum albumin)
for 30 mins at room temperature to block non-speciﬁc binding of the
secondary anti-DIG antibody to the sections.
After decanting the blocking solution hybridised probe was detected by the
addition of anti-DIG-HRP antibody (Rabbit Fab, Dako) diluted 1:100 in Buffer
November 12, 2008 68Chapter 2. Methods
A + 0.1% Triton-X/1% rabbit serum, at 4C overnight. Slides were then washed
in Buffer A for 10 mins at room temperature, followed by DEPC-H2O for 5 mins.
Endogenous biotin was blocked by the addition of Avidin D solution (Vector)
for 20 mins at room temperature, followed by DEPC-PBS for 5 mins and then
the addition on biotin solution (Vector), again for 20 mins at room
temperature.
Next, slides were washed for 5 minutes with TBS/Tween 20 before
ampliﬁcation with biotinyl tyramide and streptavidin-HRP as per
manufacturer’s protocol (Genpoint tyramide kit). After DAB treatment, slides
were rinsed in tap water, then counterstained with Meyers haematoxylin
(Gurr) for 30 seconds. Finally, sections were rinsed in water and crystal
mounted.
2.4.3.8 Controls
Appropriate controls were included to be conﬁdent that the hybridisation
reactions were speciﬁc and that probe binding was selective to target
mRNA only. Probes that were custom designed and manufactured by
GeneDetect were checked with BLAST to assess the speciﬁcity of the
sequences.
To determine if the probe was binding to the tissue in a sequence speciﬁc
fashion both labelled sense and antisense probes were used in parallel. The
antisense probe theoretically detected both the target mRNA and any
non-speciﬁc targets it can bind due to the chemical properties of the probe
(but not the probe sequence). The sense control probe gave a measure of
non-speciﬁc probe binding only due to the chemical properties of the
probe (i.e. if the sense probe detected nothing, one could be sure that any
signal detected by antisense probe was due to sequence-speciﬁc binding
to mRNA).
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2.5 Statistical analysis
All statistical analysis was performed using SPSS 13.0 or SigmaPlot
10.0/SigmaStat 3.5.
2.5.1 Analysis of histological scoring
The 2 scoring systems used produce ordinal data. To analyse this the SPSS
Ordinal Regression procedure, or PLUM (Polytomous Universal Model) is
appropriate.
2.5.2 Analysis of in vitro data
Data from experiments assessing apoptosis, total cell number and
proliferation in response to neurotrophins was assessed, for each condition
within each experimental type, to determine if the assumptions made in
order for parametric tests to be used are met. Normality was assessed by
examining distribution histograms, skewness and kurtosis statistics and the
Kolmogorov-Smirnov and Shapiro-Wilk tests (tests that compare the scores in
the sample to a normally distributed set of scores with the same mean and
standard deviation; if the test is non-signiﬁcant (p>0.05) then the distribution
of the sample is not signiﬁcantly different from a normal distribution).
If all assumptions for parametric data were not met a Mann-Whitney U Rank
Sum Test was used. When parametric assumptions were met Student’s t-tests
were used. When data was compared in each experiment to a control
condition (given the value 100) the effect of treatments was compared to
this control value by an independent one-sided Student’s t-test. 2 treatment
conditions were compared with one another with independent 2-tailed
Student’s t-test. .
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Studies to determine the expression
of neurotrophins and neurotrophin
receptors in experimental liver
ﬁbrosis and recovery
3.1 Introduction
The development of liver ﬁbrosis using intraperitoneal injection of CCl4 is a
well established experimental model. [14, 231] CCl4 ﬁrst requires conversion
to the trimethyl radical before injury occurs. This model recapitulates many
of the features of liver injury seen in some human liver diseases. A single
injection produces perivenular hepatocyte apoptosis and necrosis, with
evident hepatocyte ballooning, [232] and inﬂammation with a prominent
neutrophilic inﬁltrate. With iterative injury ﬁbrosis develops, initially
perivenular but progressing to ﬁbrotic spurs and then septa linking vascular
structures. A pericellular sinusoidal ﬁbrotic component is also observed,
similar to that seen in steatohepatitis. Four, 6 and 8 weeks of injury produce
progressive injury amounting to severe ﬁbrosis that is fully reversible. Indeed
after 8 weeks of CCl4 an incomplete but reversible cirrhosis is observed.
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Twelve weeks of injury produces advanced micronodular cirrhosis that can
remodel over 1 year of recovery to leave a macronodular pattern. [231]
As discussed, components of the neurotrophin axis are expressed in rodent
and human liver, particularly in ﬁbrotic liver or after injury. [110, 206–210]
Mature NGF increases the number of rat and human hMFBs undergoing
apoptosis in vitro. [75, 110, 209] The expression of components of the
neurotrophin axis has not been examined during recovery from liver ﬁbrosis.
Speciﬁcally, possible differences in the p75-NGF axis between 12 weeks and
4,6 or 8 weeks of injury could account for the failure of recovery observed
after 12 weeks of injury secondary to a reduction of NGF-mediated hMFB
apoptosis.
3.2 Morphological recovery from experimental liver
injury
Scoring systems have been widely employed in assessing the extent of liver
ﬁbrosis although most evidence for their usefulness and formal reproducibility
exists for systems used to assess the changes associated with hepatitis C
virus infection. [233, 234] Data derived from scoring in this manner is ordinal,
and must be analysed by statistical tests suitable for that type of data.
3.2.1 Semi-quantitative scoring of gross architectural
histological resolution
Using a previously published system speciﬁcally used for assessing rodent
liver ﬁbrosis induced by CCl4 administration [216] (Figure 3.1) and applied to
archived tissue from the rat CCl4 model conﬁrms the reversible nature of liver
ﬁbrosis (Figure 3.2). Four weeks of injury produces perivenular ﬁbrosis with
very occasional ﬁne ﬁbrous bridges between vascular structures (Figure 3.3).
No architectural distortion is evident. Recovery after the cessation of injury is
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apparently slow, given the strict application of the scoring system, although
it is complete by 168 days of recovery (Figure 3.4).
Eight weeks of injury produces a more advanced ﬁbrosis amounting to
incipient cirrhosis in some cases. Fibrous septa link vascular structures
leading to architectural distortion (Figure 3.5). By 84 days of recovery
occasional ﬁne ﬁbrous septa remain but without architectural distortion.
Prolonged injury for 12 weeks produces uniformly established cirrhosis, with
broad ﬁbrous septa linking all vascular structures (Figure 3.6). Even after
recovery for up to 366 days, 3 out of 5 animals still had numerous bridging
ﬁbrous septa with architectural distortion. Two animals showed occasional
ﬁne ﬁbrous septa without architectural distortion after this period (Figure 3.7).
The remodeling of ﬁbrosis was well described by an ordinal logistic
regression model with duration of recovery as the predictor variable
(p<0.001) (Figure 3.8).
To assess the reproducibility of this published scoring system 48 sections of
liver from a CCl4 recovery model stained with picrosirius red (See Chapter 5)
were scored twice whilst blinded to recovery time point and assigned score
(Table 3.1). The kappa statistic is often used to assess inter and
intra-observer variation in scoring systems although its statistical purity is
controversial. Kappa can range from 0 (representing more agreement than
expected by chance) to 1 (perfect agreement). Arbitrarily the architects of
the kappa statistic ascribed agreement levels to different kappa values
(Table 3.2). [235] For ordinal scales weighted kappa can be calculated to
take account of the level of disagreement. The linear weighted kappa,
assuming equal “distance” between each point on the scale, is 0.7268 (SE
0.0883, 95% CI 0.6001-0.8535). The calculated kappa statistic for inter and
intra-observer variation for a variety of liver scoring systems consistently
shows greater agreement for the assessment of ﬁbrosis, compared with
other histological features such as inﬂammation. [234, 236–239]
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Figure 3.1. Schematic representation of gross ﬁbrosis scores.
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Figure 3.2. Scoring of gross architectural ﬁbrosis in 4 week rat CCl4 injury
model. Fibrotic bands without architectural distortion are present at peak
injury with extensive remodeling by 168 days.
Second score
0 1 2 3 4 Total
First
score
0 5 3 8
1 5 1 6
2 11 4 15
3 1 3 6 2 12
4 1 1 5 7
Total 5 9 16 11 7 48
k=5
N=48
Table 3.1. Assessment of intra-observer variability of semi-quantitative
scoring. N, number of separate scored slides; k, number of mutually
exclusive categories.
November 12, 2008 75Chapter 3. Neurotrophin axis expression in liver ﬁbrosis
Figure 3.3. Fibrosis after 4 weeks CCl4 injury in rats, peak ﬁbrosis. Perivenular
ﬁbrosis with occasional bridging of vascular structures but no architectural
distortion is evident (Gross ﬁbrosis score 2). Some ﬁne perivenular pericellular
ﬁbrosis is present (inset, sinusoidal ﬁbrosis score 1). Picrosirius red, scale bars
100m.
Kappa range Level of agreement
0-0.2 Slight agreement
0.21-0.4 Fair agreement
0.41-0.6 Moderate agreement
0.61-0.8 Substantial agreement
0.81-1 Almost perfect agreement
Table 3.2. Kappa statistics and assumed level of agreement
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Figure 3.4. Fibrosis after 4 weeks CCl4 injury in rats, 84 days recovery. Minor
ﬁbrosis remains (Gross ﬁbrosis score 1), with no perivenular pericellular ﬁbrosis
(inset, sinusoidal ﬁbrosis score 0). Picrosirius red, scale bar 100m (inset 20m)
.
Figure 3.5. Scoring of gross architectural ﬁbrosis in 8 week rat CCl4 injury
model. Scoring shows an established cirrhosis at peak ﬁbrosis, with
remodeling to leave residual occasional septa by 84 days.
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Figure 3.6. Fibrosis after 12 week CCl4 injury in rats, peak ﬁbrosis. Established
micronodular cirrhosis is present (Gross ﬁbrosis score 4) with extensive
sinusoidal ﬁbrosis (Sinusoidal ﬁbrosis score 3). Picrosirius Red, scale bar 100m.
Figure 3.7. Fibrosis after 12 weeks CCl4 injury in rats, 366 days recovery. A
macronodular cirrhosis remains (Gross ﬁbrosis score 4), with only a small
amount of sinusoidal ﬁbrosis (Sinusoidal ﬁbrosis score 1). Picrosirius Red, scale
bar 100m.
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Figure 3.8. Scoring of gross architectural ﬁbrosis in 12 week rat CCl4 injury
model. Scoring demonstrates established cirrhosis that is remains after 1
year recovery.
3.2.2 Remodelling of sinusoidal ﬁbrosis is rapid and complete
Sinusoidal ﬁbrosis was assessed using a modiﬁed version of a previously
published system (Figure 3.9). [217] Four weeks of injury produces only a
minor component of sinusoidal ﬁbrosis, the majority of which is rapidly
remodeled within the ﬁrst 7 days after cessation of injury (Figure 3.10). Eight
weeks of injury leads to a more signiﬁcant degree of sinusoidal ﬁbrosis that is
still present after 28 days of recovery but has resolved by 84 days
(Figure 3.11). Twelve weeks injury produces extensive sinusoidal ﬁbrosis that
resolves gradually. Residual ﬁbrosis is present after 168 days of recovery but,
in most animals, this has been completely resolved by 366 days (Figure 3.12).
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Figure 3.9. Schematic representation of sinusoidal ﬁbrosis scores.
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Figure 3.10. Scoring of sinusoidal ﬁbrosis in 4 week rat CCl4 injury model,
demonstrating extensive rapid recovery of pericellular ﬁbrosis within the ﬁrst
7 days.
Figure 3.11. Scoring of sinusoidal ﬁbrosis in 8 week injury demonstrates
extensive recovery of pericellular ﬁbrosis throughout recovery period.
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Figure 3.12. Scoring of sinusoidal ﬁbrosis in 12 week rat CCl4 injury model.
Scoring of sinusoidal ﬁbrosis demonstrates extensive recovery of pericellular
ﬁbrosis during 1 year of recovery.
3.3 The expression of nerve growth factor during
recovery from experimental liver ﬁbrosis
Previous work has shown that after a single dose of CCl4 in cohorts of mice
there is clear induction of Ngfb mRNA, peaking 48 hours after injury. In situ
hybridisation localised this expression to hepatocytes in acinar zones 2 and 3
in areas of injury. [209]
To determine the expression of Ngfb in reversible chronic liver ﬁbrosis and
established cirrhosis, and establish if the failure of recovery from 12 weeks
injury is associated with a reduction in the levels of pro-apoptotic NGF,
samples from the archived 4 and 12 week rat CCl4 models were examined.
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Figure 3.13. Ngfb mRNA expression in whole liver from rats injured for 4 weeks
with CCl4 and allowed to recover for up to 84 days. Expression is normalised
to 18s expression and compared with olive oil treated normal control
animals ± s.e.m. (n=3)
3.3.1 Total Ngfb mRNA expression during recovery from
reversible ﬁbrosis and irreversible cirrhosis is unchanged
Real-time PCR for Ngfb mRNA in the livers of cohorts of rats injured for 4 or 12
weeks with CCl4 and allowed to recover shows that Ngfb mRNA is present
throughout recovery in both reversible and irreversible models and that
there is no signiﬁcant alteration in the amount during the recovery period
(Figures 3.13 and 3.14). This means that the failure to recover fully from
established cirrhosis after 12 weeks of injury is not due to a lack of expression
of Ngfb at the mRNA level.
3.3.2 A mixture of hepatocytes, hMFBs and biliary epithelial
cells express NGF during recovery from liver ﬁbrosis
To determine the cellular location of the NGF expression observed during
recovery from fully reversible liver ﬁbrosis and incompletely reversible
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Figure 3.14. Ngfb mRNA expression in whole liver from rats injured for 12
weeks with CCl4 and allowed to recover for up to 168 days. Expression is
normalised to 18s expression and compared with olive oil treated normal
control animals ± s.e.m.(n=3).
cirrhosis, immunohistochemical staining was performed on sections of liver
from archived samples (Figure 3.15). The polyclonal antibody used was
raised against a peptide mapping to the N terminus of the mature form of
human NGF, a peptide also present on proNGF. This staining does not,
therefore, distinguish between mature NGF and proNGF. Expression of NGF is
found in occasional hepatocytes, a proportion of myoﬁbroblast-like cells
within ﬁbrotic bands, and biliary epithelial cells.
This pattern is observed at all stages of recovery from 12 weeks of injury and
is also seen in recovery from 4 weeks injury. No staining was observed when
the primary antibody was substituted by non-immune isotype matched
antibody at the same concentration (Figure 3.16).
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Figure 3.15. Expression of NGF protein after 12 weeks CCl4 injury in rats. 12
week peak ﬁbrosis liver immunostained for NGF (Rabbit pAb, Santa Cruz
sc-548, 1:333). Expression is seen myoﬁbroblast-like cells and biliary
epithelium (A, arrowed), and in hepatocytes (B, arrowed). Scale bars 20m.
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Figure 3.16. 12 week CCl4 injury in rats, isotype matched negative control for
NGF staining in Figure 3.15. Scale bar 20m.
3.3.3 Multiple high molecular weight isoforms of NGF are
differentially modulated in recovery from liver ﬁbrosis
In many tissues it has been demonstrated that the majority of NGF observed
represents high molecular weight isoforms of proNGF [197, 240]. To examine
which isoforms of NGF are expressed during recovery from liver ﬁbrosis
protein extracts from whole liver were immunoblotted with the same
antibody used for immunohistochemical staining in Figure 3.15 (Figure 3.17).
In all whole liver homogenates there are high molecular weight forms of
NGF (28, 45, 70, 95, 185 kDa approximately) with minimal 13.2 kDa mature
NGF. There is no difference in the expression of these species throughout
recovery. High molecular weight forms are also present in rat brain
homogenate, however a different combination of forms is present
suggesting a tissue-speciﬁc pattern of expression. Equal loading of protein
was demonstrated by stripping the blots and reprobing for -actin
(Figure 3.18).
Since the presence of numerous bands is often considered to be a hall-mark
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Figure 3.17. Immunoblot for total NGF in whole liver homogenates during
recovery from 4 and 12 weeks injury (Rabbit pAb Santa Cruz sc-548, 1:200).
Rat brain homogenate and 2ng recombinant human NGF were used as
positive controls. Representative of 2 experiments.
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Figure 3.18. Blots from Figure 3.17 reprobed for -actin (total NGF).
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of non-speciﬁc antibody binding, particularly with a polyclonal antibody,
the speciﬁcity of the antibody was examined. Identical blots were probed
with the same antibody used in the previous studies (Figure 3.17), or with the
same antibody after pre-incubation at room temperature for 2 hours with
an excess of speciﬁc blocking peptide. Pre-incubation with the blocking
peptide effectively abolished binding in both liver and brain homogenates,
and the recombinant NGF signal (Figure 3.19), indicating that numerous
high molecular weight NGF species are expressed in both liver and brain.
This was also conﬁrmed by probing blots with or without preincubation of
the primary antibody with recombinant human nerve growth factor
(Figure 3.20). This demonstrates that the majority of bands identiﬁed by this
antibody are high molecular weight forms of NGF, although the distinction
between high molecular weight pro and mature species cannot be made.
3.3.4 Reduced expression of a 45kDa proNGF molecule
during recovery from reversible ﬁbrosis and
incompletely reversible cirrhosis
Using an antibody raised against the pro-domain, the expression of proNGF
alone was examined by immunoblotting (Figure 3.21). In ﬁbrotic or cirrhotic
rat liver the dominant form of proNGF migrates at 45 kDa. Levels are highest
at peak ﬁbrosis in both 4 and 12 week models, falling rapidly in the 4 week
model but persisting at high levels at least until 84 days of recovery in the 12
week model. Stripping and reprobing of the membranes for -actin
demonstrated equal loading in all lanes (Figure 3.22).
3.4 Expression of p75NTR in CCl4-induced rat liver
ﬁbrosis
Previous work has shown that a proportion of myoﬁbroblast-like -sma
positive cells express p75NTR in ﬁbrotic liver. [110, 206–208] NGF ligation of
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Figure 3.19. Immunoblots of recombinant human NGF, rat liver (12 week
peak ﬁbrosis), and rat brain probed with pAb for NGF (Rabbit pAb Santa
Cruz sc-548, 1:200). The lower membrane was probed after the antibody
had been pre-incubated for 2 hours with a speciﬁc blocking peptide.
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Figure 3.20. Immunoblots of recombinant human NGF, recombinant human
proNGF, rat liver (12 week peak ﬁbrosis), and rat brain probed with pAb for
NGF (Rabbit pAb Santa Cruz sc-548, 1:200). The lower membrane was
probed after the antibody had been pre-incubated for 2 hours with
recombinant human NGF.
November 12, 2008 91Chapter 3. Neurotrophin axis expression in liver ﬁbrosis
Figure 3.21. Immunoblot for proNGF in whole liver homogenates during
recovery from 4 and 12 weeks injury (Rabbit pAb, Chemicon AB5583, 1:666).
Rat brain homogenate was used as a positive control. Representative of 2
experiments.
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Figure 3.22. Blots from Figure 3.21 reprobed for -actin (proNGF).
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p75NTR in rodent hMFBs is pro-apoptotic [110, 209] so the expression of p75NTR
by hMFBs in recovering liver may represent a mechanism for their removal,
and irreversibility of cirrhosis may be a consequence of loss of p75NTR
expression, for example, in myoﬁbroblast-like cells that remain in residual
ﬁbrotic septa in the liver following incomplete remodelling.
3.4.1 p75NTR protein is expressed by a small proportion of
myoﬁbroblast-like cells in recovery from ﬁbrosis
Previous localisation of p75NTR in formalin-ﬁxed parafﬁn-embedded tissue
used an antibody that is no longer commercially available. [110] This
produced abundant staining of cells in ﬁbrotic septa.
Using a currently available polyclonal antibody to stain sections cut from
the original block that was previously used demonstrated, in contrast, that
only a very small number of myoﬁbroblast-like cells stained (Figure 3.23). A
similar sparse staining pattern was observed in sections of liver from 4 and 12
week rat models (Figure 3.24). As a positive control, sections of rat small
intestine were stained in parallel to demonstrate staining of ganglion cells of
the myenteric plexus (Figure 3.25). There was no staining in parallel sections
in which non-immune isotype matched Ig had been substituted for the
primary antibody (Figure 3.26).
3.4.2 Ngfr (p75NTR) gene is expressed by a similarly small
number of cells during recovery
Using antisense DIG-labeled probe designed to anneal with rat Ngfr (
p75NTR) mRNA, expression was localised to myoﬁbroblast-like cells within
residual ﬁbrotic areas, particularly perivascular areas (Figure 3.27). There
was also expression in biliary epithelial cells. Staining with the sense probe
showed no staining.
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Figure 3.23. Fibrotic rat liver stained for p75NTR. Staining of identical sections
with a p75NTR antibody no longer available produced staining of most cells
within ﬁbrotic bands (inset) [110]. Re-staining with pAb (Promega G323A)
shows only occasional cells within bands stain for p75NTR. Scale bar 20m.
Figure 3.24. Staining of 12 week CCl4 injured rat liver for p75NTR
demonstrating staining in occasional myoﬁbroblast cells within ﬁbrotic bands
(indicated by arrows), and possible sinusoidal cells (indicated by
arrowheads). Scale bar 20m.
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Figure 3.25. Staining of rat small intestine for p75NTR. Ganglion cells in the
myenteric plexus stain as positive controls (A). No staining of ganglion cells is
seen when non-immune IgG is used in place of the primary antibody (B)
(Scale bars 20m). Ganglion cells arrowed.
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Figure 3.26. Staining of parallel sections using non-immune rabbit IgG in
place of the primary antibody used in Figure 3.24, at the same
concentration. Scale bar 20m.
3.4.3 Total p75NTR protein expression during recovery from
reversible liver ﬁbrosis and irreversible cirrhosis
Total p75NTR protein in whole liver homogenates was examined by
immunoblotting (Figure 3.28). This demonstrates that there is no signiﬁcant
change in the overall expression of p75NTR in whole liver during recovery
from liver ﬁbrosis, consistent with other ﬁndings.
3.4.4 p75NTR is expressed by myoﬁbroblast-like cells within
ﬁbrotic bands in ﬁbrotic and cirrhotic human liver
To conﬁrm that p75NTR was expressed in human ﬁbrotic liver in a similar
manner to the expression observed in rat liver, sections of cirrhotic human
explant liver were examined. Sections from liver where cirrhosis was
secondary to a range of aetiologies, including autoimmune hepatitis,
alcohol, primary sclerosing cholangitis, primary biliary cirrhosis and viral
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Figure 3.27. In situ hybridisation for rat Ngfr (p75NTR) mRNA antisense (A) and
sense (B) sequences on rat liver injured for 12 weeks with CCl4 and allowed
to recover for 366 days. Ngfr (p75NTR) expression is localised to
myoﬁbroblast-like cells in ﬁbrotic areas (indicated by arrows) and occasional
biliary epithelial cells (indicated by arrowheads). There is no hybridisation
with the sense probes. Scale bars 20 m.
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Figure 3.28. Immunoblot of whole liver homogenates from 4 and 12 week
CCl4 models with pAb for p75NTR (arrowed), representative of 2 experiments.
hepatitis, were examined. p75NTR expression was observed in a majority of
myoﬁbroblast-like cells within ﬁbrotic areas (Figure 3.29). The extent of
expression was similar to that seen in rat liver using the unavailable antibody,
rather than the more limited expression observed using currently available
antibody in rat liver. No staining was observed when the primary antibody
was replaced by isotype matched non-immune immunoglobulin
(Figure 3.30).
3.5 Expression of sortilin in CCl4-induced rat liver
ﬁbrosis
The neurotrophin precursors proNGF and proBDNF have both been
described as ligands in their own right. [205, 241] Using cleavage-resistant
forms of proNGF it has been shown that this ligand produces apoptosis in
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Figure 3.29. Sections of explant cirrhotic liver from a patient with primary
sclerosing cholangitis stained for p75NTR (Abcam ab3125). Myoﬁbroblasts
within ﬁbrotic septa show immunopositivity for p75NTR. Scale bar 50m.
Figure 3.30. Staining of parallel sections using non-immune IgG in place of
the primary antibody used in Figure 3.29, at the same concentration. Scale
bar 50m.
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Figure 3.31. Immunoblot of whole liver homogenates from 4 and 12 week
CCl4 injury model for 95kDa sortilin (arrowed), representative of 2
experiments.
NGF-sensitive cell lines at lower concentrations than mature NGF [200] by
interaction with a combination of p75NTR and sortilin, a member of the
Vps10p family and neurotensin receptor. Given proNGF is regulated during
recovery in parallel with hMFB loss whereas total NGF is relatively static, the
role of sortilin in hMFB behaviour and recovery from ﬁbrosis may be
important.
3.5.1 Sortilin is expressed in whole liver homogenates during
recovery from liver ﬁbrosis
Whole liver homogenates from 4 and 12 week CCl4 injury models were
examined for the presence of sortilin by immunoblotting (Figure 3.31).
Sortilin is strongly expressed in rat brain, and the 95kD form is present
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Figure 3.32. Expression of sortilin in human explant liver from a patient with
autoimmune hepatitis (Abcam ab16640). Myoﬁbroblasts within ﬁbrotic
septa (indicated by arrows) and biliary epithelial cells (indicated by
arrowheads) show immunopositivity for sortilin. Scale bar 50m.
throughout recovery after both 4 and 12 weeks injury with CCl4, at levels
greater than that seen in normal liver. In all livers, but not in brain, there is a
band of approximately 50kD. Sortilin is a membrane protein whose
ectodomain may be shed into the extracellular environment, and there is
also speculation that signaling may involve -secretase cleavage and
intracellular domain internalisation. [242] Both of these events may
generate smaller receptor fragments that may be represented by the 50kD
band present in samples from liver.
3.5.2 Expression of sortilin in ﬁbrotic and cirrhotic human liver
Sections of cirrhotic human explant liver were stained
immunohistochemically to determine the cellular location of sortilin. A
minority of spindle-shaped cells in ﬁbrotic areas, and biliary epithelium in
areas of ductular reaction stained positively.
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Figure 3.33. Staining of parallel sections using non-immune rabbit IgG in
place of the primary antibody used in Figure 3.32, at the same
concentration. Scale bar 50m.
3.6 Discussion
3.6.1 ProNGF and NGF during recovery from fully reversible
liver ﬁbrosis and incompletely reversible cirrhosis
It has previously been shown that mature NGF is a pro-apoptotic growth
factor for rodent hMFBs. [110] Further, NGF expression is induced within the
liver by a single dose of CCl4 that produces a self-limiting injury. [209] This
expression is mainly by hepatocytes in areas of damage although
expression by recruited inﬂammatory cells is also possible. This led me to
postulate that an explanation for the failure of full recovery from established
cirrhosis could be due to an absence of pro-apoptotic mature NGF.
Data from real-time PCR for Ngfb mRNA demonstrates that NGF is expressed
throughout recovery from both 4 and 12 weeks CCl4 injury at similar levels.
This expression is by isolated hepatocytes, myoﬁbroblast-like cells in residual
ﬁbrotic areas, and biliary epithelium. The pattern and extent of expression is
November 12, 2008 103Chapter 3. Neurotrophin axis expression in liver ﬁbrosis
different after chronic injury compared to that observed after a single
self-limiting injury. [209] The upregulation of Ngfb mRNA expression following
a single acute injury is transient with maximum expression occurring 48 hours
after injury. By 96 hours expression had returned to background levels. In the
chronic injury models, both 4 and 12 weeks, the animals were sacriﬁced 72
hours after the ﬁnal injection . Data from the acute injury model suggests
that this time frame may have missed a signiﬁcant upregulation of NGF
expression following the last injury, and partly explains the discrepancy
between the 2 models.
The NGF present during recovery consists of a number of different high
molecular weight species, as has been observed in the majority of organs
and diseases examined and described in the literature. [191, 194–197] These
high molecular weights have been attributed to extensive post-translational
modiﬁcation, particularly glycosylation, of both the mature cleaved form
and pro form of NGF. The differing molecular weight forms identiﬁed may be
a mixture of mature and proNGF since both contain the domain used for
the generation of the antibody and cannot therefore be reliably
distinguished by immunoblotting.
When proNGF is examined alone using an antibody raised against the
prodomain a different pattern is observed. Levels of a 45kD form of proNGF
are highest at peak ﬁbrosis in both 4 and 12 week models, and these levels
fall during recovery. After 4 weeks of injury levels fall rapidly, but after 12
weeks injury the reduction is slower. The kinetics of the reduction of this form
of proNGF broadly match the kinetics of the loss of hMFBs and hMFB
apoptosis observed in these models. [14, 231]
The apparent paradox between the static expression of Ngfb at the mRNA
level and high levels of precursor proNGF at peak ﬁbrosis that fall during
recovery can be reconciled if the mechanisms that cleave proNGF are
themselves modulated during recovery. For example, any proNGF that is
present extracellularly could be subject to cleavage by MMPs. [187] During
recovery from ﬁbrosis there is a well-described increase in MMP activity as a
consequence of a reduction in TIMP levels. [14] Clearly this suggests that the
role of proNGF may be of more signiﬁcance than mature NGF.
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3.6.2 The number of cells expressing p75NTR is low and
unchanged during recovery
The assertion that a failure to recover fully from established cirrhosis may be
due to alteration in the expression of p75NTR by hMFBs present in those
ﬁbrotic septa that are not remodelled has been refuted. The total p75NTR
expression in whole liver homogenates over the recovery periods is
unchanged. The number and distribution of cells staining positively for
p75NTR protein and mRNA also appear similar throughout recovery from
both 4 and 12 weeks injury.
The apparent number of hMFBs expressing p75NTR in ﬁbrotic liver are much
lower than previously published. [110] This may be a result of using a
different antibody with a differing afﬁnity. The antibody previously used
stained a large number of cells, however it is no longer available. Using an
antibody that is available, the amount of staining, even in sections taken
from the same block used originally, is much lower. This staining was
performed with rigorous positive and negative controls, using replacement
of the primary antibody with isotype matched Ig rather than merely
omission of the primary antibody. The scarcity of p75NTR expressing cells was
also supported by data from in situ hybridisation.
The consequence of only a small proportion of hMFBs expressing p75NTR is
that p75NTR-mediated apoptosis would only be able to delete a small
number of cells, even in the presence of a high concentration of ligand.
However, p75NTR expression could be transient, such that a small but
changing number of cells express the receptor and a larger number of cells
would be amenable to p75NTR-mediated cell death over time. Also, p75NTR
expression may be entirely different in a situation where a pro-inﬂammatory
milieu exists, such as acute injury.
Similarly sortilin, a postulated receptor for the common prodomain of
proneurotrophins including proNGF, is expressed consistently during recovery
from ﬁbrosis and modeling of micronodular cirrhosis. This expression is, in
part, by a number of stellate-shaped cells within ﬁbrotic bands. The
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presence of both proNGF and sortilin expression by hMFBs within the ﬁbrotic
liver indicates that the proNGF-sortilin axis may be important.
3.7 Summary of key ﬁndings
• Expression of Ngfb mRNA during recovery from liver ﬁbrosis is
unchanged
• Total NGF protein levels during recovery are unchanged
• A 45kDa form of proNGF falls during recovery from completely
reversible ﬁbrosis and incompletely reversible cirrhosis
• Expression of p75NTR is similar in both completely reversible ﬁbrosis and
incompletely reversible cirrhosis
• Sortilin is expressed by myoﬁbroblast-like cells in ﬁbrotic areas in
experimental rodent ﬁbrosis and cirrhotic human liver
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In vitro studies examining the effect
of neurotrophins on primary hMFBs
4.1 Introduction
In order to examine the expression of relevant neurotrophins and their
receptors, and to examine cellular response to ligands in detail, HSCs were
isolated from normal rat livers or from the normal margins of hepatic
resections for isolated colorectal carcinoma metastasis. LX-2 cells, an
immortalised human hepatic stellate cell line, were also examined. [243]
Previous work has shown that both rat hMFBs and activated pancreatic
stellate cells express p75NTR in vitro. [110] The addition of recombinant
mature NGF in the presence of serum increased the proportion of cells
undergoing apoptosis, [110] increased the number of TUNEL positive cells
and increased caspase 3 activity. [209] NGF also increased hMFB apoptosis
in the absence of serum, an effect inhibited by TIMP-1. [211] In freshly
isolated murine hepatic stellate cells assessed 24 hours after isolation the
addition of NGF produced up to a 4-fold increase in apoptosis in a
dose-dependent manner. [244]
ProNGF has been show to be highly active, secreted extracellularly without
cleavage, and act through sortilin and p75NTR , with sortilin functioning as a
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receptor for the pro-domain common to neurotrophins.
[187–190, 192, 198, 200, 245] The effect of pure proNGF on hMFB survival or
expression of sortilin has not previously been examined.
4.2 Neurotrophin and neurotrophin receptor
expression in rodent and human hMFBs
4.2.1 Activated human, mouse and rat hMFBs express p75NTR
and sortilin but not TrkA
Quiescent human stellate cells were lysed immediately after isolation, or
hMFBs were derived by culture on plastic for 10-14 days and subsequent
passaging. Semi-quantitative RT-PCR demonstrated that human hMFBs
express both NGFR (p75NTR) and SORT1 (sortilin) whilst quiescent cells express
lower levels and increase their expression upon activation (Figure 4.1). LX-2
cells share the activated hMFB pattern of expression. No NTRK1 (TrkA)
expression is seen in quiescent HSCs or activated human hMFBs. For each
PCR reaction cDNA from normal human brain was also ampliﬁed as a
positive control, and a sample that had not undergone reverse transcription
was used as a negative control. Products of the expected size were
ampliﬁed in each case. RT-PCR for ACTB (-actin) was also performed to
demonstrate that approximately equal amounts of RNA had been used.
A similar pattern of expression is seen with quiescent rat HSCs and rat hMFBs,
although quiescent rHSCs do express Ntrk1 but this is lost upon activation
(Figure 4.2) .
Whole cell homogenates of human hMFBs were also examined for the
expression of p75NTR and sortilin by immunoblotting (Figure 4.3). Whole cell
homogenates from 2 separate cell preparations of human hMFBs show the
expression of both p75NTR and sortilin.
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Figure 4.1. Expression of NGFR (p75NTR), SORT1 (sortilin), NTRK1 (TrkA) and
NGFB (NGF) in quiescent human HSCs (Q) and activated (A) human hMFBs,
and the human HSC derived cell line LX-2. RT-PCR products on 1% agarose
gel. Representative of 3 separate human cell preparations.
Figure 4.2. Expression of Ngfr (p75NTR), Sort1 (sortilin), Ntrk1 (TrkA) and Ngfb
(NGF) in quiescent rat HSCs (Q) and activated (A) rat hMFBs . RT-PCR
products on 1% agarose gel. Representative of 3 separate rat preparations.
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Figure 4.3. Expression of p75NTR, sortilin and NGF examined by
immunoblotting. 2 separate cell preparations of human hMFBs show the
presence of p75NTR and sortilin (arrowed). Human hMFBs (and rat brain as a
positive control) express a 45 kDa form of NGF (arrowed), demonstrating
post-translational modiﬁcation not seen in commercial recombinant human
proNGF (Pro) or mature NGF (NGF).
Cultured mouse hMFBs were grown on glass coverslips and examined
immunoﬂuorescently for the expression of p75NTR and sortilin
(Figures 4.4 and 4.5). Staining was demonstrated for both receptors. No
staining was apparent when non-immune IgG was used in place of the
primary antibody.
4.2.2 Human hMFBs secrete proNGF and smaller amounts of
mature cleaved NGF
Semi-quantitative RT-PCR demonstrated that activated rat and human
hMFBs express Ngfb/NGFB. Immunoblotting human hMFB lysates using an
antibody that binds both mature and proNGF identiﬁes a 45kDa form. Both
mature and proNGF (unmodiﬁed molecular weights 13.2kDa and 32kDa,
respectively) are heavily post-translationally modiﬁed in vivo. This
immunoblot does not, therefore, determine if this band is a form of mature
or proNGF. (Figure 4.3).
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Figure 4.4. Expression of p75NTR in murine hMFBs by immunoﬂuorescent
staining. FITC-conjugated secondary antibody to identify binding of
anti-p75NTR (Abcam ab8874) antibody to murine hMFBs. DAPI nuclear
counterstain. Scale bar 100m.
Figure 4.5. Expression of sortilin in murine hMFBs by immunoﬂuorescent
staining. FITC-conjugated secondary antibody to identify binding of
anti-sortilin (Abcam ab16640) antibody to murine hMFBs. DAPI nuclear
counterstain. Scale bar 50m.
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Figure 4.6. Conditioned media from hMFBs (HSC cm), serum free DMEM
alone (-ve) or with mature NGF 100ng/ml (Mature) or proNGF 100ng/ml (Pro)
alone or concentrated 15-fold and probed with an antibody recognising all
forms of NGF. hMFB conditioned media contains minimal amount of mature
unmodiﬁed NGF and a larger amount of a 45kDa form.
Human hMFB media, conditioned for 24 hours and concentrated 15-fold,
contains small amounts of unmodiﬁed mature NGF and a larger amount of
a 45kDa NGF form (Figure 4.6). Using an antibody that recognises both
mature and proNGF does not allow the 45kDa to be identiﬁed speciﬁcally.
However when this is repeated using an antibody raised against the pro
domain of proNGF the 45 kDa form remains, identifying the majority of
secreted NGF as a form of proNGF (Figure 4.7). This also suggests that there
is not signiﬁcant cleavage of pro to mature NGF in cultured hMFBs.
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Figure 4.7. Conditioned media from hHSC (HSC cm), serum free DMEM
alone (-ve) or with mature NGF 100ng/ml (Mature) or proNGF 100ng/ml (Pro)
alone or concentrated 15-fold and probed with an antibody recognising
the prodomain of proNGF . This conﬁrms the 45kDa form is proNGF.
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4.3 Cleavage-resistant proNGF and empty vector
insect cell conditioned media have the same
effects on human hMFBs and LX2 cells
The majority of work examining proNGF has used modiﬁed growth factor
whose sequence has been altered to prevent cleavage at the furin
cleavage site, making the growth factor more durable in culture.
Cleavage-resistant proNGF was a kind gift from Professor M. Fahnestock.
Full-length murine NGF cDNA was subject to a cytosine-to-guanine point
mutation at position 633, resulting in a arginine-to-glycine substitution at the
-1 position in the proNGF polypeptide (R-1G). This mutated the cleavage site
used for processing proNGF into the 13.2kDa mature form. Recombinant
proNGF (R-1G) and wild-type (empty) baculovirus were ampliﬁed in Sf9
insect cells, and conditioned media containing secreted protein (R-1G) or
negative control conditioned media were harvested. The use of this
reagent would, in theory, reduce the conversion of proNGF to mature NGF
so that any effects could be attributed to proNGF with more certainty.
Activated cultures of human hMFBs were treated in conditions of serum
starvation for 24 hours with mature NGF, cleavage-resistant proNGF or insect
cell conditioned media after empty vector infection. Cycloheximide was
used as a pro-apoptotic control and serum was used as an anti-apoptotic
control (Figure 4.8).
Cleavage-resistant proNGF at 10ng/ml produced a small amount of
protection from serum-deprivation induced apoptosis, an effect absent with
10-fold lower concentration. However, insect cell conditioned media
produced by Sf9 cells infected with empty vector-containing baculovirus
also produced an apparently dose-dependent protective effect, albeit
small.
Similar treatment of LX2 cells was performed, and total cell number was
determined by the MTS assay since quantiﬁcation of apoptosis in these cells
in not possible by direct visualisation after acridine orange staining, as
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Figure 4.8. Effect on apoptosis of treatment of human hMFBs with
cleavage-resistant proNGF and empty vector control. Both proNGF 10ng/ml
and the equivalent empty vector control (containing the same
concentration of total protein) produced a protective effect. proNGF used
at a concentration of 1 or 10ng/ml. Mean of 3 experiments ± s.e.m.
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Figure 4.9. Effect of cleavage-resistant proNGF on total LX2 cell number vs.
control. Cleavage-resistant proNGF and empty vector control treatment of
LX2 cells produced a large increase in cell number compared with serum
free control conditions. Mean of 3 experiments ± s.e.m.
discussed (Figure 4.9). There is a large increase in cell number compared
with serum free control conditions in cleavage-resistant proNGF treated
wells (58%). However there is an almost identical increase after treatment
with the empty vector control (52%).
Taken together these data imply that the process of generating modiﬁed
proNGF introduces unknown bioactive factors in addition to proNGF into
both the cleavage-resistant proNGF and empty vector infected insect cell
media. For this reason, and the prior demonstration of minimal cleavage of
proNGF in hMFB cultures, wild-type proNGF was used for all further work.
It was also decided that LX2 cells would no longer be used for further work
as they present a number of problems compared with primary cells. LX2
cells were generated by spontaneous immortalisation produced by culture
in low serum conditions. [243] They show 98.7% similarity with primary human
hMFBs, determined by microarray analysis, and express MMP-2, TIMP-2 and
MT1-MMP . They also proliferate in response to PDGF. However their
mechanism of immortalisation necessarily means that they are viable in
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Figure 4.10. Acridine orange staining of LX2 cells (A) and human hMFBs (B),
viewed with an inverted ﬂuorescent microscope. The condensed, irregular
chromatin pattern in LX2 cells is similar to apoptotic human hMFBs (arrowed).
Human hMFBs normally have homogenous, smooth edged nuclei.
serum free media. Therefore using serum-deprivation as an apoptotic
stimulus from which to assess protection by additional factors is of
questionable use. It is also possible that other pro-apoptotic factors will be
much less efﬁcacious in LX2 cells.
Furthermore, the most reproducible method for quantifying apoptosis
directly without recourse to surrogate markers, direct visualisation after
acridine orange staining, cannot be used in LX2 cells. Identiﬁcation of
apoptotic cells is based upon characteristic morphology, particularly
nuclear condensation producing bright apoptotic bodies. The pattern of
chromatin in LX2 cells is not homogeneous and relatively loose, as seen in
primary hMFBs, but more characteristic of malignant cells, with an uneven
clumped appearance. As shown in ﬁgure 4.10 this produces “apoptotic
body-like” appearances after the addition of acridine orange.
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4.4 Human hMFBs show a differential response to
mature NGF compared with proNGF
4.4.1 ProNGF and mature NGF have opposing effects on
human hMFB apoptosis and survival1
Cultures of human hMFBs were treated in conditions of serum starvation for
24 hours with mature NGF or wild-type proNGF in the presence or absence
of cycloheximide. Apoptosis was determined by direct counting of
apoptotic cells after staining with acridine orange (Figure 4.11). Serum
protected cells from apoptosis by 45.9%, p=0.001. At 24 hours, mature NGF
had no effect on the percentage cells undergoing apoptosis, however
proNGF signiﬁcantly reduced apoptosis by 31.7%, p=0.011. Cycloheximide
induced 38.8% more apoptosis compared with serum free conditions alone,
p=0.003. The addition of proNGF to cycloheximide signiﬁcantly reduced this
to 10.9%, p=0.018.
Determining the percentage of cells undergoing apoptosis at any given
time provides no information on cells dying before this. For any given
apoptotic stimulus the kinetics of the cellular response may vary, with some
stimuli producing a rapidly apparent peak response whereas other stimuli
may have peak effects that are only apparent later. [246] To address this in
relation to apoptosis in the presence of mature NGF or proNGF, parallel
conditions were established and apoptosis was quantiﬁed after increasing
time of serum-free incubation (Figure 4.12). The peak protective effect of
proNGF was observed after 24 hours. Mature NGF produced a modest
pro-apoptotic effect that was only apparent at 4 and 8 hours (13.5% and
14.6% increases respectively) and was no longer present at 24 hours. The
increase at both time points was of a similar magnitude to that previously
observed in rodent cells [110].
1A total of 4 from n=6 of experiments quantifying apoptosis after 24 hours incubation,
and all n=3 time course experiments were performed by Selina Hennedige as part of a B.SC.
project under my supervision.
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Figure 4.11. Effect of pro and mature NGF on human hMFB apoptosis.
Apoptosis was quantiﬁed by direct visualisation with acridine orange after
24 hours incubation in serum free conditions alone or supplemented by
proNGF or mature NGF in the presence or absence of cycloheximide
(CHX/C). +, p<0.01 vs serum free; *, p<0.05 vs serum free; **, p<0.05 CHX vs
ProNGF/CHX. Mean of 6 experiments ± s.e.m.
Figure 4.12. Effect of proNGF and mature NGF on hMFB apoptosis with
increasing incubation times. Apoptosis was quantiﬁed by direct visualisation
with acridine orange after the incubation periods stated in serum free
conditions alone or supplemented by proNGF or mature NGF in the
presence or absence of cycloheximide (CHX). Mean of 3 experiments ±
s.e.m.
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Figure 4.13. Effect of proNGF and mature NGF on hMFB proliferation.
Proliferation was quantiﬁed by measuring tritiated thymidine incorporation
after incubation in serum free conditions alone or supplemented by proNGF
or mature NGF. +, p<0.05 vs serum free; *, p<0.01 vs serum free. Mean of 5
experiments ± s.e.m.
4.4.2 ProNGF has a modest proliferative effect on human
hMFBs compared with mature NGF2
In rodent hMFBs mature NGF has no proliferative effect. [110] Proliferation of
human hMFBs was quantiﬁed after treatment with mature NGF and proNGF
in serum free conditions (Figure 4.13). PDGF-BB produced a 720% increase in
proliferation (p=0.049) and proNGF induced a signiﬁcant 73.8% increase in
proliferation (p=0.004). Mature NGF did not inﬂuence proliferation.
2All n=5 experiments to quantify the proliferative effect of neurotrophins on hMFBs were
performed jointly with Selina Hennedige and formed part of a B.Sc. project under my super-
vision.
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Figure 4.14. Human hMFB seeding number versus absorbance after addition
of MTS reagent. Human hMFBs were trypsinised and seeded at
concentrations between 0 and 80000 cells/well in quadruplicate in a 96 well
plate. MTS reagent was added after 24 hours.
4.4.3 Effect of mature NGF and proNGF on total cell number3
The effect of mature NGF and proNGF on cellular apoptosis and
proliferation provides information which is useful, however the most pertinent
question is whether this sum total of these effects is to increase or decrease
the overall population.
In an experiment to validate the MTS assay as a determinant of cell number,
and to optimise which starting density was to be used, it was shown that
absorbance at 492mm after incubation and the addition of MTS reagent
was directly proportional to seeding density over the range 0-10000
cells/well (Figure 4.14). At higher densities the absorbance rapidly became
saturated. Over the linear range the relationship between cell number and
absorbance was very strong (R2=0.9993) (Figure 4.15).
To allow both increases and decreases in cell number after seeding, 2000
3A total of 3 from n=6 experiments to quantify the effect of neurotrophins on hMFB number
were performed by Selina Hennedige as part of a B.Sc. project under my supervision.
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Figure 4.15. Human hMFB seeding number versus absorbance after addition
of MTS reagent (0-10000 cells/well). Human hMFBs were trypsinised and
seeded at concentrations between 0 and 80000 cells/well in quadruplicate
in a 96 well plate. MTS reagent was added after 24 hours.
cells/well was chosen for subsequent experiments. Human hMFBs were
treated with the same conditions used for apoptosis and proliferation
(Figure 4.16).
This assay shows that, despite larger changes seen, particularly with
proliferation, the overall change in cell number versus control conditions
(normalised to 100) is modest with both positive, (serum and PDGF) and
negative (cycloheximide) regulators of cell numbers. The effects of both
serum (p<0.001) and cycloheximide (p<0.05) on total cell number are
signiﬁcant. Mature NGF produces a modest decrease in cell number,
however this effect is not signiﬁcant (p>0.05). The effect of proNGF on total
cell number is negligible compared with serum free conditions alone.
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Figure 4.16. Effect of mature NGF and proNGF on total hMFB number.
Human hMFBs were trypsinised and seeded at 2000 cells/well in triplicate in
a 96 well plate. After 24 hours neurotrophins in serum free condition, in the
presence or absence of cycloheximide (C), were added. MTS reagent was
added after a further 24 hours. +, p<0.01 vs serum free; *, p<0.05 vs serum
free. Mean of 6 experiments ± s.e.m.
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4.5 Discussion
Originally pro-neurotrophins were thought to be inactive intracellular
precursors. At most the prodomain aided intracellular trafﬁcking and
folding. Once the prodomain was cleaved the active neurotrophin was
liberated, secreted and exerted its inﬂuence. However recent work has
shown this to be only the beginning of the role of a pro-neurotrophin.
4.5.1 ProNGF and mature NGF have differential effects on
hMFB apoptosis
Artiﬁcially modiﬁed proNGF whose furin-cleavage site has been rendered
cleavage-resistant has been the tool of choice examining this activity. In all
cell types examined thus far, all of which have well described
NGF-mediated cellular responses, proNGF has produced the same type of
response; for example if NGF stimulated apoptosis in a particular cell type
then proNGF also produced apoptosis. There has been disagreement on
the relative potency of NGF vs proNGF; a murine proNGF rendered
cleavage-resistant by a single nucleotide change that produced a single
amino acid substitution was less active than mature NGF [188] at stimulating
neurite outgrowth in PC12 cells, a p75NTR/TrkA mediated effect. An alternate
form of cleavage-resistant proNGF was generated by more numerous
modiﬁcations, [187] with the addition of 6 histidine residues at the
C-terminus, and 2 RR to AA substitutions, one to prevent cleavage of the His
tag and one at the furin-cleavage site to disrupt cleavage. This more
heavily modiﬁed form was at least 10 times more potent than mature NGF
at stimulating apoptosis in vascular smooth muscle cells that express p75NTR
alone. Whilst these 2 rival cleavage-resistant proNGF forms have never been
compared “head-to-head”, by directly measuring the same cellular
response with identical methods in the same cells, both forms are active
and produce the same type of effect as that seen with NGF alone.
The data in this chapter shows a profoundly different response by primary
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human hMFBs to proNGF and mature NGF. Previous work in activated rat
hMFBs has demonstrated p75NTR expression in the absence of TrkA. The
addition of mature NGF triggered apoptosis but had no effect on
proliferation. I have demonstrated that human hMFBs also express p75NTR
but not TrkA. In the absence of serum, mature NGF caused a modest
increase in apoptosis measured after an incubation of 4-8 hours. However
when incubation is extended to 24 hours there is no longer any effect
apparent on apoptosis.
The difference in apoptosis in response to mature NGF treatment after
different periods of incubation may be partly explained by the speed with
which apoptosis occurs; once a cell engages its apoptotic machinery it
can rapidly complete its destruction to the extent that it can no longer be
identiﬁed as apoptotic, depending on the apoptogen concentration. [246]
Additionally, the time taken to engage the apoptotic sequence varies
depending on the mechanism of the stimulus, for example, on the same cell
line ricin triggered apoptosis independent of the cell cycle after 3 hours
compared with the cell cycle dependent proapoptotic effect of taxol, only
apparent after 12 hours. [246] This means that if an apoptogen has a peak
effect after a given time it would be critical to quantify apoptosis at that
time. Choosing an incubation period that did not coincide with a peak
effect may lead to underestimation of the apoptogenic potential of any
given factor. [247]
In contrast proNGF treatment of human hMFBs protected them from
serum-deprivation induced apoptosis. This effect was reproducible despite
the difﬁculties presented by the heterogeneity of different human cell
preparations when compared with rodent cell preparations. For the ﬁrst
time the precursor of a speciﬁc neurotrophin has been show to have the
diametrically opposite effect from its mature counterpart.
The only candidate receptor mechanism to mediate the effects of proNGF,
apart from stimulation of p75NTR and TrkA in a similar manner to mature NGF,
is sortilin. Sortilin has been shown to be essential, in partnership with p75NTR,
for the superior efﬁcacy of the more heavily modiﬁed cleavage-resistant
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proNGF. [200] I have demonstrated sortilin expression in rat and human
hMFBs in vitro, and sortilin expression during the resolution of liver ﬁbrosis in a
rat model and cirrhotic human liver. However, this is circumstantial evidence
and it is not clear if sortilin is mediating any differential effect of proNGF in
human hMFBs. Sortilin is predominantly an intracellular sorting protein so its
presence in any given cell would not be unexpected. To be a candidate
receptor mediating the effect of an extracellular ligand it ought to be
present on the cell membrane.
4.5.2 ProNGF has a proliferative effect on hMFBs
ProNGF may also have a differential effect on hMFB proliferation. Mature
NGF has no effect on human hMFB proliferation, conﬁrming the observation
made in rat hMFBs [110]. However proNGF appears to have a modest but
signiﬁcant proliferative effect.
The data from the MTS assay does show a reproducible small but
non-signiﬁcant decrease in cells when treated with mature NGF, as one
would expect from an apoptogen with no proliferative effect. However in
proNGF treated cells with a demonstrable protective effect and proliferative
effect there is no increase in cell number over control treated cells. It is
possible that, despite a signiﬁcant change in apoptosis and a proliferative
effect, this produced only a small change in cell number and the assay was
too insensitive to measure this change.
Data published on the effect of proNGF has predominantly used modiﬁed
cleavage-resistant forms. The data I have generated used wild-type
proNGF, so there was no possibility that the modiﬁcations themselves
produced confounding effects. It is also likely that commercially available
proNGF is less affected by contaminants from the generation method and
has been puriﬁed to a greater extent. Some work was carried out using
cleavage-resistant proNGF kindly provided by Professor Margaret
Fahnestock. This form was created with only a single aminoacid substitution,
and was harvested from the media of Sf9 insect cells infected by
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baculovirus containing the sequence. As a control, media from Sf9 cells
infected with empty vector baculovirus was used. Whilst the
cleavage-resistant proNGF produced a signiﬁcant increase in LX2 cell
numbers the same was also true of the control empty vector condition. The
possibility that insect cell media contained bioactive factors that were
inﬂuencing LX2 behaviour meant that only wild-type proNGF was
subsequently used. However, demonstration of proNGF and only minimal
mature NGF in hMFB conditioned media suggests that there is minimal
cleavage of endogenous proNGF in vitro. It is, therefore, probable that
there is also little cleavage of wild-type exogenous proNGF in vitro, further
negating the need to use modiﬁed proNGF.
4.6 Summary of key ﬁndings
• Human and rat hMFBs express p75NTR , sortilin, and NGF but not TrkA
• Human hMFBs secrete proNGF
• Mature NGF is proapoptotic at early time points
• ProNGF is protective against serum-deprivation and cycloheximide
induced apoptosis at extended time points
• ProNGF has a proliferative effect on human hMFBs
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Studies to determine the role of
p75NTR in the development of, and
recovery from, liver ﬁbrosis
5.1 Introduction
Having undertaken initial studies to deﬁne the expression of components of
the p75NTR- NGF axis in recovery from liver ﬁbrosis, and having deﬁned a
differential role for proNGF and mature NGF on the survival of human hMFBs
in vitro, the next goal was to determine the role of p75NTR in the
development of, and recovery from, liver ﬁbrosis in a mechanistic manner.
This was addressed using an established murine model of reversible liver
ﬁbrosis utilising a commercially available p75NTR gene targeted mouse.
Numerous studies have been undertaken with a mutant produced by
targeting exonIII of the Ngfr (p75NTR) gene (generating p75NTR/exonIII-/-
mice). [248] p75NTR/exonIII-/- mice exhibit numerous defects including
defective innervation of the peripheries leading to ulcers [248] and
defective sympathetic innervation that relates to reduced responsiveness of
isolated p75NTR/exonIII-/- sensory neurons to neurotrophins. More recently,
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expression of a short isoform of p75NTR (s-p75) has been described. [167] This
splice variant lacks exonIII, generating a protein identical to full-length
p75NTR but lacking 3 of the 4 cystein-rich domains that correspond to the
ligand binding region. Expression of this receptor alongside full-length p75NTR
has been demonstrated across species, although no binding of
neurotrophins to s-p75NTR has been shown. [167] p75NTR/exonIII-/- mice
express both the transcript and protein of this short isoform. As such they
should be considered hypomorphs rather than complete knockouts.
In light of this, a mutation was targeted at exonIV of Ngfr, with the aim of
developing a true p75NTR knockout. p75NTR/exonIV-/- mice have a more
severe phenotype than p75NTR/exonIII-/- mice in many respects. For
example p75NTR/exonIV-/- mice show a larger increase in cholinergic
septohippocampal neurons of the medial septal nucleus than
p75NTR/exonIII-/- mice, [249] and also have a high rate of intra-uterine
mortality compared with p75NTR/exonIII-/- mice. However the molecular
probity of the p75NTR/exonIV-/- mouse has been called into question. It has
been reported that p75NTR/exonIV-/- mice express a Ngfr gene product that
encodes a truncated protein containing the extracellular stalk region
together with the entire transmembrane and intracellular domains. [250] This
product is transcribed from within a region of exon IV located 3’ to the
pGK-Neo insertion site. The overexpression of this fragment has been shown
to cleave procaspase-3 and lead to apoptosis, and suggests that some of
the phenotypic ﬁndings using this animal are a result of a gain of function. In
view of this the p75NTR/exonIII-/- mouse was chosen for our model, since the
speciﬁc loss of p75NTR-ligand interaction was of most interest.
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Figure 5.1. Genotyping of founder p75NTR/exonIII-/- mice. Six founder mice
purchased from Jackson Labs (1-6) show a single 280bp band
corresponding to the Neo cassette but lack the 345bp band corresponding
to exonIII, conﬁrming them as p75NTR/exonIII-/- by RT-PCR. A sample from a
mouse wild-type for p75NTR but containing an identical Neo cassette in a
different gene on a different chromosome (C) conﬁrms a successful duplex
reaction.
5.2 Studies using a p75NTR/exonIII-/- mouse model
of reversible liver ﬁbrosis
5.2.1 Genotyping of founder pairs
3 p75NTR/exonIII-/- breeding pairs were purchased from Jackson
Laboratories. Before expanding the colony and establishing the model of
ﬁbrosis the founding animals were genotyped following the protocol cited
by Jackson Laboratories (published by Yeo et al [215]). PCR performed on
the tail snips of the animals showed a band representing the Neo cassette in
each case, and did not show a band for a product of the Ngfr gene
disrupted by the cassette. As a control, PCR was also performed on an
animal that was wild-type for Ngfr but contained the same Neo cassette
disrupting an alternative gene on a different chromosome (Figure 5.1).
5.2.2 Murine model of reversible hepatic ﬁbrosis
21 wild-type and 16 p75NTR/exonIII-/- male adult mice were injured by twice
weekly injection of CCl4 for 11 weeks, and allowed to recover for up to 10
days. 4-6 mice were sacriﬁced for analysis at each time point of recovery. 5
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wild-type and 6 p75NTR/exonIII-/- animals received 11 weeks injection of olive
oil vehicle only. This model of liver injury recapitulates many features of
pericentral injury in humans. [251–253] Compared with the rat model of
CCl4 liver injury the murine model produces less advanced ﬁbrosis that
remodels more rapidly. [217, 254]
5.2.3 Biochemical indicators of hepatocyte damage are
similar in p75NTR/exonIII-/- and wild-type mice
Serum levels of the transaminases alanine aminotransferase (ALT) and
aspartate transaminase (AST) were measured in blood taken from each
animal at the time of culling to assess hepatocyte damage. Serum ALT
(Figure 5.2) and AST (Figure 5.3) levels were raised in both genotypes at day
1 of recovery but had fallen to the baseline levels seen in olive oil treated
animals by day 3 of recovery. This indicates that there is no difference in the
degree of hepatocyte damage as a consequence of the lack of ligand
competent p75NTR.
5.2.4 p75NTR/exonIII-/- mice show retarded histological
resolution compared with wild-type animals
The degree of ﬁbrosis in each animal was assessed by a semi-quantitative
scoring system and computerised image analysis.
5.2.4.1 Semiquantitative scoring
A score was assigned to each animal after examination of a picrosirius red
stained section using a scoring system identifying gross architectural
distortion [216]. There is a suggestion by naked eye examination of the
scoring that there may be delayed recovery in p75NTR/exonIII-/- compared
November 12, 2008 131Chapter 5. p75NTR/exonIII-/- model of ﬁbrosis
Figure 5.2. Serum alanine aminotransferase levels (iu/l) at the time of culling
in wild-type of p75NTR/exonIII-/- mice after 11 weeks CCl4 injury and recovery
of up to 10 days. Olive oil treated mice from both genotypes included as
controls.
Figure 5.3. Serum aspartate transaminase levels (iu/l) at the time of culling in
wild-type of p75NTR/exonIII-/- mice after 11 weeks CCl4 injury and recovery
of up to 10 days. Olive oil treated mice from both genotypes included as
controls.
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Figure 5.4. Scoring of gross architectural distortion in p75 model.
with wild-type animals (Figure 5.4). There is persistence of intact septa
between vascular structures still evident at day 7 of recovery in
p75NTR/exonIII-/- animals compared with residual incomplete fragmented
septa in WT animals (Figure 5.5) . The small numbers of animals in each
group for each time point means that analysis by ordinal logistic regression
using genotype as the comparator does not give a statistically signiﬁcant
result.
5.2.4.2 Image analysis using k-means clustering
Image analysis to quantify the amount of ﬁbrosis demonstrated signiﬁcantly
retarded histological resolution in p75NTR/exonIII-/- animals. An automated
method of thresholding each image to allow quantiﬁcation of picrosirius red
positive areas alone was employed, removing any operator variation that is
observed in other methods such as a point counting technique or
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Figure 5.5. Persistence of ﬁbrous septa in p75NTR/exonIII-/- mice. Incomplete
ﬁbrous septum (+) are evident at day 7 of recovery in wild-type animals (a)
compared with persisting intact septum (++) present in p75NTR/exonIII-/-
animals (b). Picrosirius red stain. Scale bar 50m.
thresholding an image by eye on an image analysis package. The k means
clustering plug-in for ImageJ using the clustering algorithm of Coleman and
Andrews was used. [255] The algorithm automatically divides the image into
k (in this study k=4) clusters of pixels such that the pixels of any given cluster
were a similar colour. In picrosirius red stained sections one cluster
corresponded with positive matrix, and images were thresholded to allow
calculation of only this proportion of the image area. For each image a
copy overlayed with the mask generated by this method was saved to
allow manual assessment of the data. An example of an image with
accompanying masked image is shown (Figure 5.6).
Whilst there was a similar amount of sirius red positive matrix identiﬁed in
both WT and p75NTR/exonIII-/- animals (3.19% v 3.54%, respectively) at peak
ﬁbrosis (day 1 of recovery), WT animals showed a steady fall in ﬁbrosis, with
minimal ﬁbrosis remaining after 10 days, in keeping with previous work. [256]
p75NTR/exonIII-/- animals showed an increase in ﬁbrosis after cessation of
injury to day 3, from 3.54% to 5.0%, p=0.048. At day 3 of recovery there was
signiﬁcantly more ﬁbrosis in p75NTR/exonIII-/- livers compared with WT livers,
2.65% vs. 5.05% respectively, p=0.009. There remained a signiﬁcantly higher
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Figure 5.6. Automated thresholding to quantify ﬁbrosis. Image of picrosirius
red stained section of ﬁbrotic liver (a) and the thresholded image from
which positive staining was calculated (b). Scale bars 100m.
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Figure 5.7. Quantiﬁcation of ﬁbrosis by image analysis of sirius red stained
sections of WT and p75NTR/exonIII-/- liver. Fibrosis persists at day 3 and day 7
of recovery in p75NTR/exonIII-/- animals. +, p=0.009; ++, p=0.022; +++,
p=0.048.
amount of ﬁbrosis present at day 7 in p75NTR/exonIII-/- animals, 1.99% vs.
3.17%, p=0.022. By day 10 of recovery ﬁbrosis was similar in both wild-type
and p75NTR/exonIII-/- animals (2.14% v 2.26% respectively).
5.2.5 Loss of hMFBs is retarded in p75NTR/exonIII-/- mice
Hepatic myoﬁbroblasts are the major cellular source of ﬁbrotic matrix.
During histological resolution of ﬁbrosis there is loss of these cells, largely by
apoptosis. [14] To determine if the delayed histological resolution seen in
p75NTR/exonIII-/- livers was a consequence of a reduction in hMFB apoptosis
leading to a persistence of the ﬁbrogenic population I stained sections of
liver for -sma, and probed immunoblots of whole liver protein extracts for
the same protein. I also stained sections for cleaved caspase-3, a marker of
apoptotic cells, and dual stained with both cleaved caspase-3 and -sma.
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Figure 5.8. Quantiﬁcation of -sma +ve cell numbers in wild-type and
p75NTR/exonIII-/- livers. Signiﬁcantly more -sma +ve cells remain at day 3
and day 7 of recovery in p75NTR/exonIII-/- livers. +, p=0.001; ++, p=0.021.
5.2.5.1 a-smooth muscle actin positive cells persist during recovery in
p75NTR/exonIII-/- mice
After the livers from p75NTR/exonIII−/− and WT animals were stained for -sma
the number of positive cells was determined (Figure 5.8). The number of
-sma positive cells at peak ﬁbrosis in WT and p75NTR/exonIII-/- livers livers is
similar (49.8 v 44.5 cells/high power ﬁeld). Signiﬁcantly more -sma positive
cells were present in p75NTR/exonIII-/- livers vs. WT livers at day 3, 46.45 vs.
36.69/high power ﬁeld (hpf), respectively (p=0.001), and day 7 of recovery,
18.26 vs. 13.84/hpf, respectively (p=0.021). By day 10 of recovery the
number of residual -sma positive cells was similar in both genotypes.
5.2.5.2 Immunoblot determination of a-smooth muscle actin protein
In order to support the a-sma immunohistochemical data, the same
antibody was used to probe immunoblots of protein extracts of the same
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Figure 5.9. Normalised expression of -smooth muscle actin protein by
immunoblotting in p75NTR/exonIII-/- and wild-type livers
livers. In order to allow loading quantity to be controlled for, the blots were
stripped and reprobed for -actin. Bands were quantiﬁed using Quantity
One (Biorad) on images acquired using a Versadoc imaging system
(Biorad). Since the samples could not all be examined on a single blot, the
same 2 samples were included on every blot to allow inter-blot differences
to be controlled for.
Once corrected for loading and inter-blot variation the data was similar to
that obtained by immunohistochemistry (Figure 5.11). However some
marked outliers were apparent in samples for both genotypes. Without
excluding outliers there was 10.5 fold (1052%) more a-sma in the livers of
p75NTR/exonIII-/- animals at day 3 of recovery. However the standard error of
this data is unacceptably large, and may reﬂect the sampling error in the
preparation of the protein extract; since a-sma is also present in vessel walls,
the presence of a large vessel in the small piece of tissue sampled will inﬂate
the apparent content. In contrast examination of random ﬁelds throughout
the entirety of a slide that contains half of each lobe of the liver will give a
more consistent ﬁgure.
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Figure 5.10. Lack of ligand-competent p75NTR reduces hMFB apoptosis. (a)
Cleaved caspase-3 immunopositivity with few remaining spindle-shaped
cells in WT liver at day 7 of recovery. Scale bar 50m. Negative control inset.
(b) Cleaved caspase-3 immunopositivity amongst a large number of
spindle-shaped cells in p75NTR/exonIII-/- liver at day 7 of recovery. Scale bar
50m. Negative control inset.
If outlying data points are excluded there is 32.5% less a-smooth muscle
actin in the livers of p75NTR/exonIII-/- animals at day 1 of recovery compared
with wild-type, but 5.1% more at day 3. Given the large standard error of
these data sets these differences are not signiﬁcant.
5.2.5.3 Apoptosis of hMFBs in p75NTR/exonIII-/- animals is reduced
A number of means of identifying apoptotic cells within tissue sections are
available. Terminal uridine deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL staining) has been used extensively to label the DNA strand
breaks seen in cells actively undergoing apoptosis. However there have
been reports of obviously necrotic cells staining positively with TUNEL.
[257, 258] Cleavage of procaspase-3 to active cleaved capase-3 is one of
the events occurring early in apoptosis initiated by NGF ligation of p75NTR,
[166] and measurement of the apoptotic index of tissues using an antibody
raised speciﬁcally against the cleaved form of caspase-3 is a reliable
method of determining cellular apoptosis. [259] Sections of liver from WT
and p75NTR/exonIII-/- animals were stained for cleaved caspase-3, and the
number of cells staining positively were counted (Figure 5.10).
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Figure 5.11. Quantiﬁcation of apoptotic (cleaved caspase-3 positive) cells,
normalized to -sma +ve cell numbers. A signiﬁcantly larger proportion of
-sma +ve cells are apoptotic in WT livers at day 7 of recovery. +, p=0.021.
The number of cells staining positively for cleaved caspase-3 was controlled
for the total number of a-sma positive cells to give an apoptotic index (AI).
The AI was similar for both WT and p75NTR/exonIII-/- livers at days 1 and 3 of
recovery. However at day 7 of recovery there was a 54.4% higher AI in WT
livers compared with p75NTR/exonIII-/- livers, 75.0 vs. 34.2 caspase-3 positive
cells per a-sma positive cells/high power ﬁeld (p=0.021), a time point at
which there are far larger numbers of a-sma positive cells persisting in
p75NTR/exonIII-/- livers, and the time point at which the largest proportion of
hMFBs in WT liver are apoptotic (Figure 5.11).
Apart from occasional cells with the morphology and distribution of
inﬂammatory cells, the majority of cells staining positively for cleaved
caspase-3 were distributed within ﬁbrotic areas and had the morphology of
hMFBs. However to demonstrate this more conclusively dual staining for
cleaved caspase-3 and a-sma was undertaken immunoﬂuorescently
(Figure 5.12). This staining conﬁrmed that the caspase-3 positive cells within
ﬁbrous bands were a-sma positive and therefore likely to be hMFBs.
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Figure 5.12. Immunoﬂuorescent dual staining of -smooth muscle actin and
cleaved caspase-3. Sections of wild-type and p75NTR/exonIII-/- liver were
dual stained with antibodies against cleaved caspase-3 and -smooth
muscle actin, demonstrating that the majority of apoptotic cells in
recovering liver are hMFBs. DAPI nuclear counterstain. Representative
images shown. Scale bar 25m
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5.2.6 Loss of ligand binding capacity of p75NTR reduces the
number of proliferating hMFBs in recovery
Sections of liver from WT and p75NTR/exonIII-/- animals were stained for Ki-67,
a protein preferentially expressed by proliferating cells during G1, S, G2 and
M phases of the cell cycle but not by resting cells in G0 phase. [260] Based
on their morphology, positively staining hepatocytes and non-parenchymal
cells were counted separately (Figure 5.13). Most positively staining
non-parenchymal cells were morphologically myoﬁbroblasts, both portal
and sinusoidal, but also included a small number of inﬂammatory cells.
The number of Ki-67 positive non-parenchymal cells was signiﬁcantly higher
in WT vs. p75NTR/exonIII-/- livers at peak ﬁbrosis, 45.1 vs. 6.5 positive cells/hpf
(p<0.001), and at day 3, 12.8 vs. 7.1 positive cells/hpf respectively (p=0.003).
This demonstrates that the mitotic effects of p75NTR signalling on hMFBs in
proﬁbrotic liver injury are reduced in animals lacking ligand-competent
p75NTR. The vast majority of non-parenchymal cells staining positively for
Ki-67 in both wild-type and p75NTR/exonIII-/- livers were distributed in the
same location as a-sma positive cells.
At day 3 of recovery there was a peak in hepatocyte proliferation of equal
magnitude (9.7-fold more than day 1) in both p75NTR/exonIII-/- and WT livers
(p<0.001 vs. day 1 for each genotype). However a smaller burst of
hepatocyte proliferation at day 10 in WT livers was absent in p75NTR/exonIII-/-
livers (3.21 vs. 0.39 Ki-67 positive hepatocytes/hpf, respectively, p<0.001).
5.2.7 Expression of proﬁbrogenic genes mirrors hMFB numbers
After demonstrating both a persistence in ﬁbrosis and hMFBs during the
intermediate stages of recovery in p75NTR/exonIII-/- animals I sought to
conﬁrm that the expression of ﬁbrogenic genes within the livers mirrored
hMFB numbers. Acta2 (a-smooth muscle actin), Timp-1 and Col1a1
(collagen type 1, alpha 1) are key proﬁbrogenic genes and hMFBs are the
major cellular source of expression.
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Figure 5.13. Lack of ligand-competent p75NTR reduces non-parenchymal
cell proliferative capacity. Based on morphology, immunpositive
non-parenchymal cells are predominantly myoﬁbroblasts, both portal and
sinusoidal, but also may include inﬂammatory cells. (a) Ki-67 cell positivity in
WT liver at day 1 of recovery. Scale bar 50m. Negative control inset. (b)
Ki-67 cell positivity in p75NTR/exonIII-/- liver at day 1 of recovery. Scale bar
50m. Negative control inset. (c) Quantiﬁcation of non-parenchymal Ki-67
+ve cell numbers. +, p<0.001; ++, p=0.003. (d) Quantiﬁcation of hepatocyte
Ki-67 +ve cell numbers. +, p<0.001.
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5.2.7.1 Selection of appropriate house-keeping genes for real-time PCR in
ﬁbrotic murine liver
To enable accurate quantiﬁcation of gene expression by real-time PCR the
amount of starting template in the PCR reaction must be normalised. A
common strategy is to normalise to the total mass of RNA. However the
majority of total RNA is ribosomal RNA, and there is often poor correlation
with the mRNA fraction. Also, the relative abundance of 18S and 28S rRNA is
many fold greater than most mRNA species, making the use of the former to
assess the latter problematic. Internal control genes (house-keeping genes)
are often used instead. An ideal house-keeping gene should be expressed
at about the same level in the tissue examined as the target genes, and its
own expression should not change in the different conditions examined.
However the expression of many of the commonly used house-keeping
genes is known to vary under different treatment or disease conditions,
[227–229] and this is often not formally assessed when data is analysed.
In order to address this problem a strategy has been developed to assess a
panel of candidate house-keeping gene on the cell or animal model in
question, using equal numbers of treated and non-treated samples. The
data derived from real-time PCR for these genes is then analysed by
geNorm, a freely available software tool. This determines the relative
stability of each gene, and also allows estimation of the number of genes to
ultimately choose. The geometric mean of these chosen house-keeping
genes is then used for normalisation in the experimental analysis. [230]
Using the PrimerDesign 12 gene geNorm kit I determined the relative stability
of the 12 housekeeping genes using cDNA derived from the livers of 10
wild-type animals, 5 treated with 11 weeks CCl4 and 5 treated with olive oil.
A pragmatic choice between using the number of housekeeping genes to
achieve an acceptable level of stability and practical consideration of the
amount of sample needed was made, and a combination of 4
house-keeping genes was considered a suitable compromise (Figure 5.14).
The increase in stability gained by including further house-keeping genes
(represented by the pairwise variation, V) was only minor. The 4 most stable
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Figure 5.14. Determination of the number of house-keeping genes for
normalisation in ﬁbrotic murine liver. The addition of further house-keeping
genes does not increase the stability (lower y-axis value) after a
combination of the most stable 4 genes is used.
based on this analysis were B2m (-2-microglobulin), Ywhaz (tyrosine
3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta
polypeptide), Rpl13a (ribosomal protein L13a), and Sdha (succinate
dehydrogenase complex, subunit A, ﬂavoprotein) (Figure 5.15).
5.2.7.2 Expression of Acta2 (a-smooth muscle actin), Col1a1 (collagen,
type 1, alpha 1) and Timp-1 during recovery from liver ﬁbrosis
The relative expression of the proﬁbrotic genes Acta2 (a-smooth muscle
actin), Timp-1 and Col1a1 (collagen, type 1, alpha 1) was determined in
cDNA derived from the livers of wild-type and p75NTR/exonIII-/- animals at
each time point. The geometric mean of the 4 house-keeping genes was
used to normalise for starting mRNA quantity.
The expression of Acta2 was 65.9% greater in livers of p75NTR/exonIII-/-
animals compared with wild-types at day 1 of recovery, and 263.4% greater
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Figure 5.15. Average expression stability values of house-keeping genes in
murine liver ﬁbrosis. The most stable pair of house-keeping genes is show to
the right, with decreasing stability of genes along the left of x-axis.
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Figure 5.16. Expression of Acta2 (a-smooth muscle actin) in recovery from
ﬁbrosis. There is greater expression of Acta2 in livers from p75NTR/exonIII-/-
animals compared with wild-types at day 1 and day 3 of recovery. n=4-6
animals/cohort.
in p75NTR/exonIII-/- livers than wild-types at day 3 (Figure 5.16) . Expression at
other time points was similar. The expression of Timp-1 was 65% greater in
p75NTR/exonIII-/- livers compared with wild-type livers at day 1 of recovery,
and similar at all other time points (Figure 5.17) . The expression of Col1a1
was 36.1% lower in the livers of p75NTR/exonIII-/- animals compared with
wild-type animals at day 1, but 83.6% higher at day 3 (Figure 5.18) .
These data broadly support Acta2, Timp-1 and Col1a1 being by hMFB since
the pattern of expression is in keeping with both hMFB numbers and
architectural appearances although the differences in architectural
resolution and hMFB loss identiﬁed earlier are not as apparent.
5.3 Discussion
To deﬁne the role of p75NTR-ligand interactions in the recovery from liver
ﬁbrosis I have used a p75NTR/exonIII-/- mouse in an established model of
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Figure 5.17. Expression of Timp1 in recovery from liver ﬁbrosis. There is greater
expression of Timp1 in livers from p75NTR/exonIII-/- animals compared with
wild-types at day 1 of recovery. n=4-6 animals/cohort.
Figure 5.18. Expression of Col1a1 (collagen type 1, alpha 1) in recovery from
liver ﬁbrosis. There is greater expression of Col1a1 in livers from
p75NTR/exonIII-/- animals compared with wild-types at day 3 of recovery.
n=4-6 animals/cohort.
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remediable liver ﬁbrosis. This has allowed the mechanistic demonstration of
the importance of p75NTR-ligand mediated events in the deletion of
proﬁbrotic hMFBs during recovery from liver ﬁbrosis. I have shown that the
lack of ligand-related p75NTR-mediated events delays the histological
resolution of liver ﬁbrosis. The reduction in hMFB numbers that occurs in
parallel with histological resolution is also retarded, and that this may be
due to a failure of p75NTR triggered hMFB apoptosis.
5.3.1 hMFBs persist during retarded histological resolution in
p75NTR/exonIII-/- mice
Recovery from liver ﬁbrosis relies upon matrix metalloproteinase-mediated
degradation of ﬁbrotic matrix to restore the normal hepatic architecture. In
parallel with this there is a dramatic reduction in the number of hMFBs, the
cells largely responsible for the ﬁbrotic neomatrix during the development of
ﬁbrosis. The loss of hMFBs is largely attributable to apoptosis. Apoptosis may
result from the removal of a survival signal or from a pro-apoptotic signal.
Hepatic MFBs are sensitive to their structural environment; ﬁbrotic matrix rich
in ﬁbrillar collagens I and III is known to maintain the activated phenotype
and have proliferative effects. [5] When this ﬁbrillar matrix is lost the signals to
the local hMFBs are lost too, leading to hMFB apoptosis. Signals from the
extracellular matrix may be mediated via ligation of integrins expressed by
hMFBs; v3 integrins are expressed by hMFBs and ligation enhances both
survival and proliferation. [261] This may account, in part, for the loss of
hMFBs observed, and establishes a positive feedback loop of architectural
resolution and hMFB loss. Soluble factors also function as mediators of hMFB
survival. IGF-1 and TIMP-1 (through MMP inhibition) have both been shown
to be protective from serum-deprivation induced apoptosis. [75, 87]
However another signiﬁcant factor enhancing the loss of hMFBs are the
pro-apoptotic mediators. When hMFB apoptosis is augmented during
recovery histological resolution is more rapid. Neurotrophin-mediated p75NTR
signalling has been shown to be pro-apoptotic for a number of cells,
November 12, 2008 149Chapter 5. p75NTR/exonIII-/- model of ﬁbrosis
including hMFBs. I have demonstrated that the absence of
ligand-competent p75NTR leads to retarded histological resolution, with the
persistence of hMFBs due to a failure of apoptosis at the intermediate time
points. However by 10 days of recovery the architectural appearance and
numbers of hMFBs are the same in both WT and p75NTR/exonIII-/- livers. This
indicates that whilst p75NTR mediated events are important during the early
phases of recovery other mechanisms compensate to achieve the same
ultimate outcome.
I have shown that proNGF is a survival factor for human hMFBs in vitro.
Previous work has indicated that pro-neurotrophin signalling may be p75NTR
dependent, in addition to sortilin. If the proNGF effect is a p75NTR mediated
event in murine hMFBs then the absence of ligand-binding p75NTR at the
times when proNGF is present in signiﬁcant quantities should reduce the
survival signal for hMFBs. ProNGF levels in the rat model of recovery are
highest at peak ﬁbrosis and decline during recovery. This suggests that
proNGF-mediated survival may be important during the development of
ﬁbrosis. However the degree of ﬁbrosis achieved at peak injury in both
p75NTR/exonIII-/- and WT animals was similar, as was the number of hMFBs.
This suggests that either the proNGF-mediated survival is mediated through
p75NTR but is unimportant during the development of ﬁbrosis, or that p75NTR
plays no part in mediating such events.
5.3.2 Loss of ligand-competent p75NTR reduces the
proliferative capacity of cell in the liver
In vitro work suggested that proNGF was a mitogen for human hMFBs.
Interestingly there was signiﬁcantly less hMFB proliferation in p75NTR/exonIII-/-
livers compared with WT livers at peak ﬁbrosis, suggesting that p75NTR
ligand-binding capacity is needed for some mitogenic effect. In this
instance the mitogenic effects of proNGF may be mediated by p75NTR. It is
of note that although the amount of hMFB proliferation was signiﬁcantly less
in p75NTR/exonIII-/- livers the number of hMFBs appeared to be the same as
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in wild-type liver. In recently published work using p75NTR-/- mice and a
model of spontaneous liver injury using plasminogen deﬁciency (Plg-/-),
there was reduced total liver cell proliferation in Plg-/- / p75NTR-/- mice
compared with Plg-/- mice that were wild-type for p75NTR. [212] Whole liver
homogenates from these animals contained signiﬁcantly lower amounts of
hepatocyte growth factor (HGF). Co-culture of hepatocytes with p75NTR-/-
hMFBs resulted in a reduction in hepatocyte proliferation compared with
co-culture with wild-type hMFBs. The addition of HGF “largely restored” this
effect.
5.4 Summary of key ﬁndings
During spontaneous resolution of experimental liver ﬁbrosis:
• Histological resolution is retarded in p75NTR/exonIII-/- livers
• Hepatic MFB loss is retarded in p75NTR/exonIII-/- livers
• Fewer hepatic MFBs undergo apoptosis in p75NTR/exonIII-/- livers
• Hepatic MFB proliferation is reduced at peak ﬁbrosis in p75NTR/exonIII-/-
livers
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Studies using p75NTR/exonIII-/- cells
in tissue culture models
6.1 Introduction
Previous work in other systems has loosely suggested that p75NTR may have a
role in modulating ﬁbrotic processes independently of cell survival. Diseases
such as multiple sclerosis, [262] stroke, [263] nerve injury, [264, 265] and spinal
cord injury [241] are associated with ﬁbrin deposition, and p75NTR
upregulation has been described in each case. However apoptosis is also a
feature in some of these examples, such as neuronal cell death in cerebral
iscahemia [263] and oligodendrocyte death after spinal cord injury. [241]
In non-neuronal tissue and diseases p75NTR expression has also been shown
to correlate with ﬁbrin deposition, situations in which apoptosis also plays a
signiﬁcant role. For example, in athersclerotic plaques p75NTR is expressed by
-sma positive neointimal cells in experimentally induced lesions and also by
cultured human endarterectomy-derived cells (HEDC). [266] This correlates
with TUNEL positivity in vivo, and HEDC undergo apoptosis in response to
neurotrophins. These plaques are also ﬁbrin rich. In skin and lung ﬁbroblasts
prolonged NGF treatment was found to induce p75NTR expression and
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increase migration, although not proliferation, collagen production, MMP
production or activation. [267]
Recent work has suggested that p75NTR plays a signiﬁcant role in mediating
activation of hepatic stellate cells into hMFBs. Indeed, there was a
complete failure of activation and proﬁbrotic gene expression in isolated
p75NTR knockout cells. [212] In the in vivo model of recovery from liver ﬁbrosis
described earlier there was no evidence of a failure of activation of hMFBs.
However in view of the data linking p75NTR to activation and ﬁbrogenesis it
was important to examine the behaviour of p75NTR/exonIII-/- hMFBs more
closely.
6.2 Activation of p75NTR/exonIII-/- hMFBs is similar
to wild-type
Hepatic stellate cells were isolated from the pooled livers of 3 or 4 WT or
p75NTR/exonIII-/- animals following an established protocol. [254] Cells were
activated to hMFBs by culture on plastic, and used between passage 1 and
3.
6.2.1 Adoption of myoﬁbroblast morphology and -smooth
muscle actin expression
During activation quiescent hepatic stellate cells change from a rounded
retinoid-storing cell to adopt a myoﬁbroblast-like phenotype. These
activated cells are considerably larger and have a stellate morphology.
Expression of -sma is observed, and is regarded as a marker for hMFBs.
After 7 days of culture after isolation both WT and p75NTR/exonIII-/- cells
adopted typical stellate morphology. Cells from both genotypes also
expressed -sma, demonstrated by immunoﬂuoresence. The typical ﬁbrillar
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cytoplasmic distribution of this protein is observed in both WT and
p75NTR/exonIII-/- cells (Figure 6.1).
6.2.2 Expression of proﬁbrotic genes by p75NTR/exonIII-/-
hMFBs
In contrast to quiescent hepatic stellate cells, hMFBs express a number of
proﬁbrotic genes, reﬂecting their role as the major cellular source of
neomatrix in liver ﬁbrosis. In addition to Acta2 (a-smooth muscle actin),
Timp-1 and Col1a1 (collagen type 1, alpha 1) are also expressed. TIMP-1
inhibits matrix metalloproteinase activity allowing the persistence of the
ﬁbrillar collagen.
Real-time PCR on cDNA derived from WT and p75NTR/exonIII-/- hMFBs
demonstrates that cells from both genotypes express Acta2, Timp-1 and
Col1a1 to the same extent (Figure 6.2). In WT cells this represented a
612-fold increase in Col1a1 expression, a 383-fold increase in Acta2
expression and a 33-fold increase in Timp-1 expression compared with newly
isolated quiescent HSCs (Figure 6.3).
6.3 p75NTR/exonIII-/- hMFBs show an attenuated
proliferative response to mitogens
Culture activated hMFBs from WT and p75NTR/exonIII-/- animals were
assessed for their response to neurotrophins and the known mitogens PDGF
and serum. Compared with serum deprivation, the addition of serum
produced a 4.2-fold increase in thymidine incorporation in WT cells,
compared with only a 2.5-fold increase in p75NTR/exonIII-/- cells (p=0.04).
Similarly recombinant human PDGF produced a 2.3-fold increase in
thymidine incorporation compared with only a 1.3-fold increase in
p75NTR/exonIII-/- cells (p=0.003) (Figure 6.4).
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Figure 6.1. -smooth muscle expression by WT and p75NTR/exonIII-/- murine
hMFBs. After 7 days of culture on plastic WT and p75NTR/exonIII-/- HSCs were
stained for -smooth muscle actin. Loss of ligand-competent p75NTR does
not inﬂuence expression of a-smooth muscle actin and adoption of
myoﬁbroblast-like phenotype. Scale bars 50m.
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Figure 6.2. Expression of proﬁbrotic genes in p75NTR/exonIII-/- and WT hMFBs.
The expression of Col1a1, Acta and Timp1 is similar in both WT and
p75NTR/exonIII-/- hMFBs. n=2/3 separate cell preparations.
Figure 6.3. Change in expression of proﬁbrotic genes with activation in WT
hMFBs. The expression of Col1a1, Acta and Timp1 is dramatically increased
during activation to hMFBs. n=3 separate cell preparations.
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Figure 6.4. Absence of ligand competent p75NTR stunts the proliferative
response of hMFBs. Proliferation of WT and p75NTR/exonIII-/- hMFBs in
response to NGF 100ng/ml, proNGF 10ng/ml, PDGF-BB 10ng/ml or 16% fetal
calf serum, quantiﬁed by [3H]-thymidine incorporation. +, p=0.04; ++,
p=0.003. n=6.
In human hMFBs, recombinant human proNGF produced a modest 73.8%
increase in thymidine incorporation (p=0.008 vs control). In WT murine
hMFBs, recombinant human proNGF produced a 27% increase, compared
with no increase in p75NTR/exonIII-/- cells. Mature cleaved NGF produced no
increase in proliferation in either WT or p75NTR/exonIII-/- cells, consistent with
the result observed in human hMFBs.
6.4 p75NTR/exonIII-/- hMFBs express TrkA and fail to
undergo apoptosis after addition of NGF
Human and rat hMFBs show an increase in the number of cells undergoing
apoptosis after treatment with mature cleaved NGF after 8 hours of
treatment. In human cells this effect is no longer apparent after 24 hours of
treatment. Human and rat hMFBs express p75NTR and sortilin but not TrkA.
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Isolated murine hMFBs were assessed for their apoptotic response to
neurotrophins and their expression of neurotrophin receptors was
determined.
6.4.1 p75NTR /exonIII-/- hMFB response to apoptotic stimuli
Wild-type and p75NTR/exonIII-/- hMFBs were treated in serum free conditions
in the presence or absence of cycloheximide with mature or proNGF for 6
hours. Apoptosis was determined by direct observation of the
morphological features of apoptosis after the addition of acridine orange
(Figure 6.5). Neither WT nor p75NTR/exonIII-/- cells signiﬁcantly increased their
apoptotic index after the addition of mature NGF. The protective effect of
proNGF on serum deprivation induced apoptosis was small (20.7%, p>0.05 vs
serum free) and there was no effect on cycloheximide-induced apoptosis.
The small protective effect of proNGF from serum deprivation induced
apoptosis was not observed in p75NTR/exonIII-/- cells.
6.4.2 Neurotrophin receptor expression by murine hMFBs
To assess whether the responses of murine hMFBs to treatment with NGF and
proNGF were a consequence of a different proﬁle of neurotrophin receptor
expression compared with human hMFBs, cDNA derived from murine cells
was examined by RT-PCR.
6.4.2.1 Trk receptor expression
Quiescent WT murine HSCs express low levels of Ngfr (p75NTR) and do not
express Ntrk1 (TrkA). However, in contrast to human and rat hMFBs, murine
hMFBs express Ntrk1 (TrkA) in addition to Ngfr (p75NTR). Ntrk3 (TrkC) is not
expressed by quiescent cells but is expressed by activated cells. Ntrk2 (TrkB)
is expressed by quiescent cells but is expressed at lower levels by activated
cells (Figure 6.6).
November 12, 2008 158Chapter 6. p75NTR/exonIII-/- hMFB cell studies in vitro
Figure 6.5. Effect of genotype on murine hMFB apoptosis in the presence of
NGF and proNGF. proNGF had a small protective effect on serum
deprivation induced apoptosis in WT cells, not observed in p75NTR/exonIII-/-
cells. There was no protection from CHX-induced apoptosis. Mature NGF
had no signiﬁcant effect on apoptosis in either genotype. n=7.
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Figure 6.6. Expression of Trk receptors in murine hMFBs. Quiescent murine
HSCs (Q) express Ntrk2 (TrkB) and a low level of Ngfr (p75NTR). Murine hMFBs
(A) express Ntrk1 (TrkA) and Ntrk3. Expression of Ngfr increases and
expression of Ntrk2 decreases after activation. Mouse brain included as
positive control, no-RT sample included as negative control. Equal
expression of Actb demonstrates equal starting template. Representative of
3 separate cell preparations.
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Figure 6.7. Expression of s-p75 in exonIII-/- murine hMFBs. Ampliﬁcation of
cDNA from WT murine hMFBs with primers recognising exons III (eIII) or VI
(eVI) shows complete expression of Ngfr. p75NTR/exonIII-/- hMFBs, as
expected, do not express exonIII, but do show ampliﬁcation using primers
recognising exonVI. This represents continued expression of s-p75, lacking
the ligand-binding domain coded by exonIII. Brain included as positive
control, no-RT sample included as negative control. Ampliﬁcation of Actb
(-actin) demonstrates equal starting template. Representative of 3 cell
preparations of each genotype.
6.4.2.2 p75NTR exonIII expression
p75NTR/exonIII-/- cells have been described as expressing a truncated form
of p75NTR lacking the extracellular ligand binding domain. [167] To establish
if this was also the case in hMFBs derived from these mice, cDNA was
examined by RT-PCR using primers directed speciﬁcally against exonIII, in
addition to primers directed towards exon VI. In keeping with the previous
observation, p75NTR/exonIII-/- cells did not express exonIII but did express the
other exons (Figure 6.7).
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6.5 Discussion
6.5.1 p75NTR/exon III-/- cells activate and express proﬁbrotic
genes normally
The data in this chapter demonstrate that HSCs isolated from
p75NTR/exonIII-/- mice transdifferentiate to hMFBs after isolation and culture
on plastic with the same kinetics as WT cells. Morphologically the same
myoﬁbroblast appearance is achieved, and the expression of the proﬁbrotic
genes Timp-1, Col1a1, and Acta is similar. However the response of
p75NTR/exonIII-/- cells to mitogens is signiﬁcantly attenuated compared with
WT cells. In addition, the pro-apoptotic response of WT murine hMFBs to
mature NGF is absent, compared with that observed in both rat and human
cells. The expression of neurotrophin receptors by WT murine hMFBs is also
different compared with rat and human cells, with TrkA expression
demonstrable after activation.
The phenotype of p75NTR/exonIII-/- animals after treatment with CCl4 at
peak injury (one day after the ﬁnal injection) is similar to that seen in WT
animals. During recovery the p75NTR/exonIII-/- animals show retarded
resolution after an initial progression of ﬁbrosis. At peak injury the expression
of hMFB derived proﬁbrotic genes is similar in both genotypes. However in
recent work published by Passino et al, [212] isolated hepatic stellate cells
from p75NTR knockout mice failed to activate when cultured. The cells failed
to adopt myoﬁbroblast-like morphology, with reduced production of
collagen I and -smooth muscle actin protein, and reduced expression of
Col1a1 and Tgfb (TGF-) genes. This phenotype was recapitulated in WT
cells by lentiviral delivered RNAi targeted towards Ngfr (p75NTR), and
restored in p75NTR -/- cells by the adenoviral delivery of full length p75NTR or
intracellular domain alone. The apparent discrepancy between the in vitro
activation properties of p75NTR in the published work and the phenotype
observed in my data meant that examination of the properties of cells
isolated from p75NTR/exonIII-/- animals genetically identical to those used in
my in vivo model was essential.
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Isolated murine p75NTR/exonIII-/- hepatic stellate cells activated with the
same kinetics and to the same extent as WT cells, in contrast to the data
published by Passino et al. [212] This is consistent with the -sma positive
spindle cells that are evident, and fail to be removed, from the chronically
injured p75NTR/exonIII-/- livers. The ﬁnding that there is an attenuated
response to mitogens in p75NTR/exonIII-/- cells is also consistent with the
signiﬁcantly reduced proliferative rate of non-parenchymal cells in vivo.
6.5.2 Murine hMFBs express a different panel of neurotrophin
receptors, and respond differently to neurotrophins
No proapoptotic response to mature NGF was observed in WT or
p75NTR/exonIII-/- cells, in contrast to both the behaviour of human hMFBs
and to previously published data. [212, 244] A dramatic 3-4 fold increase in
apoptosis was observed after NGF treatment of isolated murine HSCs. [244]
This, however, was allowing only 12 hours after isolation prior to treatment, a
time at which the activation process is barely starting. I have shown by
RT-PCR that quiescent murine HSCs do not express Ntrk1 (TrkA), but do
express Ngfr (p75NTR). This pattern of neurotrophin receptor expression
favours a pro-apoptotic response to NGF. However upon activation to
hMFBs in murine cells there is expression of Ntrk1 (TrkA). The presence of both
p75NTR and TrkA typically favours a survival or differentiation effect of NGF,
explaining the absence of an apoptotic effect in my data, and accounting
for the difference to the effect observed in human and rat cells that do not
express TrkA and do respond to NGF treatment by undergoing apoptosis.
Two points requiring explanation remain. The work by Passino et al used fully
activated murine hMFBs, and an apoptotic response to NGF was
demonstrated in WT cells, in contrast to my work. The same paper showed
that isolated p75NTR-/- HSCs did not activate normally, a situation resolved by
expressing full length or ICD p75NTR. The murine HSCs isolated from
p75NTR/exonIII-/- in my work continue to express the Ngfr gene in the
absence of the ligand binding domain, equivalent to s-p75. This obviously
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includes the ICD, so these cells should be considered analogous to the ICD
transfected cells used by Passino et al. In keeping with this analogy, cells
expressing p75NTR ICD activate normally. It is, therefore, clear that the HSCs,
both WT and p75NTR-/- cells isolated by Passino et al are not the same as
those in my work. The isolation procedure used by Passino et al differs from
the method I used in that it involved in situ perfusion of the liver prior to
dissection. Whether this means a different sub-population of cells is isolated
is not clear, parallel isolation by the method I have employed and the
method used by Passino et al would allow this to be examined.
The apparent failure of mature NGF to produce an apoptotic response in
murine hMFBs, explained though it is by the expression upon activation of
TrkA in vitro, seems inconsistent with the failure of recovery due to a
retardation of hMFB apoptosis in p75NTR/exonIII-/- mice. A possible
explanation is that the expression of TrkA observed by hMFBs in vitro is not
present in vivo in the context of liver ﬁbrosis. This is supported by the
observation by Asai et al that there is no TrkA expression in mouse livers after
partial hepatectomy that produces increased expression of both NGF and
p75NTR-/-. [244] However the lack of a p75NTR receptor capable of binding
ligand will prevent all available ligand interactions, rather than merely NGF
alone. The lack of an in vitro apoptotic effect of NGF suggests that, in mice
at least, other neurotrophin(s), or unknown ligands, play(s) a pro-apoptotic
role via p75NTR ligation in vivo. The candidates for this include the ligands
whose corresponding Trk receptor is not expressed by murine hMFBs.
Human hMFBs are protected from both serum-deprivation and
cycloheximide induced apoptosis by proNGF. Although not statistically
signiﬁcant, proNGF does protect WT murine hMFBs from serum-deprivation
induced apoptosis, an effect not observed in p75NTR/exonIII-/- hMFBs. This
suggests that p75NTR acts as a receptor for proNGF, consistent with published
work. [200] The apparently weaker effect of proNGF in murine cells
compared with human cells may be explained by the fact that the data
was obtained after 8 hours incubation, a time point at which the effect in
human cells was also less noticeable.
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6.5.3 Loss of ligand-competent p75NTR abrogates hMFB
response to mitogens
hMFBs derived from p75NTR/exonIII-/- animals had a signiﬁcantly stunted
response to serum and PDGF, well described hMFB mitogens. This is
consistent with the marked reduction in Ki-67 immunopositive
non-parenchymal cells at day 1 of recovery in livers from p75NTR/exonIII-/-
animals (Chapter 5). This suggests that tonic proliferation of hMFBs depends
on a property of the p75NTR ICD unrelated to ligand binding. p75NTR has
been demonstrated to mediate proliferation in other cell lines, for example
breast carcinoma cells, but this was ligand-related (NGF) signalling. Equally
the p75NTR ICD mediates demonstrable effects, and is actually generated
by secretase cleavage from full length p75NTR after ligation. However,
translocation of p75NTR ICD to the nucleus mediates apoptosis in the
situations described. [268] The exact mechanism by which p75NTR ICD
facilitates hMFB proliferation is not, therefore, clear.
6.6 Summary of key ﬁndings
• p75NTR/exonIII-/- HSCs activate normally after isolation
• p75NTR/exonIII-/- hMFBs express Ntrk1 (TrkA) and fail to undergo
apoptosis after the addition of mature NGF
• p75NTR/exonIII-/- hMFBs show attenuated proliferative responses to
established mitogens
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7.1 Overview
It is well established that liver ﬁbrosis can be fully reversible, and even
advanced cirrhosis has some capacity to regenerate, with evidence of
matrix remodelling and regession of ﬁbrosis. Examples of this process have
been well documented in numerous cases of human liver ﬁbrosis from a
variety of aetiologies. The cellular and molecular mechanisms behind this
recovery have been, and continue to be, studied in rodent models of
ﬁbrosis and cirrhosis.
Recovery is characterised by the resolution of ﬁbrotic matrix with a partial or
complete restitution of normal architecture. This is accompanied by a loss of
the cellular source of ﬁbrotic matrix, the hepatic myoﬁbroblast. During
recovery from ﬁbrosis there is a reduction in hMFB numbers paralleling the
observed levels of non-parenchymal cell apoptosis. [14] Research into the
mechanisms regulating hMFB survival and apoptosis has identiﬁed
numerous factors that either promote cell death or survival, for example
serum deprivation and cycloheximide promote cell death in vitro, [87] and
TIMP-1 [75] and IGF-1 promote survival. [87] Furthermore, proof of concept
that enhancement of hMFB loss promotes faster resolution has been
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published. [225] Clearly factors that selectively promote hMFB apoptosis
without extensive effects on other cells may represent a means of
stimulating recovery from ﬁbrosis in vivo.
It has been shown previously that rat hMFBs express p75NTR and undergo
apoptosis when exposed to NGF. [110] After a single dose of carbon
tetrachloride in mice there is upregulation of NGF expression, localised to
hepatocytes. [209] The expression of mature and proNGF was studied
during recovery from experimental liver ﬁbrosis and cirrhosis produced by
chronic carbon tetrachloride. The differential effects of mature and proNGF
on human hMFB behaviour in vitro was determined. Finally the role of p75NTR
mediated events in recovery from liver ﬁbrosis in vivo was examined
mechanistically using a mouse expressing a ligand-incompetent form of
p75NTR.
7.2 Summary of key ﬁndings
7.2.1 Mature and proNGF are regulated differently in recovery
from liver ﬁbrosis
In contrast to the upregulated expression of NGF following a single dose of
carbon tetrachloride producing a self-limiting injury, the expression of NGF
during recovery from 4 or 12 weeks of chronic injury is much more level.
Assessing by both real-time PCR and immunoblotting of whole liver, the
amount of NGF is similar throughout recovery at a level similar to control
normal liver. The stark contrast between data for NGF expression from the
acute and chronic injury may reﬂect the profound difference between a
single acute injury and chronic iterative injury. It is incorrect to think of the
effects of chronic repeated doses as being merely summative effects of
single doses. Similarly the processes during recovery from chronic injury are
also distinct from the self-limiting phase of an acute injury.
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After a single dose of CCl4 a profound inﬂammatory reaction is initiated.
Any measurement made in the 24-48 hours following this may be
contributed to signiﬁcantly by this inﬂammatory cell population. In the
chronic injury models used in this work acute inﬂammation follows each
injection. However with iterative injury the nature of the inﬂammatory cell
population in the liver changes and chronic inﬂammatory cells are also
present. The ﬁrst animals, those designated “Peak ﬁbrosis”, in each model
were harvested 24 hours after the ﬁnal dose, which may limit the
identiﬁcation of changes associated with the most acute phase of injury.
During recovery the acute inﬂammatory cell population in the liver
diminishes rapidly, within the ﬁrst 14 days, although other cells implicated in
the restitution, such as macrophages, remain. If NGF expression requires an
acute inﬂammatory milieu, either the acute inﬂammatory cells themselves
or factors they secrete, then expression would be lower during all but the
early time points of recovery. The human liver biopsies previously studied,
showing high levels of NGF expression, were all from patients with ﬂorid
steatohepatitis. This is characterised partly by increased numbers of
neutrophils, so whilst being undoubtedly a chronic disease process there is a
heavy acute inﬂammatory contribution. [209]
Expression of NGF in recovery from chronic ﬁbrosis is localised to isolated
hepatocytes, myoﬁbroblast-like cells in residual ﬁbrotic bands and biliary
epithelial cells. This is largely in keeping with other published expression of
NGF. [207, 208]
In many tissues and diseases NGF is present almost entirely as high
molecular weight forms, with almost no mature unmodiﬁed 13.2kDa NGF
present. However, most of these high molecular weight species have been
designated as unmodiﬁed or glycosylated forms of proNGF purely on the
basis of their high molecular weight [191, 194, 196, 269, 270] although they
were identiﬁed by methods that do not distinguish between mature and
proNGF. Whilst it is correct to conclude from these studies that there is little
unmodiﬁed mature NGF present it is not accurate to say these large species
must be precursor forms, although one may expect at least some of the
high molecular weight species to be proNGF.
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In those papers in which speciﬁc antibodies raised against the prodomain of
proNGF have been used to identify high molecular weight species, some of
those high molecular weight species previously identiﬁed on immunoblots
using an antibody raised against mature NGF are not present when an
antibody raised speciﬁcally against the prodomain is used. [196, 197]
I have demonstrated that during recovery from liver ﬁbrosis there is minimal
13.2kDa unmodiﬁed mature NGF, with a number of high molecular weight
forms. When an antibody raised against the prodomain of proNGF is used a
number of these higher weight species are no longer observed, suggesting
that they are heavily post-translationally modiﬁed mature NGF species
rather than proNGF species. Furthermore, whilst the overall amount of NGF
protein remains unchanged during recovery, one of the species identiﬁed
as proNGF falls from highest levels at peak ﬁbrosis in both 4 and 12 week
models to those seen in normal liver during recovery. The kinetics of this
reduction in proNGF matches that of hMFB loss during recovery.
The implications of the ﬁnding that proNGF levels fall in an apparently
regulated manner in parallel with the loss of hMFBs during recovery suggest
that proNGF may be functioning as a ligand. Furthermore, its effects may be
different from mature NGF, and regulation of its conversion could represent
the critical step.
7.2.2 ProNGF and mature NGF have functionally opposed
effects on hMFB survival
Originally pro-neurotrophins were thought to be inactive intracellular
precursors. At most the prodomain aided intracellular trafﬁcking and
folding. Once the prodomain was cleaved the active neurotrophin was
liberated, secreted and exerted its function. Recent work has shown this to
be only the beginning of a pro-neurotrophin’s role.
Pro-neurotrophins have biological activity of their own. Artiﬁcially modiﬁed
proNGF whose furin-cleavage site has been rendered cleavage-resistant
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has been the tool of choice examining this activity. In all cell types
examined thus far, all of which have a traditional NGF-mediated cellular
response, proNGF has produced the same type of response; for example if
NGF triggered apoptosis in a particular cell then proNGF also produced
apoptosis. There has been disagreement on the relative efﬁcacy of this
response; a murine proNGF rendered cleavage-resistant by a single
nucleotide change that produced a single aminoacid substitution was less
active than mature NGF [188] at stimulating neurite outgrowth in PC12 cells,
a p75NTR/TrkA mediated effect. An alternate form of cleavage-resistant
proNGF was generated by more numerous modiﬁcations, [187] with the
addition of 6 histidine residues at the C-terminus, and 2 RR to AA
substitutions, one to prevent cleavage of the His tag and one at the
furin-cleavage site to disrupt cleavage. This more heavily modiﬁed form was
at least 10 times more potent than mature NGF at stimulating apoptosis in
vascular smooth muscle cells that express p75NTR alone. Whilst these 2 rival
cleavage-resistant proNGF forms have never been compared
“head-to-head” measuring the same cellular response by the same
methods in the same cells both are active, producing the same type of
effect as that seen with NGF alone.
The data presented here shows a profoundly different response to proNGF
and mature NGF. In rat hMFBs there is p75NTR expression in the absence of
TrkA, and the addition of mature NGF triggered apoptosis but had no effect
on proliferation. I have demonstrated that activated human hMFBs also
express p75NTR but not TrkA. In the absence of serum mature NGF caused a
modest increase in apoptosis measured after an incubation of 4-8 hours.
However when incubation is extended to 24 hours there is no longer any
effect on apoptosis.
The difference in apoptosis after mature NGF treatment with different
periods of incubation may be partly explained by the speed with which
apoptosis occurs; once a cell engages its apoptotic machinery it can
complete its destruction to the extent that it can no longer be identiﬁed as
apoptotic within 15-30 minutes. This means that if a give apoptogen has a
peak effect after a given time it would only be measurable by the currently
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available methods used to quantify apoptosis for a short period. Choosing
a length of incubation that did not coincide with a peak effect may lead to
underestimation of the apoptogenic potential of any given factor. [247]
Previous work demonstrating the pro-apoptotic effect of mature NGF on rat
hMFBs has been in the presence of serum. Under these conditions the
background level of apoptosis is low and may favour the recognition of
pro-apoptotic effects as a consequence of a favourable signal-to-noise
ratio.
In contrast, proNGF treatment of activated human hMFBs protected them
from serum-deprivation induced apoptosis. This effect was reproducible
despite the difﬁculties presented by the heterogeneity of different human
cell preparations when compared with rodent cell preparations. For the ﬁrst
time the precursor of a speciﬁc neurotrophin has been shown to have the
diametrically opposite effect from its mature counterpart. Furthermore the
mechanism by which this effect is mediated is likely to be more complex
than merely blocking mature NGF/p75NTR interaction. hMFBs in culture
secrete mature proNGF which may represent an autocrine survival factor.
The only candidate receptor mechanism to mediate the effects of proNGF,
apart from stimulation of p75NTR and TrkA in a similar manner to mature NGF,
is sortilin. Sortilin is essential, in partnership with p75NTR, for the superior
efﬁcacy of the more heavily modiﬁed cleavage-resistant proNGF. [200] I
have demonstrated sortilin expression in rat and human hMFBs in vitro, and
sortilin expression during the resolution of liver ﬁbrosis in a rat model.
However, this is circumstantial evidence and it is not clear if sortilin is
mediating the differential effect of proNGF in human hMFBs. Sortilin is
predominantly an intracellular sorting protein so its mere presence in any
given cell would not be unexpected. To be a candidate receptor
mediating the effect of an extracellular ligand it must be present on the cell
membrane.
ProNGF may also have a differential effect on hMFB proliferation. Mature
NGF has no effect on human hMFB proliferation, conﬁrming the observation
made in rat hMFBs. [110] However proNGF appears to have a modest
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proliferative effect although this does not reach statistical signiﬁcance. An
effect of this magnitude could be an artefact of the protective effect of
proNGF since the presence of more cells at the end of the extended
incubations used for proliferation assays would lead to an increase in
absolute thymidine incorporation over that seen in a smaller number of
cells, even if the stimulus had no effect on the rate of apoptosis. However
an increase in total cell number of the same magnitude as that seen in
proliferation is not seen in proNGF versus control cells, using the MTS assay,
suggesting that a modest proliferative effect of proNGF may be present.
Data published on the effect of proNGF has predominantly used modiﬁed
cleavage-resistant forms. The data I have generated used wild-type proNGF
so there was no possibility that the modiﬁcations themselves produced
confounding effects. Some work was carried out using cleavage-resistant
proNGF kindly provided by Professor Margaret Fahnestock. This form was
created with only a single amino acid substitution, and was harvested from
the media of Sf9 insect cells infected by baculovirus containing the
sequence. As a control, media from Sf9 cells infected with empty vector
baculovirus was used. Whilst the cleavage-resistant proNGF produced a
signiﬁcant increase in LX2 cell numbers the same was also true of the control
empty vector condition. The possibility that insect cell media contained
bioactive factors that were inﬂuencing LX2 behaviour meant that only
wild-type proNGF was subsequently used, and indicates problems inherent
in artiﬁcially modiﬁed proteins.
7.2.3 The role of p75NTR in liver ﬁbrosis
I have demonstrated that ligand incompetent, but ICD expressing,
p75NTR/exonIII-/- murine HSCs transdifferentiate into hMFBs, both by culture
on plastic in vitro and after proﬁbrotic hepatic injury in vivo. This is consistent
with published data indicating that failure of murine p75NTR-/- HSC activation
in vitro was restored by transfection of either full length p75NTR or the ICD
alone. [212] This suggests that some function of the p75NTR ICD, unrelated to
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ligand-receptor interaction, is critical to allow activation. The p75NTR ICD
possesses a number of domains allowing interaction with cytosolic proteins,
although these have been studied principally in relation neurotrophin
ligation.
The absence of ligand-binding capacity in murine p75NTR/exonIII-/- hMFBs
does, in contrast, affect the proliferative response to mitogens. Both PDGF
and serum, both potent hMFB mitogens, stimulated signiﬁcantly less
increase in proliferative activity in p75NTR/exonIII-/- hMFBs than in WT cells.
Similarly there were markedly fewer Ki-67 +ve non-parenchymal cells, the
majority with a morphology and histological location consistent with hMFBs,
in the livers of p75NTR/exonIII-/- animals after 11 weeks of injury compared
with WT animals. The number of hMFBs at this time point were, however,
similar in both genotypes indicating that persistence/survival of hMFBs was
increased in p75NTR/exonIII-/- animals during liver injury. There was also
reduced hepatocyte Ki-67 positivity during the later stages of the recovery
period in p75NTR/exonIII-/- animals. In the work of Passino et al reduced “liver
cell” proliferation was described in p75NTR-/- animals, and failure of HGF
production by hMFBs in these animals was proffered as the explanation. It is
not clear by what mechanism the failure of hMFB proliferative activity I
describe is mediated. Tonic ligand-related p75NTR mediated events may be
required to allow normal responses to mitogens, and the production of
proNGF by human hMFBs in vitro may represent part of this proliferation
priming function.
A biphasic role for p75NTR ligand-related events was suggested by in vitro
studies with pro and mature NGF. The use of the p75NTR/exonIII-/- animal in
vivo allowed determination of the dominant role of p75NTR ligand-related
events in the development of, and recovery from, liver ﬁbrosis. The degree
of ﬁbrosis after injury was similar in WT and p75NTR/exonIII-/- animals but there
was signiﬁcant retardation of architectural remodelling and hMFB loss in
knockouts. This suggests that the dominant effect of p75NTR ligand-mediated
events is to enable resolution by hMFB apoptosis although after 10 days
these differences were absent. This also indicates that other factors
promoting hMFB loss and architectural remodelling eventually compensate
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later in recovery. Any loss of protective effect afforded by pro-neurotrophins
via p75NTR , as suggested by in vitro study, have also been compensated for
during injury.
7.2.4 A role for the mature NGF/proNGF balance in liver
ﬁbrosis?
A speculative role for neurotrophins orchestrating resolution from liver ﬁbrosis
can still be posited. Under conditions that dominate the landscape during
inﬂammation and ongoing injury, where TIMP levels are high and MMP
activity is largely held in check, hMFB numbers are high. ProNGF produced
by hMFBs and other cells in areas of damage remains in the extracellular
milieu since its MMP dependent degradation is inhibited. This helps to
maintain the survival of hMFBs, with contributions undoubtedly made by
other soluble factors such as TIMPs [271] and IGF, [87] and the ﬁbrotic matrix
itself via integrins such as v3. [261] The hierarchy of importance of these
signals is unclear although it is likely that a degree of biological redundancy
is present.
Upon the cessation of injury the extracellular environment changes. TIMP
levels fall so MMP activity is unharnessed. This allows degradation of ﬁbrotic
matrix but may also degrade proNGF, either completely or to the traditional
mature form. In neurological systems extracellular cleavage of proNGF to
mature NGF has been demonstrated in vivo to be plasmin mediated whilst
MMP-9 had no effect on this event but did degrade mature NGF. [272]
ProBDNF is also cleaved to BDNF extracellularly by tPA/plasmin such that this
may represent a common mechanism of pro-neurotrophin processing.
Plasmin has also been shown to activate MMPs, [273] and active MMP-7 has
been shown to cleave proNGF to mature NGF. [187] With the proNGF/NGF
balance now favouring apoptosis hMFB numbers fall in parallel with
architectural restitution.
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7.3 Evaluation of experimental models of rodent
ﬁbrosis used
There are clearly practical and ethical barriers to following the cellular and
molecular mechanisms mediating recovery from ﬁbrosis in humans. The use
of serial biopsy, particularly in patients who appear to be improving
clinically, is not possible or desirable. The use of animal models permits
frequent sampling and control over the time course and extent of liver
ﬁbrosis and resolution, and allows manipulation of these complex processes
in vivo.
Carbon tetrachloride intoxication in rodents is probably the most widely
studied experimental model of liver ﬁbrosis and is well characterized. It
recapitulates the pattern of disease seen in human ﬁbrosis and cirrhosis
associated with alcohol damage. [253, 274] Furthermore, the 12 week rat
CCl4 model (used in this thesis) induces micronodular cirrhosis which
undergoes dramatic but incomplete remodeling during a year of
spontaneous recovery. [231] Fibrotic neomatrix that appears not to have
undergone crosslinking, possibly mediated by tissue transglutaminase
activity, is degraded resulting in an attenuated macronodular cirrhosis.
These observations mirror the ﬁndings of Wanless and colleagues [85] in
explanted human cirrhosis of various aetiologies, where progressive septal
resorption leads to the formation of large cirrhotic nodules. Furthermore,
CCl4 appears to elicit a reproducible ﬁbrotic response, such that it is
frequently used as a model for mechanistic or proof of concept therapeutic
studies.
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7.4 Suggestions for future study
7.4.1 Exploration of the role of sortilin in liver ﬁbrosis
The role of sortilin in mediating the differential effect of proNGF in hMFBs
presented in this thesis is circumstantial. A sortilin (Sort1) -/- mouse has
recently been generated, and a role for sortilin in neuronal aging has been
deﬁned. [275] This mouse would provide a tool to study the role of
pro-neurotrophins in the development and recovery of liver ﬁbrosis. If the
effect on hMFBs during ﬁbrogenesis of sortilin-mediated pro-neurotrophin
related events is critical in allowing both proliferation and subsequent
persistence of hMFBs then the absence of Sort1 would be expected to result
in reduced ﬁbrosis and hMFB numbers at peak ﬁbrosis. Furthermore during
recovery, when the TIMP/MMP balance favours degradation of both
extracellular matrix and proNGF, then p75NTR-mediated apoptosis of hMFBs
should be unaffected by the lack of Sort1.
To determine if the protective and proliferative effects of proNGF on human
hMFBs in vitro are mediated by sortilin two approaches could be taken.
SORT1 expression can be inhibited by targeted siRNA, and an excess of
neurotensin can be added to cultures when treating with proNGF.
Neurotensin has been used to competitively inhibit pro-neurotrophin ligation
of sortilin in other systems. It would be anticipated that inhibition of the
interaction between sortilin and pro-neurotrophins would reduce the
anti-apoptotic and proliferative effects. Since sortilin functions as an
intracellular sorting protein, in addition to a receptor on the plasma
membrane, then global inhibition of SORT1 expression may have
confounding effects on cellular behaviour. Additionally, blockade of the
receptor function of sortilin with an excess of neurotensin may be troubled if
neurotensin itself has an effect, an issue not addressed in studies that have
used this technique. Careful controls would, therefore, be critical.
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7.4.2 Examination of other models of liver ﬁbrosis
Whilst the presence of proﬁbrotic hMFBs is generic to liver ﬁbrosis of all
aetiologies, the source of these cells has been the subject of some debate.
In addition to activation of sinusoidal HSCs, hMFBs are thought to derive
from portal or interstitial myoﬁbroblasts. [208, 276–279] The CCl4 model of
liver ﬁbrogenesis acts through perivenular inﬂammation to produce HSC
activation and subsequent ﬁbrosis. This distribution of injury and ﬁbrosis is
similar to that seen in steatohepatitis in human disease. However, ﬁbrosis
and cirrhosis can develop in humans in a periportal initial distribution, for
example in hepatitis C virus infection or primary biliary disorders. In these
situations portal myoﬁbroblast may contribute more to the ﬁbrogenic cell
population. It is, therefore, important to examine an animal model that
recapitulates these features to conﬁrm that observations in the CCl4 model
hold true.
Both p75NTR/exonIII-/- and Sort1-/- mice could, therefore, also be examined
in an alternative model of liver ﬁbrosis. In the bile duct ligation model the
primary lesion develops around biliary epithelium after the mechanical
stress on that epithelium initially leads to compensatory biliary epithelial cell
proliferation. Following this initial phase, chronic biliary obstruction leads to
activation of myoﬁbroblasts in periportal areas, ultimately leading to biliary
ﬁbrosis/cirrhosis. [280, 281] The initial source and location of myoﬁbroblasts
differs from those activated in other models, and whilst it is assumed, with
much data supportive, that generic processes occur in all models ﬁrm
experimental data is required to conﬁrm this.
7.4.3 Exploration of the therapeutic potential of
p75NTR-neurotrophin axis
The potential therapeutic approach of manipulation of the p75NTR-
neurotrophin axis can be assessed by augmenting hMFB apoptosis in liver
recovery. Recombinant human mature NGF has been used in phase II
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clinical trials for diabetic polyneuropathy. [282] Rodent models indicated
that reduced levels of NGF in tissues were associated with nerve ﬁbre
dysfunction, and that administration of NGF reduced the manifestations of
both toxic and diabetic polyneuropathy. [283–285] The phase II trial
indicated that subcutaneous administration was safe and well tolerated
[282] but the early evidence of symptom relief was not borne out by
subsequent phase III trials. [286] Similarly, recombinant human NGF has
been used in phase II and III clinical trials for HIV-associated distal sensory
polyneuropathy that is commonly seen in AIDS. Once again NGF was safe
and well tolerated but the optimism of efﬁcacy of phase II trials measured
by biological indices was largely dashed by larger phase III trials, although
signiﬁcant symptom relief was reported. [287, 288]
In pilot studies mature NGF has been administered to mice after an acute
self-limiting proﬁbrotic liver injury, deﬁning a dose that enhances recovery
and increases hMFB apoptosis. This can be extended to chronic liver injury
by administering mature NGF during both injury and recovery. It would be
expected that additional mature NGF would enhance hMFB apoptosis,
since no TrkA expression is demonstrable in vivo, and hasten histological
restitution.
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A.1 Primer sequences for real-time PCR
Primer and probe sequences used for rat NGF real-time PCR are [209]:
Forward: GTGGGTTGGAGATAAGACCACAG
Reverse: CACCTCGCCCAGCACTG
Probe: ACGGACATCAAGGGCAAGGAGGTG
A.2 Primer sequences for semi-quantitative RT-PCR
Sequences for semi-quantitative RT-PCR were selected after uploading the
full coding sequence for the mRNA of interest (from NCBI Nucleotide
database) into OLIGO, a computer programme facilitating primer design.
Automated primers were selected and analysed for favourable
thermokinetics and the absence of mispriming and primer-primer
interactions. These sequences were then compared against all sequences
in the BLAST database to ensure no other mRNA sequences from the same
organism were recognised. The following sequences and annealing
temperatures were used (See table A.2):
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A.3 GeneDetect Greenstar hyperlabeled
oligonucleotide probe details
Rat p75NTR probe hybridises to nucleotides 1142-1200 located within the
coding sequence of NM_012610.
CGCCTGCCAGATGTCGCCAGGTATCCCCGTTGAGCAGTTT
CTCTACCTCCTCACGCTTG
November 12, 2008 182Appendix B
Generic techniques
B.1 Preparation of DNase/RNase-Free Equipment
All glassware was washed, dried and covered in aluminium foil. For
DNase/RNase-free conditions, glassware was baked in a dry oven at 240C
for a minimum of 4 hours. All microscope slides used for histology sections
were placed in metal racks, wrapped in aluminium foil and were also baked
at 240C for a minimum of 4 hours. Plastic ﬁlter tips were bought as
DNase/RNase-free (Greiner, UK), or alternatively, tips were autoclaved at
121C for 20 minutes. All bench surfaces and micropipettes were wiped
down with “RNase Away” (Molecular Bio-Products, USA) before use.
B.2 DEPC-treated water
1ml of diethyl-pyrocarbonate (DEPC, Sigma) was added to 1 litre of distilled
water, left to stand for at least 12 hours, then autoclaved at 121C for 20
mins to deactivate DEPC.
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B.3 Preparation of Adhesive Coated Slides
All slides were coated with VECTABOND (Vector Laboratories, UK), which
was prepared by adding 7 ml of VECTABOND Reagent to 350 ml of acetone
(BDH, UK). The coating of slides was carried out at room temperature.
DNase/RNase-free frosted coated microscope slides (2.6 x 7.6 x 1.0 cm,
Surgipath Europe Ltd) were washed with acetone for 5 minutes. The slides
were then soaked in the VECTABOND solution for 5 minutes, before being
rinsed with DEPC-treated distilled water for 1 minute. Slides were covered in
low density polyethylene wrap and then dried overnight in a 37C incubator.
B.4 Tissue Sectioning
A microtome was used to cut 3 m sections from 10% formalin-ﬁxed
parafﬁn-embedded tissues. The microtome was cleaned and sterilised with
absolute alcohol between each tissue block to avoid cross-contamination
of tissue. Tissue sections were picked up from a water bath (previously
cleaned and sterilised with absolute alcohol) containing DEPC water (at
45C) onto DNase/RNase-free Vectabonded microscope slides and
incubated in a 37C incubator to dry tissue sections onto the slides. All tissue
sections were stored at room temperature in DNase/RNase-free conditions
until further use in immunohistochemistry or in situ hybridisation.
B.5 Haematoxylin and Eosin Staining
The staining procedure was carried out room temperature. Tissue sections
were de-parafﬁnised through xylene twice, each time for 5 minutes and
then through IMS twice, each time for 5 minutes, before being re-hydrated
in distilled water for 1 minute. Tissue sections were dipped in ﬁltered Mayer’s
Haemalum (BDH, UK) for 30 seconds before washing the slides thoroughly in
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tap water. Sections were next dipped in Eosin (BDH, UK) for 30 seconds
before being rinsed off with tap water, then de-hydrated through IMS twice,
each time for 5 minutes and then through xylene twice, again each time for
5 minutes. Sections were mounted in DPX (BDH, UK) and coverslipped
(Surgipath Ltd., UK).
B.6 Sirius red staining
B.6.1 Solution A
• Sirius red F3B (C.I. 35782) 0.5g
• Saturated aqueous picric acid solution 500ml
• Al little solid picric acid to ensure saturation
B.6.2 Solution B: Acidiﬁed water
• Add 5ml acetic acid (glacial) to 1 litre of water (distilled)
Sections are dewaxed and hydrated, and then stained in solution A for 1
hour. Sections are washed in 2 changes of solution B, and the slides are then
dried by shaking prior to dehydration, clearing in xylene and mounting.
B.7 Agarose gel electrophoresis
A 2% agarose gel was cast by melting 2 g agarose 3:1 HRB (Promega, UK) in
120 ml of 1x TBE containing 10g/ml ethidium bromide. The mixture was
boiled using a microwave set at full power for 2 minutes and the melted
solution poured into a standard gel plate/mould, producing a ~5 mm thick
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gel. A tooth comb was positioned 0.5 mm above the gel plate so that a
complete well formed once the gel had set. The gel was allowed to stand
at room temperature for 1 hour to harden. Once the gel had set, the comb
was removed and the gel submerged into 1x TBE/ethidium bromide in a gel
electrophoresis unit.
B.8 NuPage Buffers (Invitrogen)
B.8.1 NuPAGE® LDS Sample Buffer
Catalogue No. NP0007 (4X) 10ml
• Glycerol 4.00g
• Tris Base 0.682g
• Tris HCl 0.666g
• LDS (lithium dodecyl-sulfate) 0.800g
• EDTA 0.006g
• Serva Blue G250 0.75ml of 1% solution
• Phenol Red 0.25ml of 1% solution
• Ultrapure Water to 10ml
1x buffer should be pH 8.5
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B.8.2 Tris-Acetate Running Buffer
Catalogue No. LA0041 (20X) 500ml
• Tricine 89.5g (1M)
• Tris Base 60.5g (1M)
• SDS 10g (70 mM)
• Ultrapure Water to 500 ml
1x buffer should be pH 8.25
B.8.3 MOPS SDS Running Buffer
Catalogue No. NP0001 (20X) 500ml
• MOPS 104.6g (1.00M) 3-(N-morpholino) propane sulfonic acid
• Tris Base 60.6g (1.00M)
• SDS 10.0g (69.3mM)
• EDTA 3.0g (20.5mM)
• Ultrapure Water to 500ml
1x buffer should be pH 7.7
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B.8.4 NuPAGE® Transfer Buffer
Catalogue No. NP0006 (20X) 125ml
• Bicine 10.2g (500mM)
• Bis-Tris 13.08g (500mM)
• EDTA 0.75g (20.5mM)
• Ultrapure Water to 125ml
1x buffer should be pH 7.2
B.8.5 MES SDS Running Buffer
Catalogue No. NP0002 (20X) 500ml
• MES (2-(N-morpholino) ethane sulfonic acid) 97.6g (1.00M)
• Tris Base 60.6g (1.00M)
• SDS 10.0g (69.3mM)
• EDTA 3.0g (20.5mM)
• Ultrapure Water to 500ml
1x buffer should be pH 7.3
B.8.6 NuPAGE® Reducing Agent
Catalogue No. NP0009
The NuPAGE® Reducing Agent is 0.5 M DTT. It is 98% Research Grade.
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